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The quantification of pregnancy-induced bone mineral mobilisation in the maternal appendicular 
skeleton with novel peripheral quantitative computed tomography (pQCT) techniques. 
Mícheál Ó Breasail 
 
Adaptations in maternal calcium (Ca) economy occur during pregnancy to meet fetal demand 
and by birth a typical new-born contains 25-30g Ca. At the individual-level if Ca is mobilised 
it is important to identify where this occurs to identify any potential impact on fracture risk. 
At present, pregnancy is not considered a risk factor for osteoporosis but data are few. 
Trabecular bone is more metabolically active than cortical bone in part due to its structure, 
orientation and much greater surface area. During lactation, studies have consistently reported 
significant transient bone mineral mobilisation from trabecular-rich axial sites such as the hip 
and spine, while newer peripheral quantitative computed tomography (pQCT) techniques have 
found trabecular microarchitectural change in the appendicular skeleton also. My primary 
objective was to explore whether a similar pregnancy-induced bone mineral mobilisation could 
be observed in two distinct cohorts of pregnant women using novel pQCT techniques from 
mid- to late-pregnancy. These techniques provide non-invasive measurements of bone density, 
mass, geometry, distribution and strength at the radius and tibia.  
This thesis aims to determine: whether pregnancy-induced changes occur in a) the trabecular 
compartment, b) the cortical compartment, c) any potential predictors of a) and b); d) to 
explore the correlation and agreement of pQCT techniques in-vivo. Single-slice and high-
resolution (HR) pQCT data were used to characterise maternal appendicular skeletal change 
during pregnancy in two studies in contrasting populations: 1) a resource poor subsistence 
farming Sub-Saharan African community with an habitually low Ca intake and high parity; 2) 
an affluent Cambridge based population, where Ca intake is higher but parity much lower. In 
The Gambia, existing pQCT data obtained at 14 and 30 weeks of pregnancy from women 
(n=811), aged 18-45 and accustomed to low habitual Ca intake, were analysed. In Cambridge, 
ii 
 
UK, I designed a study where pregnant women (n=53) and non-pregnant non-lactating (NPNL, 
n=37) controls aged 30-45 years were scanned with pQCT and HRpQCT at 14 and 36 weeks. 
These data were modelled to explore the maternal response to pregnancy in these distinct 
populations. 
Contrary to my primary hypothesis there was no evidence of trabecular bone mobilisation in 
Gambian women, however in contrast in the UK study a -0.5 SD decrease in trabecular vBMD 
was observed. In The Gambia total vBMD did not change at the radius or tibia, while in 
Cambridge both techniques detected decreases in total vBMD at the distal tibia. Changes in 
cortical bone were documented during pregnancy in both populations. In Gambian women 
small but significant increases in cortical vBMD and BMC were observed at the radius and 
tibia. In Cambridge at the tibia HRpQCT showed a decrease in cortical vBMD and cortical 
thickness with an increase in cortical porosity. There were fewer pregnancy-induced changes 
at the radius but at the cortical- rich diaphysis cortical thickness decreased and endosteal 
circumference increased. No consistent predictors of these changes were found in either 
population. 
These data from two contrasting populations show a “one size fits all” approach cannot be 
applied to the maternal skeletal response to pregnancy. In Gambian women with a habitually 
low Ca intake we have observed the conservation of bone mineral in the appendicular skeleton 
into the third trimester. In contrast in the Cambridge women evidence of trabecular and 
cortical mobilisation was observed at the distal tibia. At the radius changes were confined to 
the cortical-rich proximal radius and supported endosteal resorption during pregnancy. These 
data suggest that the maternal skeleton is a significant source of fetal Ca in a population 
accustomed to higher dietary Ca intakes. Further work is needed to determine what this 
mobilisation means at the individual level and to determine if the mobilised bone mineral is 
restored postpartum or whether there are lasting consequences for the woman’s bone health. 
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1 Background and Introduction 
 Introduction  
Through the lifecourse the skeleton experiences significant change and many factors determine 
whether healthy bones are maintained at each life-stage and into advanced age. Bone strength in 
later life depends on optimal skeletal growth, development, and maintenance during childhood, 
adolescence and adulthood (Ward, 2012). At birth the skeleton contains 25-30 g of calcium, the 
primary bone forming mineral. Rapid mineral accrual occurs during childhood growth and into 
puberty, where 30-40% of total bone mass is accrued (Bonjour et al., 1991, Slemenda et al., 1994, 
Holroyd et al., 2012). Peak bone mass (PBM) is achieved at end of longitudinal growth between 
the late-second to early-third decade of life (Teegarden et al., 1995). Steady bone remodelling 
follows, with little net change in mineral content, until midlife when remodelling shifts in favour 
of resorption beginning a slow gradual decline from PBM (Nordin et al., 1998, Uusi-Rasi et al., 
2007). However significant bone mineral loss does not occur in women until the onset of 
menopause, where large quantities are irreversibly lost. Half of women aged over 50 years will be 
affected by osteoporosis, a disease of the bones, which occurs when you lose too much bone, make 
too little bone, or both. Bones become weak and are at risk of fragility fractures i.e. non-traumatic 
fractures from minor falls (at the hip and distal radius) or in the absence of any insult (vertebral 
fractures) (NOS, 2014, NOF, 2015). Fractures result in pain, loss of independence, increased 
morbidity and mortality. 
Reproduction can occur across a significant proportion of the lifecourse both before PBM is 
achieved and until shortly before the mineral losses of menopause. Pregnancy and lactation are not 
considered risk factors for osteoporosis (Kalkwarf and Specker, 1995). There are few, conflicting, 
studies concerning maternal skeletal adaptation to pregnancy, while we have well documented 
evidence of transient mineral mobilisation during lactation. It is known that adaptations in maternal 
Ca economy occur during gestation to facilitate fetal Ca demand including elevated gastrointestinal 
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absorption and decreased urinary excretion (Prentice, 2000a). While there is a lack of consensus 
from maternal biochemistry and bone turnover data, some studies support the possibility of 
maternal mineral mobilisation occurring in late pregnancy. Currently data are too few from 
pregnancy to definitively assert that the maternal mineral reserves are a source of fetal Ca, however, 
if mineral is mobilised from the maternal skeleton and not replaced later there may be lasting 
implications for future bone health. 
Common clinical densitometry techniques have been of limited use in pregnancy for several 
reasons: a) typical scans of common axial skeletal sites would involve exposing the abdomen to 
ionising radiation; b) the position of the fetus would obscure measures of the lumbar spine; c) 
although the appendicular skeleton can be imaged published data have been inconsistent. If bone 
mineral mobilisation occurs during pregnancy the extent to which mineral is released may vary due 
to maternal life stage or could be modulated by environmental factors, combinations of which may 
determine the maternal skeletal response to pregnancy and potentially increase the pressure on 
maternal mineral reserves. Newer research techniques allow for the measurement of bone 
compartments where decreases in bone mineral density (BMD) might be observed in late 
pregnancy with very low ionising radiation exposure. 
The aim of this thesis is to investigate the maternal skeletal response to pregnancy using novel 
imaging techniques to measure the appendicular skeleton in two distinct populations. The first of 
these populations was located in rural Sub-Saharan Africa, where Ca intakes are low and the diet is 
of poor quality (Prentice et al., 1993, Prentice, 1994a), data were collected as part of an add-on to 
a larger pregnancy dietary supplementation trial in Gambian women aged 18-45 years. The second 
study recruited pregnant and non-pregnant women in Cambridge, UK, where Ca intakes are higher 
and dietary quality is high, with a focus on women aged 30-45 years. 
The primary objective of this thesis was to determine if total and trabecular volumetric bone 
mineral density (vBMD, see section 1.5) decreased between mid- to late pregnancy at the distal 
radius and tibia using novel peripheral QCT techniques. These measures were obtained using 
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conventional single slice peripheral pQCT in both studies, while the Cambridge study also used 
High Resolution pQCT (HRpQCT) to measure vBMD and trabecular microarchitecture. Both 
studies also aimed to explore whether any changes occurred in the cortical compartment using 
pQCT at the proximal radius and tibia to measure cortical vBMD in addition to measures of bone 
mass, geometry, distribution and strength. HRpQCT allowed for the investigation of cortical 
porosity and thickness at the distal radius and tibia during pregnancy in Cambridge women. 
Here I will outline the structure of this thesis and briefly describe the contents of each chapter. 
Chapter 1 introduces a brief background to the basic structure and cytology of bone, prefacing a 
description of the natural history of bone across the lifecourse: the rapid mineral accrual of 
childhood and adolescence; the attainment of PBM; maturity and reproduction; and the declines 
of natural ageing, and osteoporosis. This is followed by a brief section covering the heritability of 
bone mass and its major environmental determinants. Finally I introduce the bone densitometry 
techniques used to estimate surrogates of bone strength such as BMD in clinical and research 
settings. Chapter 2 provides a focused literature review of maternal pregnancy-induced skeletal 
changes through the examination of Ca homeostasis, bone biochemistry, biomarkers of bone 
turnover, bone histomorphology, and bone densitometry. Here I have collated the available data 
to provide detailed tables that summarise the evidence base from which I drew my hypotheses and 
research questions. 
Chapter 3 presents the methodology I applied to pQCT data collected across pregnancy in The 
Gambia, which I was fortunate to have available to me from the Bone add-on to the Early Nutrition 
and Immune Development Trial (ENID, ISRCTN49285450). Here I detail my approach from 
initial data auditing of the pQCT data to longitudinal statistical analysis to describe the pattern of 
maternal bone homeostasis in this unique Sub-Saharan African cohort. Chapter 4 consists of the 
findings from the statistical analysis of the ENID Bone study pQCT data. My findings are discussed 
within the context of the scientific literature, and the potential for further exploration within the 
cohort is considered. 
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Chapter 5 introduces the Pregnancy and Bone Study (PABS) where I was responsible for the 
design, ethical approval and management of the study together with all data analysis and 
interpretation. With the hindsight of the ENID Bone analysis and my hypotheses clear from my 
literature review, I attempted to optimise my study design to maximise the ability to measure 
pregnancy-induced changes in the maternal skeleton. To exclude the possibility of observed 
changes being the result of natural ageing I recruited a group of healthy non- pregnant non-lactating 
women. This chapter describes the planning of the study, screening and recruitment process, 
methodology of data collection, and statistical methods applied to the data. Chapter 6 presents the 
results from PABS with a focus on the bone mineral changes in the pregnant group; the collection 
of NPNL data allowed me to control for natural age- related changes that may occur during this 
stage of the lifecourse. My findings of significant pregnancy-induced changes in the between mid- 
to late-pregnancy are discussed in the context of the scientific literature.  
Chapter 7 is a brief technical comparison of the two pQCT (single-slice pQCT and HRpQCT) 
techniques used in PABS, here I explore between-scanner correlation and agreement. While 
somewhat aside from the main focus of the thesis I feel it is a useful exercise, which explains the 
similarities in the results the two techniques in PABS. This work and the results of the PABS 
chapters highlight that pQCT is as capable as HRpQCT in detecting pregnancy-induced changes 
in vBMD and cortical thickness outcomes. Chapter 8 discusses my findings from both populations 
in the context of the scientific literature. Finally supporting documents and supplementary 
materials are provided in the appendices.   
 
 Bone 
Bone is a highly mineralised connective tissue capable of adapting to changes in its biomechanical 
environment to maintain a bone that is “fit-for-purpose” (Ward, 2012). The key roles of the 
skeleton are:  
5 
 
1. Mechanical: provides a scaffold for the body, together with skeletal muscles it facilitates 
movement;  
2. Protective: shields internal organs against external injury;  
3. Metabolic: supports metabolic processes; hematopoietic processes by red and yellow 
marrow within the medullary cavity of long bones and interstices of trabecular bone; 
storage of fat as yellow bone marrow. Storage of minerals such as calcium and phosphorus 
needed for acid–base balance by absorbing or releasing alkaline salts to maintain ionic 
homeostasis (Wojnar, 2010, Ward, 2012).  
 
1.2.1 Determinants of bone strength 
The major determinants of bone strength are its material properties, bone mass, structural design 
(shape, geometry, and distribution), and the loading conditions to which it is subjected (ESHRE-
CAPRI, 2010, Cointry et al., 2014). Bone mass encompasses all the matter within whole bone 
including the collagen fibres, mineral crystals, and extracellular fluid. The mineral mass of a bone 
refers to the amount of mineral within the tissue, this mass or bone mineral content (BMC, g or 
mg/mm) is the product of the volume and density of the bone (Figures 1.1, 1.2, & 1.3) (Rauch and 
Schoenau, 2001). 
 
1.2.2 Material properties  
Bone’s unique material properties result from its composition of both organic (collagen and ground 
substance) and inorganic phases (hydroxyapatite or HA) (Figures 1.1, Figure 1.2), which allow bone 
to be stiff yet tough. Stiffness is the mechanical quality of the bone (i.e to withstand strain without 
permanent deformation), while toughness refers to the energy required to break the bone (Currey, 
1984). A healthy bone requires a balance between these two defining attributes to resist damage. 
When loaded the collagen within the bone can absorb and disperse the energy (elasticity) induced 
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through loading by deforming; when the load abates the bone can return to its original shape and 
length (Ward, 2012). The stiffness of bone is determined by the quantity of HA crystals within the 
collagen matrix. However, a bone can be too stiff, if mineralisation exceeds that required for 
strength, the bone becomes increasingly brittle. At lower loads than usual it will behave plastically 
with a reduced ability to deform and absorb the energy from loading leading to the accumulation 
of micro-fractures (Rauch, 2006). Conversely when stiffness is reduced due to under mineralisation, 
toughness increases as more strain is placed upon the collagen fibrils which can result in softening 
of bone tissue. An example of where bones might have a high toughness/low stiffness can be 
found in children with vitamin D/Ca deficiency rickets. These children have bowed legs due to 
decreased stiffness (low mineralisation) with “softening” of the skeleton and poor skeletal support 
but without increased fragility fracture risk (Pettifor and Prentice, 2011). 
 
Figure 1.1 The mineral and organic components of human bone 
Mineral component and collagen (organic) component of bone sample compared following the removal of the 
other in two respective fragments. Source: https://www.slideshare.net/anr3664/skeletal-system-slides 
 
1.2.3 Distribution of mineralised tissue  
Bone comprises two distinct compartments (Figure 1.2) the shape, size, spatial distribution and 
internal organisation of which contribute to the overall strength (Ward et al., 2005c, Laskey et al., 
2010, Ward, 2012). Fractures occur when loading exceeds bone strength (Ammann and Rizzoli, 
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2003, Ward, 2012). However, the properties contributing most significantly to fracture risk depend 
on the skeletal site (Gordon et al., 2017). Cortical bone provides a compact protective outer layer 
with a mechanical function, while trabecular bone provides internal structural strength and in part 
due to its greater surface area is more metabolically active (Fleisch, 1996). In trabecular bone 
mineralized tissue makes up 10 - 35% of the total tissue volume compared to >90% of the volume 
of cortical bone (Petit et al., 2005). Cortical bone accounts for about 80% of bone within the mature 
skeleton (Wojnar, 2010, Seeman, 2013) and consists of osteons centred on extracellular fluid-filled 
Haversian canals (Figures 1.2) (Seeman, 2013). Haversian canals and the perpendicular Volkmann 
canals account for most of the cortical porosity in a healthy bone, and form the intra-cortical 
surface area (Carter et al., 2000). 
 
Figure 1.2 The composition of a human long bone.  
Diagram of the femur showing both the cortical and trabecular compartments, their distribution and composition 
from whole bone to the bone ultrastructure. All components pictured, in addition to other factors, ultimately 
influence bone strength. Image source: Boskey and Coleman (2010) 
 
Trabecular bone accounts for the other 20% of the skeleton and, due to its high metabolic activity, 
80% of bone turnover occurs here (Fleisch, 1996). Trabecular bone is primarily located within the 
medullary cavity at the ends of long bones and vertebral bodies but also occurs through the length 
of shorter bones (e.g. carpals), in large flat bones (e.g. scapula), and in protuberances such as the 
muscle attachment sites (Currey, 2012, Seeman, 2013). The distribution, arrangement, and 
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interconnectivity of this porous cancellous network of trabeculae is vital to trabecular bone strength 
(Bouxsein and Seeman, 2009). Trabeculae change through the lifecourse; during growth and 
development they thicken and change orientation, while during ageing they thin and are lost 
(Section 1.2.4). Adaption to this loss includes the preferential conservation of the most supporting 
trabeculae to prevent fracture (i.e. in the direction of load). 
 
1.2.4 Geometry and shape  
Bone cross-sectional area (CSA) is a major determinant of bone strength. CSA may change in 
response to growth, ageing, changes in mechanical loading, and general health (Garn et al., 1991, 
Rantalainen et al., 2013, Warden et al., 2014). Cross-sectional bone strength increases the further 
from the central axis of the bone that mineral is placed (Schoenau et al., 2001). For two long bones 
with equal amounts of mineral but differing CSA, their moments of inertia (CSMIs, i.e. resistance 
to bending) differ greatly (Figure 1.4) because resistance to bending and torsional loading is 
proportional to CSMI, which is influenced by the distribution of mineral from the central axis. If 
bone stiffness is reduced, due to low mineralisation, strain may be over-estimated leading to bone 
mineral being distributed further away from the axis thus increasing CSA through the laying down 
of mineral on the outer perimeter (i.e. periosteal apposition). Periosteal apposition of mineral would 
reduce fracture risk as an increase in CSMI improves resistance to bending and torsion. Mineral 
redistribution within a bone with an unaltered CSA may also confer an increase in bone strength, 
however, but not as great as that achieved by periosteal apposition (Warden and Fuchs, 2009). 
Particularly for tubular bones such as the radius maintaining a consistently large cortical CSA at the 
midshaft through the lifecourse is advantageous as CSA is a major determinant of resistance to 




Figure 1.3 An explanation of bone mineral densities.  
The above diagram explains the definitions of the various types of mineral density. BMDmaterial and 
BMDcompartment (A and B) in trabecular and (C and D) in cortical bone. The mass of mineral (darker) determining 
BMDmaterial and BMDcompartment is identical (mass 1 = mass 2), but the volume (encircled by blue lines) differs 
(volume 2 > volume 1). Therefore, BMDmaterial is higher than BMDcompartment. (E) BMDtotal is defined as the 
mass of mineral divided by the volume enclosed by the periosteal envelope. This definition can be applied to the 
entire bone, part of the bone (e.g., the distal or proximal end), or a cross section as illustrated above. Source: Rauch 
and Schoenau (2001) 
 
 
Figure 1.4 Schematic of long bone cross-sections and the effect of bone geometry and size on measures of bone 
strength. 
Cross-sectional view of two long bone diaphysis: Both have equal cortical thickness and cortical volumetric bone 
mineral density, but the diameter of the right bone is 50% greater. As a result total CSA of the right bone is more 
than twice that of the left. Cortical CSA (i.e., the area between the periosteal and endocortical surfaces) and bone 
mineral content are about 50% higher in the right bone. Section modulus (a parameter reflecting resistance to 
bending forces) is almost three times higher in the right bone, even though the total vBMD is lower by almost a 
third. Source: Rauch and Schoenau (2008)
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1.2.5 Bone Cells  
Cells make up 2-5% of the total volume of bone, they are surrounded in an extracellular matrix 
(ECM) composed of ground substance and collagen fibres (Sims and Baron, 2000). Ground 
substance includes proteinaceous components (proteoglycans, matrix proteins, and water) 
excluding collagen. The remaining volume is composed of non-living material (Heaney, 2014), 
which can be described as “a fibrous collagen scaffolding reinforced in, around and within its fibres 
by crystal platelets and needles of calcium hydroxyapatite mineral” (Seeman, 2007). This material 
component is constructed and maintained by bone cells including: osteoblasts, osteoclasts, 
osteocytes, and their progenitor cells, each of which have discrete and interconnected roles in the 
maintenance of a healthy bone. 
 
Figure 1.5 Osteoclastic resorption of bone mineral.  
Left scanning electron microscope image of osteoclast and resorption pit, Right in vitro resorption. Sources Prof 
Tim Arnett UCL (left) and Dr Fraser Coxon, University of Aberdeen (right). © Bone Research Society 2015-2018 
Osteoclasts are large multinucleated bone-resorbing cells that differentiate from precursors in the 
myeloid/monocyte lineage and are uniquely capable of resorbing mineralised bone matrix 
(Miyamoto and Suda, 2003, Bonewald, 2004, Boyce et al., 2009, Raggatt and Partridge, 2010, 
Bonewald, 2013). Under appropriate conditions osteoclast precursor cells (OCP) are attracted to 
sites on the bone surface, where they fuse to form multinucleated osteoclasts (Boyce et al., 2009), 
which primarily resorb bone mineral and create resorption pits (Figure 1.5). They play a regulatory 
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role in bone turnover by regulating the differentiation of osteoprogenitor cells (Boyce et al., 2009, 
Cappariello et al., 2014). Osteoblasts are bone- forming cells that differentiate from pluripotent 
mesenchyme stem cells in the periosteum (Raggatt and Partridge, 2010). They operate in clusters 
along the bone surface and are found lining unmineralised organic bone matrix (osteoid) prior to 
its calcification (Sims and Baron, 2000). Osteoblasts produce bone matrix proteins (BMPs), that 
mineralise osteoid, forming new bone matrix where osteoclasts have resorbed the bone surface. 
They secrete type I collagen (90% of total bone protein), in addition to calcium binding proteins 
(e.g. osteocalcin and osteonectin), multiadhesive glycoproteins (e.g. bone sialoproteins I and II, 
ostepontin and thrombospontin), various proteoglycans and alkaline phosphate (AP). They also 
express osteoclastogenic factors macrophage colony stimulating factor (M-CSF) and receptor 
activator of NF-κB ligand (RANKL) for the differentiation of OCP into osteoclasts (Boyce and 
Xing, 2008, Raggatt and Partridge, 2010). RANKL/OPG expression ratio determines the degree 
of osteoclast differentiation and function (Zupan et al., 2010). A small number of mature 
osteoblasts become engulfed within the mineralised osteoid leading to their terminal differentiation 
into osteocytes (Guo and Bonewald, 2009, Bonewald, 2013). Protein production changes: 
cytoplasm declines and numerous dendritic processes form (Guo and Bonewald, 2009) and they 
begin to produce AP and matrix gla protein. Eventually collagen production slows and is followed 
by osteocalcin (OC) and osteopontin production. Osteocytes inhabit lacunae, fluid filled cavities, 
deep within the bone where they produce BMPs at a reduced rate. Osteocytes can sense mechanical 
forces and can instigate bone remodelling through the regulation of osteoclast and osteoblast 




Figure 1.6 The osteocyte a mechanosensing cell. 
Electron microscope image of several osteocytes (top) with a schematic overview (bottom) of the role of the 
osteocyte in mechano-transduction in bone. Left electron scanning microscope image of osteocytes, note the 
interconnected dendritic links between cells facilitating communication between cells. A schematic diagram of the 
stages involved in bone mechanotransduction is presented to the right, to which osteocytes are vital. Sources: Left 
Kevin Mackenzie. © Bone Research Society 2015-2018. The schematic was prepared with the use of images from 
Servier Medical Art through Creative Commons Attribution 3.0 
 
 
1.2.6 Bone modelling and remodelling  
During adulthood the mature skeleton is continuously renewed and regenerated through 
remodelling (Figure 1.7), this maintains the integrity of the skeleton by removing old and damaged 
bone with a high prevalence of fatigue micro-fractures, replacing it with newly formed bone which 
when fully mineralised will have better mechanical properties (Marie and Kassem, 2011). The basic 
multicellular unit (BMU) is responsible for resorption and includes osteoclasts, osteoblasts and 
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their precursor cells (Frost, 1987). Bone-lining cells and osteocytes are also known to contribute to 
the process. BMUs consist of 9-10 osteoclasts and several 100 osteoblasts and act in microscopic 
trenches (resorption lacuna) on the surfaces of bone formed by the BMU. These pits are refilled 
by the osteoblasts which secrete bone matrix into the cavity (Sims and Baron, 2000, Marie and 
Kassem, 2011). Many factors can modulate bone remodelling including, but not limited to, 
mechanical strain (Section 1.3.2), cytokines, hormones and growth factors (Frost, 1987, Boyce et 
al., 2009). Remodelling times can vary but Figure 1.7 provides a schematic over view of the 
processes of resorption and formation. 
 
Figure 1.7 A schematic overview of bone remodelling. 
Bone remodelling and the actions of bone cells in the process. (a & b) Remodelling of bone by a BMU starts with 
osteoblastic activation of osteoclast differentiation, fusion, and activation. (c) Resorption lacunae are formed, the 
osteoclast leaves the area, and mono-nucleated cells of uncertain origin “clean up” the organic matrix remnants 
left by the osteoclast, also possibly forming the cementum line (dotted line) at the bottom of the lacunae. (d) During 
resorption, coupling factors, including IGF-I and TGF- β, are released from the bone extracellular matrix and 
contribute to the recruitment and activation of osteoblasts to the resorption lacunae. (e) The osteoblasts fill the 
lacunae with new bone. Remodelling ends when an equal amount of bone is deposited as was resorbed, and the 




 Bone through the lifecourse  
1.3.1 Development and Growth 
At birth the skeleton contains 25-30 g of Ca, the majority of this is accrued late in pregnancy when 
Ca transfer to the fetus peaks (Hosking, 1996, Olausson et al., 2012), within a year this increases to 
about 90 g (Abrams, 2003). Rapid growth continues from childhood into puberty, almost 90% of 
adult bone mass is gained in the first two decades of life (Binkley et al., 2008). Peak bone mass 
(PBM), which is achieved at the end of longitudinal growth (late teens or early twenties), can be 
regarded as a “bone bank” or mineral reservoir for later life (Figure 1.8) (Bachrach, 2001, Kuh et 
al., 2013). Failing to reach an optimal PBM is associated with an increased risk of osteopaenia and 
osteoporosis in later life (Cooper et al., 2006, Zhu and Prince, 2012). Twin studies suggest that 
genetic factors explain up to 80% of the variability within PBM (Clarke and Khosla, 2010), in 
contrast a vast array of environmental factors influence the residual variability of PBM and 
subsequent bone health through the lifecourse, most with relatively modest effects. 
Two of the most important environmental factors related to achieving an optimal PBM are 
adequate Ca intake in childhood and sufficient mechanical loading through physical activity (Ward 
et al., 2007). Within the skeleton, site- and compartment-specific differences in the timing of when 
PBM is reached are influenced by sex, maturational timing, and lifestyle factors (Teegarden et al., 
1995, Gordon et al., 2017). Pre-pubertal growth follows a pattern of increased growth and mineral 
acquisition in the appendicular skeleton. However, during the pubertal growth spurt (~10 years in 
girls) accelerated growth occurs in the axial skeleton (Clarke and Khosla, 2010). During puberty 





Figure 1.8 Female bone mass across the life course.  
Healthy aging is represented by the solid blue line. If a low PBM is attained at the end of longitudinal growth the individual will continue through life with a low bone mass (orange 




Major pubertal events in females are: 1) the onset of puberty; 2) peak height velocity (PHV); and 
3) menarche. The onset of puberty is marked by the development of breast tissue (thelarche), while 
PHV is the highest height velocity observed during the pubertal growth spurt (Karapanou and 
Papadimitriou, 2010). The onset of menarche (age of first menstruation) occurs rather late in 
puberty typically 6 months after PHV. These events are often investigated in the context of PBM 
attainment and later life BMC however, many such studies are retrospective wih data collected 
decades after these events. This is particularly true of age of menarche where an earlier age of 
menarche has been hypothesised as protective for the future bone health (Fox et al., 1993, 
Tuppurainen et al., 1995, Gerdhem and Obrant, 2004, Ho and Kung, 2005, Chevalley et al., 2008, 
Kuh et al., 2016a). Longer lifetime exposure to endogenous oestrogens is proposed as a possible 
mechanism. However, more recent data suggest that a lower PBM may not be the main conduit 
for increased osteoporosis risk associated with later menarche, because both low peak bone mass 
and later puberty share genetic determinants (Chevalley et al., 2009). 
 
1.3.2 Adolescent mineral accrual and sexual dimorphism  
Three distinct phases of mineral acquisition are documented during adolescence (Baxter- Jones et 
al., 2003): 
1. Increase in height velocity indicates accelerated longitudinal growth 
2. Increase in bone CSA  
3. Increase in BMC mineralisation of the skeletal envelope during peak mineral accretion 
These peak velocities are asynchronous, bone area continues to increase 4 years post peak height 
velocity, and BMC increases up to 6 years post PHV. During adolescence sex-specific adaptations 
occur, bone mass increases more rapidly in girls than boys with similar lean body mass (LBM) in 
addition to sex-specific changes in bone mineralisation and geometry (Rauch et al., 2004) (Figure 




Figure 1.9 Schematic overview of changes in cortical bone geometry and distribution with aging by sex in the 
peripheral skeleton.  
Cortical bone through the lifecourse in men (above) and women (below) greater compensatory periosteal 
apposition in men (highlighted orange) than in women shown with aging. Periosteal apposition increases bone 
cross sectional area and increases resistance to torsional forces. Source: Seeman (2003) 
 
Stanley Garn and others from the 1970s onwards hypothesised that the additional mineral laid 
down on the endosteal surfaces (mainly researching the metacarpals) in the female skeleton could 
form a mineral reserve mobilised during pregnancy and lactation. (Frisancho et al., 1970, Greer and 
Garn, 1982, Frost, 1987, Schiessl et al., 1998, Schoenau et al., 2001, Ward et al., 2005c). High 
resolution imaging techniques have also shown that it is a surface from where mineral is lost during 
the years following the menopause. A 12-year longitudinal HRpQCT study in boys and girls 
supported sex specific adaptations, finding that accelerated periosteal apposition during 
adolescence was more evident in boys than girls (Gabel et al., 2015). The authors suggested that 
rather than endosteal apposition, girls experience diminished endocortical resorption than boys 
(Gabel et al., 2015). However, these data were obtained from distal long-bone sites (radius and 
tibia) rather than the midshaft of the bone where Garn and colleagues had hypothesised a mineral 




1.3.3 Maturity to mid-life  
From PBM, remodelling maintains “fit for purpose” bones, new BMUs are formed at a slow but 
constant rate with an equal amount of BMUs involved in the forming and resorbing of bone 
(Seeman, 2013). However, during midlife, bone remodelling shifts slowly in favour of bone 
resorption; this change is referred to as uncoupling. This imbalance of bone formation and 
resorption sees the volume of bone deposited by BMU decrease and though the volume of bone 
resorbed also falls, the reduction in the former exceeds the latter, producing a net negative balance 
(i.e. mineral loss) (Lips et al., 1978, Vedi et al., 1983, Seeman, 2013). Garn et al. (1991) reported 
that cortical CSA attained by the fourth and fifth decades (in metacarpals II to IV) is highly 
predictive of cortical CSA two decades later. Newer techniques allow for more detailed exploration 
of compartmental change from mid-life onwards. Axial and peripheral QCT data (cross sectional 
and longitudinal) of an age- and sex-stratified US population aged 20–97 years (n=553) reported 
that until midlife, cortical vBMD remained stable at multiple sites with cortical bone loss beginning 
in midlife in women, while decreases in trabecular vBMD began earlier in young adulthood and 
accelerated during perimenopause (Riggs et al., 2004, Riggs et al., 2008). 
A 5-year longitudinal pQCT study of Finnish pre-menopausal women (n=79) also reported an 
annualised reduction of ~0.3% in both trabecular and cortical density (Uusi-Rasi et al., 2007). Data 
from studies using HRpQCT techniques have added greater detail to our understanding of 
premenopausal bone mineral maintenance and loss. A study of pre- menopausal and post-
menopausal Danish women, reported small but statistically significant yearly increases in total and 
cortical vBMD in pre-menopausal women at both the distal radius and tibia, while significant 
increases in cortical thickness and cortical porosity were reported at the tibia only (Shanbhogue et 
al., 2016). These data may seem at odds with the reductions found with pQCT by Uusi-Rasi but in 
this study the age range in the premenopausal arm at baseline was much wider (20 years until age 
at onset of menopause). However another study, reporting longitudinal data for women stratified 
into 10-year age bands, also reported small yet statistically significant annual increases in cortical 
19 
 
and trabecular vBMD at the distal radius (0.3% and 0.6% respectively per year) in women around 
mid-life (aged 30-39 years n=23), further changes in cortical structure were observed with changes 
from baseline in cortical thickness (-0.6%), cortical porosity (-3.7%) and cortical area (-0.6%). At 
the tibia small changes in cortical thickness (-0.7%), cortical area (-0.6%), and trabecular area (0.2%) 
were reported in this age band.  
 
1.3.4 The reproductive years: pregnancy and lactation 
One of the major sex-specific roles of the skeleton in women is considered to be its function as a 
source of Ca for the fetus in pregnancy and the infant during lactation. Childbearing years can form 
a significant portion of the lifecourse and although there are physiological limits to when a woman 
can conceive, this time frame is wide, close to three decades. Studies suggest that optimal fertility 
is maintained until 30 years of age and decreases sharply thereafter (Tatone, 2008), however, the 
proportion of women delaying childbearing beyond 35 years of age has increased greatly in recent 
decades in high income countries (HIC) (Balasch, 2010); pregnancies >35 years are defined as 
occurring at advanced maternal age (Harrison et al., 2017). The number of women becoming 
pregnant at an advanced maternal age is increasing in England and Wales (Figure 1.10, grey and 
yellow lines) and in 2016 54% of all live births in England and Wales were to women aged 30 years 
and above (ONS, 2016) (Figure 1.10). 
Pregnancy places many physiological demands on a variety of maternal body systems and given 
that we know changes take place in maternal Ca economy it is not unreasonable to hypothesise 
some skeletal involvement. At birth the fetus contains up to 30 g of Ca, though the sources of this 
Ca are not yet fully established (maternal dietary intake, maternal skeletal reserves, etc.). In the 
context of the maternal skeleton, 30 g Ca is 2-3% of total Ca stores. Limited bone densitometry 
data at present cannot fully confirm pregnancy-induced changes in the maternal skeleton. However, 
longitudinal data during lactation have consistently shown transient mobilisation of maternal bone 
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mineral to satisfy the Ca demands of the infant via breastmilk. Mobilisation has been observed 
mainly from trabecular-rich axial sites with repletion occurring following weaning (Kalkwarf and 
Specker, 1995, Krebs et al., 1997, Laskey and Prentice, 1997, Laskey et al., 1998, Laskey and 
Prentice, 1999, Kalkwarf and Specker, 2002, Holmberg-Marttila et al., 2003). Newer techniques 
move beyond density and can determine changes in bone microarchitecture (appendicular sites), 
and add further nuance to existing knowledge by questioning the nature of repletion with 
suggestions of lasting micro-architectural adaptation (Bjornerem et al., 2017). Should the maternal 
skeleton be established as a source of fetal Ca, and with further mineral mobilisation in lactation, 
we need to consider whether full repletion is possible prior to the onset of menopause in women 




Figure 1.10 Age-specific fertility rates, 1938 to 2016 England and Wales.   
These data show the number of live births per 1000 women in each age group, note the increases in bands 30-34 (blue), 35-39 (grey), and 40 and over (yellow). In 2016 54% of all live 




1.3.5 Menopause and Ageing   
The mean age of natural menopause ranges from 48-52 years in US and European populations 
(Sowers and La Pietra, 1995). The skeletal changes associated with menopause are complex, 
multifaceted, and ultimately foreshadow the trajectory of bone strength into advanced age. During 
the menopause transition bone mineral is lost from both compartments. However, importantly, 
compartmental mineral loss can differ in magnitude and timing. Also it is vital to consider that 
decreased bone strength is not just the result of the absolute quantity of mineral lost but also from 
where within the skeleton mineral is lost e.g. whether from cortical or trabecular sites, or from axial 
or appendicular, and even from where within the compartment loss occurs such as the endosteal 
or periosteal surface in the cortical compartment, or rods or plates in the trabecular compartment 
(Seeman, 2013). An important difference between the compartments is the ratio of their surface 
area to mineralised bone matrix volume. As the surface area of the trabecular compartment is large 
relative to its mineralised bone matrix volume (Petit et al., 2005), unbalanced remodelling (net 
negative) results in thinning, and perforation of these structures (Figure 1.11) (Seeman, 2013). 
Perforation irreversibly reduces the number of trabeculae and thus the mechanical properties and 
strength of the bone (van der Linden et al., 2001, Marie and Kassem, 2011, Fonseca et al., 2014). 
Age related-deterioration of cortical bone in the female skeleton is not only limited to decreasing 
density but also cortical micro-architectural alterations; cortical porosity increases and endosteal 
resorption, without compensatory periosteal apposition reduces the thickness of the cortex (Figure 
1.12) (Seeman, 2013, Shanbhogue et al., 2016). Haversian canals may coalesce creating large pores, 
which at the endosteal surface lead to “trabecularisation” of the cortex (Figure 1.12) (Augat and 
Schorlemmer, 2006, Zebaze et al., 2010). This makes it difficult to define the transition of the 
junction between compartments, and can obscure both the age associated increase in cortical 




Figure 1.11 Normal trabecular architecture and age associated trabecular thinning and perforation at the 3rd 
lumbar vertebra.  
Left, the 3rd lumbar vertebrae of a 30 year old woman with trabecular rods and plates highlighted. Right trabecular 
thinning (bottom) and perforation (top) in a 71 year old woman. Source Tim Arnett, University College London. © 









Figure 1.12 Scanning electron micrographs of female anterior subtrochanteric specimens at different ages: 
(A) 29-year-old: Pores are regular in shape and evenly distributed in the cortex;  (B) 67-year-old: Pores are large, irregularly shaped, and have coalesced in cortex adjacent to the marrow 
producing cortical remnants; (C) 90-year-old: Trabecularisation of the cortex – large and coalesced pores; (D) 78-year-old woman – extensive intracortical porosity, associated with 
cortical thinning due to transformation of the inner cortex into a trabecularised structure. Cortical remnants (white arrows); (E) Cortex adjacent to periosteum – enlarged pores without 
trabecularisation; (F) Preserved endocortical envelope (arrows) suggests that cortical thinning occurred from within the bone; (G) 90-year-old woman – cortex largely porous. Source: 
Zebaze et al. (2010)  
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1.3.5.1 The menopause transition  
Cross-sectional data from the OFELY cohort in French women aged 31–89 years (n=1,039) 
compared DXA measured areal BMD from total body, hip, anteroposterior and lateral spine, and 
forearm scans by age, and the number of years post-menopause. Cross-sectionally, significant 
trabecular bone loss premenopause at the lateral spine and Ward's triangle was reported, with 
accelerated bone loss reported during the 10 years following the onset of menopause. Accelerated 
bone loss continued thereafter at all sites except the anteroposterior (AP) spine, up to 25 years 
postmenopause (Arlot et al., 1997). When compared to reference data from young healthy adults 
(T-scores) at various sites they found the percentage of postmenopausal women identified as 
osteoporotic varied widely depending on site (T score - 
1.6 to -3.4) with the greatest bone loss at Ward's triangle and the mid- and distal radius (Arlot et 
al., 1997). 
 
Figure 1.13 Bone mineral (aBMD) changes across the menopause transition in the axial skeleton. 
Annual rate of change in BMD of the lumbar spine and total hip in premenopausal (red bars), early perimenopausal 
(blue bars), late perimenopausal (yellow bars), and postmenopausal (green bars) women (n = 1902). Rates of 
change were estimated from multivariable linear mixed models and adjusted for multiple covariates. Error bars 
represent 95% confidence limits. Comparisons were made across status categories: early peri- vs. premenopausal, 
P < 0.001 (spine) and P = 0.002 (hip); late peri- vs. early perimenopausal, P < 0.001 (spine) and P < 0.001 (hip); and 
post- vs. late perimenopausal, P = 0.002 (spine) and P < 0.001 (hip). Source: Finkelstein et al. (2008) 
Longitudinal data from SWAN (Study of Women’s Health across the Nation) a multi-centre study 
of the menopause transition in a community-based sample from multiple ethnic groups in the USA, 
provided further evidence of bone mineral loss across the transition from premenopause to 
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postmenopause (Finkelstein et al., 2008). Significant annual reductions in areal BMD (aBMD) at 
the spine and hip showed increasing mineral loss as women progressed from early to late 
menopause, with further increased mineral loss postmenopause at both sites (Figure 1.13). Changes 
in the axial skeleton as measured by DXA are clinically relevant but do not provide a compartment 
specific description of age-related skeletal deterioration. 
 
 
Figure 1.14 Total and compartmental volumetric bone mineral density across the lifecourse in both sexes    
Cross-sectional volumetric bone mineral density at the radius and tibia in men and women aged 20-80 obtained 
with HR-pQCT Source: Dalzell et al. (2009) 
 
The use of quantitative computed tomography (QCT) can also be used to image the axial skeleton 
allowing for the assessment of age- and sex-specific changes in vBMD, in addition to bone size, 
geometry, and structure. Central QCT allows for highly detailed scans to be obtained at sites in the 
axial skeleton similar to DXA measurement sites (i.e. lumbar spine and femoral neck) but can assess 
change in the trabecular and cortical compartment. pQCT allow for compartment specific changes 
in the appendicular skeleton during aging to be documented also. Age-related decline in the axial 
(QCT: femoral neck and lumbar spine) and peripheral skeleton (pQCT Densiscan: radius) was 
documented cross-sectionally in both sexes by Riggs and colleagues from midlife into older 
adulthood reporting that women experienced 37% (men 42%) of their total lifetime trabecular 
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bone loss before 50 years of age compared with 6% (men 15%) for cortical bone (Riggs et al., 2004, 
Riggs et al., 2008). Dalzell and colleagues also showed the later decline in cortical bone 
postmenopause in the appendicular skeleton with newer HR-pQCT (Figure 1.14). 
1.3.5.2 Postmenopausal bone loss in the appendicular skeleton  
Menopausal bone mineral loss and postmenopausal bone mineral loss differ in both their 
annualised rate of loss and the sites from where mineral is lost, particularly in the peripheral 
skeleton where cortical bone loss has been documented with HRpQCT (Zebaze et al., 2010, 
Seeman, 2013). Shanbhogue et al. (2016) reported postmenopausal women had significant 
decreases in both trabecular vBMD (radius) and cortical vBMD (radius and tibia), accompanied by 
increasing cortical porosity at both sites and decreasing cortical thickness at the radius. This was in 
contrast to men, who had a lower rate of bone loss with advancing age with smaller increases in 
cortical porosity at both the radius and tibia (Shanbhogue et al., 2016). Burt et al. (2017) found 
statistically significant annualised changes in postmenopausal women aged 60-69 years at the radius; 
cortical vBMD (-0.4%), cortical porosity (9.8%), cortical area (-1.1%), and trabecular area (0.4%); 
and at the tibia total vBMD (-0.4%), cortical vBMD (-0.7%), cortical porosity (6.5%), and trabecular 
area (0.2%).  
Bjornerem et al. (2018) and colleagues documented age related change in 199 monozygotic and 
125 dizygotic twin pairs aged 25 to 75 years. Annual increases in tibial cortical porosity differed 
between women remaining premenopausal (0.44%), transitioning to perimenopause (0.80%), and 
from perimenopausal to postmenopause (1.40%). Porosity increased in all regions of the cortex. 
Annual decreases in the ratio of trabecular bone volume to total (BV/TV) also accelerated in the 
3 groups 0.17%, 0.26%, and 0.31%, respectively, due to a decrease in trabecular number (p<0.001). 
The greatest mineral loss occurred in women transitioning from peri-menopause to 
postmenopause and, of this, 80% was cortical. Similar observations were made at the distal radius 
but despite earlier microarchitecture changes, no significant mineral loss was observed before 
menopause (Bjornerem et al., 2018). 
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HRpQCT data of postmenopausal cortical bone loss are in line with epidemiological data showing 
that fractures occurring in advanced age predominantly occur at cortical-rich peripheral sites, with 
women having a higher incidence of non-vertebral fractures than men at any given age (Schuit et 
al., 2004, Zebaze et al., 2010). Data suggests that combining variables derived from HRpQCT may 
with DXA give useful information regarding fracture risk (Litwic et al., 2018). Research suggests 
the measures of cortical porosity or thickness parameters are associated with non-vertebral fracture 
independent of FRAX® and Garvan estimates in postmenopausal women which may help to 
improve identification of women at risk for fracture (Kral et al., 2017). 
The underlying physiology and biochemistry behind these stark changes are complex. However, 
one of the primary drivers of mineral loss is the abrupt reduction of circulating oestrogen during 
menopause that has repeatedly been associated with accelerated bone turnover (Seeman and 
Delmas, 2006, de Villiers, 2009, Marie and Kassem, 2011). The protective role of oestrogen in bone 
health is apparent during menopause, where deficiency influences bone remodelling, 
osteoclastogenesis, osteoblastogenesis, osteoclast and osteoblast numbers, as well as bone 
resorption and formation (Manolagas et al., 2013). Resorption exceeds formation leading to bone 
mineral loss. Oestrogen is known to act via oestrogen receptors (ERα) (Khosla, 2010) and 
stimulates osteoclast apoptosis while suppressing osteoblast and osteocyte apoptosis (Tomkinson 
et al., 1997, Falahati-Nini et al., 2000, Chen et al., 2005, Nakamura et al., 2007, Martin-Millan et al., 
2010). In a state of oestrogen sufficiency the rate of bone remodelling is maintained as formation 
and resorption are balanced. Oestrogen replacement therapy (ORT) alone or as part hormone 
replacement therapy (HRT) is recognised as protective against bone loss (Cauley et al., 1995, 
Seeman and Delmas, 2006, de Villiers, 2009). However, HRT was withdrawn as a first line 
treatment for osteoporosis following findings that indicated a number of serious adverse effects 
including increased risk of venous thromboembolism (VTE), stroke and breast cancer after five 
years of HRT (de Villiers, 2009). 
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1.3.5.3 Osteoporosis – a disease of the ageing skeleton  
The cumulative effects of our lifecourse from in utero onwards can determine how our bones will 
adapt through life and into aging. At the extreme end of age related mineral loss is osteoporosis. 
This is a disease of the bones, which occurs when too much bone is lost, too little bone is made, 
or both (NOS, 2014). Bones become weakened due to decreasing mineral mass and micro-
architectural deterioration and may break from minor falls resulting in a fragility fracture (NOS, 
2014, NOF, 2015). These result in pain, loss of independence, increased morbidity and mortality, 
and significant healthcare costs. Osteoporosis is estimated to affect 200 million women globally 
(Kanis, 2007), and in the UK one in two women will suffer from osteoporosis after the age of 50 
years (van Staa et al., 2001). Clinically osteoporosis is diagnosed using Dual-energy Photon 
Absorptiometry (DXA) to compare femoral neck or total hip aBMD to that of a healthy young 
adult reference population. Despite DXAs role as the clinical gold standard for diagnosis of 
osteoporosis through the measurement of femoral neck BMD (aBMD) and its use in FRAX® to 
calculate future fracture risk, clinically not all individuals who fracture have a low BMD or BMC, 
which are related to fracture risk in populations at high risk of fracture (Marshall et al., 1996). In 
addition to this there are world- wide differences in age-adjusted fractures (Lau et al., 1990, Johnell 
et al., 1992, Zebaze and Seeman, 2003, Dhanwal et al., 2011, Curtis et al., 2017).  
 
 Determinants of bone health during the lifecourse  
While the previous sections aim to provide a brief overview of bone as we move through the 
lifecourse, it is obvious that individual’s do not all follow the same trajectory from birth to advanced 
age. Both genetic and environmental determinants modulate our journey across the lifecourse. 
While PBM has been found to have a strong genetic basis, it can modulated by environmental 
determinants beginning in utero and continuing throughout the lifecourse. This section will briefly 
summarise the evidence for the strong heritability of bone (mass) and will subsequently touch on 
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two of the main environmental factors associated with reaching an optimal PBM: adequate 
childhood Ca intake and musculoskeletal loading. 
 
1.4.1 Bone and heritability   
Studies of families have proved very useful as genetic factors can be identified more easily due to 
the shared environmental factors. A study by Krall and Dawson-Hughes (1993) followed up 160 
adult members of 40 families in the USA using dual-energy (DXA: total body, femoral neck, and 
lumbar spine) or single-photon absorptiometry (SXA: radius and os calcis) finding in the study 
population that 46-62% of aBMD variance was hereditable. An Australian study of mother-
daughter pairs, including postmenopausal women with osteoporotic compression fractures (n=25) 
and their premenopausal daughters (n=32) reported evidence for the heritability of reduced bone 
mass compared to normal controls (Seeman et al., 1989). Mothers with osteoporosis had lower 
BMC in the lumbar spine, femoral neck, and femoral midshaft (all p<0.001) compared to 
postmenopausal controls but crucially their daughters had statistically significant lower BMC at the 
lumbar spine and femoral midshaft compared to premenopausal controls. These data suggested 
that achieving a relatively low PBM rather than excessive loss through aging alone may partly 
explain osteoporosis (Seeman et al., 1989). 
Twin studies have provided the most compelling evidence for genetic variance being the major 
determinant of BMD and PBM. Pocock et al. (1987) measured lumbar spine and proximal femur 
aBMD and forearm BMC by dual photon absorptiometry (DPA) in 38 monozygotic and 27 
dizygotic Australian twin pairs, mostly female, and reported strong correlation between bone 
outcomes at spine, proximal femur, and forearm. These data suggest a substantial genetic 
component in adult bone mass, with further studies confirming these findings with DPA, DXA, 
and qualitative ultrasonography (QUS)(Christian et al., 1989, Kelly et al., 1993, Flicker et al., 1995, 
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Seeman et al., 1996, Slemenda et al., 1996, Howard et al., 1998, Knapp et al., 2003, Videman et al., 
2007). 
More recent studies have benefited from higher resolution imaging and advances in the field of 
genetics. Yang et al. (2018) in an Australian study of 177 mother-offspring pairs from 162 families 
measured trabecular and cortical bone outcomes with HRpQCT and Oligogenic Linkage Analysis 
Routines (SOLAR) software to conduct quantitative genetic analyses. Heritability estimates ranged 
from 24% to 67% at the radius and from 42% to 74% at the tibia. Most interestingly they found 
the relationship for most bone geometry measures was significantly stronger in mother-son pairs 
(n=107) compared with mother-daughter pairs (n=70) (p<0.05), whereas the heritability for most 
vBMD and microarchitecture measures were higher in mother-daughter pairs (Yang et al., 2018). 
Although genetic determinants influence mineral accrual during growth in both sexes, a failure to 
achieve an optimal PBM may be very detrimental to later bone health in females. Accumulating 
evidence suggests that diminished bone accrual in girls is the basis for the lower PBM in young 
women, a recent review article cited this as a major determinant of the 2- to 4-fold higher incidence 
of vertebral fractures vs men in later life (Gordon et al., 2017).  
 
1.4.2 Environment and its effect on bone 
Professor David Barker initially hypothesised developmental origins of ischaemic heart disease 
which led to many other adult health outcomes being associated with the earliest stages of the 
lifecourse (Barker et al., 1989). Strong evidence has accumulated to support developmental origins 
of bone health in later life and several large epidemiological birth cohorts in the UK such as the 
Hertfordshire Cohort Study (HCS) and the MRC National Survey of Health and Development 
(NSHD) have collected longitudinal data at various stages of the lifecourse to explore the 
determinants of osteoporosis and healthy bone ageing. The HCS cohort demonstrated a positive 
association between weight at 1-year and aBMD in late adult life (Oliver et al., 2007) in addition to 
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more recent data demonstrating that muscle strength and function decrease faster than muscle 
mass with aging and reporting further evidence that changes in bone structure with age differ by 
sex (Patel et al., 2018). NSHD followed a cohort born in the early post-war period finding higher 
birth weight, gaining weight and height faster than others, particularly through the prepubertal and 
postpubertal periods, was positively related to bone strength in late adulthood mainly as a result of 
greater bone CSA (Kuh et al., 2014). Furthermore the cohort revealed the association between later 
puberty and lower BMD persists into early old age (Kuh et al., 2016b). More recent prospective 
British studies such as the Southampton Women’s Study (SWS) and the Avon Longitudinal Study 
of Parents and Children (ALSPAC) have collected data from mothers and their offspring. These 
studies have demonstrated the necessity of taking a lifecourse approach to bone health and also 
interactions of our intrauterine environment, early life environmental exposures, and later lifestyle 
can shape our skeletal phenotype with inter-individual differences observable during growth and 
still detectable into advanced age (Fall et al., 1998, Godfrey et al., 2001, Backstrom et al., 2005, 
Javaid et al., 2006, Cole et al., 2009, Dennison et al., 2009, Harvey et al., 2010a, Harvey et al., 2010b, 
Steer and Tobias, 2011). From in utero to later-life the skeletal phenotype is modulated by its 
environment, the greatest effects can be found during childhood growth and development which 
ultimately influence PBM. Two of the most important factors during this period are mechanical 
loading (via physical activity) of the skeleton and adequate nutrition (primarily Ca intake) (Bonjour 
et al., 1997, Ward et al., 2005c, Gunter et al., 2008a, Gunter et al., 2008b, Burrows et al., 2009, 
Gunter et al., 2012, Ward, 2012). 
1.4.2.1 Mechanical loading  
The mechanostat model is a refinement and expansion of Wolff's law (i.e. bone adapts to 
mechanical stress) described by its greatest proponent Harold Frost as “the bone itself, plus 
mechanisms that transform its mechanical usage into appropriate signals, plus other mechanisms 
that detect those signals and then direct the above three biologic activities” (Frost, 1987). This 
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feedback system is led by mechanosensing osteocytes detecting strains in the bone’s structure by 
mechanical loading of the skeleton.  
 
Figure 1.15 The mechanostat model: A biomechanical feedback loop 
Schematic highlighting external modulators and the regulatory feedback loop. Refined version of Frost's 
mechanostat functional model of bone development and strength Source: Rizzoli et al. (2014).  
 
Osteocytes regulate osteoblastic and osteoclastic processes to respond as determined principally by 
regional muscle contractions and impact forces (Frost, 1987, Cointry et al., 2004). Physiological set 
points act as thresholds for the initiation or inhibition of bone modelling and remodelling (Figure 
1.15). With increased strain (i.e. physical activity) the mechanostat may modulate bone strength in 
several ways to distribute the mechanical strain over a larger area throughout the bone by 1) 
increasing BMC, 2) widening the bone via periosteal apposition, and 3) increasing trabecular 
thickness, improved trabecular connectivity (Warden and Fuchs, 2009, Ward, 2012). It has long 
been established that the opposite also holds true as is demonstrated with prolonged 
immobilisation (Uhthoff and Jaworski, 1978) where strain decreases there is: 1) increasing cortical 
porosity, 2) endosteal resorption, and 3) trabecular thinning, and a deterioration of trabecular 
connectivity (Lee et al., 1997, Modlesky et al., 2004). 
Much research, including randomised controlled trials (RCTs) and longitudinal cohorts, has 
focused on the muscle-bone unit during childhood development and adolescence, with weight 
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bearing exercise, which appears to enhance bone mineral accrual in children (especially in early 
puberty), though it is difficult to define an optimal exercise programme (Hind and Burrows, 2007). 
Tan et al. (2014) in a systemic review of activity PA interventions and observational studies, 
including organised sports participation studies with child/adolescent bone strength as the main 
outcome, concluded that pre-puberty and peri-puberty may be the most opportune time in both 
sexes to enhance bone strength through PA. The authors also highlighted a lack of data in more 
mature groups, and that few studies were able to discern the specific contribution of muscle 
function to bone strength (Tan et al., 2014). Conversely where there is disuse of the musculoskeletal 
system, the role of mechanical loading as a determinant of skeletal size, shape and mass has been 
also been observed, in children with osteopenia due to immobilisation, adequate nutrition cannot 
reverse abnormal bone shape and thin cortices (Ward et al., 2007). Non-mechanical factors can 
modulate the mechanostat such as nutritional deficiencies, hormonal imbalance, medication, and 
lifestyle choices (Figure 1.15) (Frost, 1987, Schoenau and Fricke, 2008, Ward, 2012). 
1.4.2.2 Nutrition and bone health  
Dietary factors associated with bone strength and longitudinal growth include bone-forming 
minerals (Ca, P, Mn, and Zn), vitamins (D, K, and C involved in Ca–P homoeostasis and/or bone 
metabolism), energy, amino acids, and ions (e.g. Cu, Mn, CO3 and citrate) (Prentice and Bates, 
1994, Ward, 2012). Nutrients can alter the bone matrix and its composition (i.e. Ca, P, vitamins; 
D, C and K), while deficiencies in single nutrients or food groups can lead to inadequate bone 
development and poor longitudinal growth (e.g. protein, Ca and Zn) (Prentice, 2004, Ward, 2012). 
Some nutrients (e.g. B vitamin complex) indirectly influence bone health regulating the metabolism 
of other key nutrients that play a more direct role in bone health (Dai and Koh, 2015). In addition 
to deficiencies or malnutrition, chronic illnesses affecting the absorption of nutrients along the 
gastro-intestinal tract such as inflammatory bowel disease (IBD) or coeliac disease may be 
associated with abnormal bone mineral accrual or deficits in bone microarchitecture (Stein et al., 
2015, Zanchetta et al., 2015, Haschka et al., 2016). Conditions that alter nutrient intake such as 
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anorexia nervosa are associated with decreased fat, muscle, and bone mass (Faje and Klibanski, 
2012). While increased body mass was once considered protective against fractures, growing 
evidence is showing that obesity has no protective effect and may be associated with fractures in 
growing children (Seeley et al., 2014) and fragility fractures in later life (Leslie et al., 2014).  
1.4.2.3 The importance of calcium as a bone forming mineral  
Adequate Ca intake is required for optimal bone health across the lifecourse but the ability to 
absorb Ca depends on endogenous factors including the efficiency of absorption in the gut and 
gastric acid production, and exogenous factors including vitamin D status and the consumption of 
dietary components that enhance or inhibit Ca absorption (Kerstetter et al., 2005, Wigertz et al., 
2005). Active Ca transport is vitamin D dependent intestinal absorption of Ca is facilitated by 
mediating active Ca transport across the intestinal mucosa (Heaney, 2008). Active Ca transport 
involves; the synthesis of the Ca transport protein calbindin, which shuttles Ca from the brush 
border across to the basolateral side of the mucosal cell (Heaney, 2008). It is beyond the scope of 
this background chapter to delve into the intricacies of population Ca requirements but it must be 
noted that there is a paradox that countries with the highest Ca intakes (and requirements) have 
the highest rates of fracture (Dhanwal et al., 2011, Warensjö et al., 2011). Some have suggested that 
a relationship with other-macro or micronutrients of this may help to explain the apparently higher 
Ca requirement of HIC vs LMIC (Nordin et al., 1998). Studies have suggested a positive correlation 
between dietary protein and urinary Ca (Linkswiler et al., 1981, Nordin et al., 1998), for 40 g of 
animal protein (representing ~ 800 mg (26 mmol) of elemental phosphorus) ~ 40 mg (1 mmol) of 
Ca is lost in the urine (Nordin et al., 1998), though there are few data in LMIC. How this influences 
Ca requirements depends on concurrent Ca intake due to the curvilinear relationship between Ca 
ingestion and Ca absorption (Nordin et al., 1998). In addition sodium (Na) and Ca excretion are 
also strongly positively correlated (Nordin et al., 1998), for every 2.3 g (100 mmol) of Na ingested, 
40 mg (1 mmol) Ca is lost in the urine (Nordin and Polley, 1987, Nordin et al., 1993). 
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Globally Ca intakes vary widely and are particularly low in populations where milk and dairy 
products are not major dietary components, which may be due to the local unavailability (Prentice 
et al., 1993, Prentice, 2002, Prentice, 2004, Prentice, 2011), a lack of regional food fortification, or 
lactose intolerance (Erinoso et al., 1992, Heaney, 2013). In countries with populations primarily of 
European ancestry Ca rich foods of dairy origin are consumed throughout childhood into 
adulthood, while in other parts of the world, a mix of low bioavailability, no traditional place in the 
diet, and to a lesser extent lactose maldigestion mean little to no dairy is consumed with the notable 
exception of some fermented products (Scrimshaw and Murray, 1988, Wittenberg and Moosa, 
1990, Erinoso et al., 1992). 
In HIC, Ca is a threshold nutrient and adult bone mass has a linear relationship with intake until a 
physiological threshold is reached, however in these replete populations, once reached the two are 
unrelated meaning that the skeletal response will occur when Ca intake is increased from deficiency 
levels to a threshold zone (Ilich and Kerstetter, 2000) and that increasing intake when the level of 
dietary Ca already exceeds the threshold will most likely not produce further gains in bone mass 
(Ilich and Kerstetter, 2000). UK Ca dietary requirements were set by Committee on Medical 
Aspects of Food Policy (COMA) in 1991 (COMA, 1991) with a further report of Ca, Vitamin D 
and Bone health was published by COMA in 1998 (COMA, 1998). 
  
Given the importance of Ca intake for skeletal development, much research has focused on the 
adequacy of Ca intakes and the effects of supplementation during periods of growth. Despite the 
evidence of Ca intake being important for bones evidence from trials is less conclusive. In a RCT 
of UK children (pre-pubertal gymnasts) meeting their Ca RNI (Reference Nutrient Intake) no 
additional benefit of Ca supplementation was found (Ward et al., 2007). A large US multi-centre 6-
year longitudinal assessment of Ca intake on bone in (n=1743), reported that dietary Ca had a 
positive effect on bone accrual at the lumbar spine in non-black females only, while no effect was 
found in other ethnic groups or males (Lappe et al., 2015). To control for genetic variability in 
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aBMD another study recruited twin pairs (monozygotic n=27, and dizygotic n=24) of 
premenarcheal Australian females into a randomized, single- blind, placebo-controlled trial with 
one twin of each pair receiving 1200 mg of CaCO3 (Caltrate) over a 24 month study period 
(Cameron et al., 2004). Adjusted total body BMC was higher vs placebo at all points to 24 mo 
(p<0.001). Supplementation was associated with increased aBMD adjusted for age, height, and 
weight at the total hip up to 18 mo (2.4%), lumbar spine 12 mo (1.0%), and femoral neck up to 6 
mo (1.9%) (all p<0.05). While supplementation appeared to be effective in increasing regional 
aBMD in the first 12-18 months these gains were not maintained to 24 months of supplementation 
(Cameron et al., 2004). There is conflicting evidence whether increased Ca intakes via 
supplementation translate into sustained benefits for skeletal health, particularly in non-white 
populations and especially those with habitually low Ca intakes (Ward et al., 2007, Lambert et al., 
2008, Jarjou et al., 2010, Sawo et al., 2013). In Gambian children increasing Ca intake from 300 to 
700 mg/d increased BMC and size adjusted BMD, but not bone width (possible endosteal rather 
than periosteal apposition) (Dibba et al., 2000). At one year follow up, differences in size adjusted 
BMC remained despite normalisation of bone turnover (Dibba et al., 2002, Prentice et al., 2012). 
By young adulthood, no positive lasting effects of supplementation were observed, the amount of 
bone accrued (mineral or size) or the rate of bone growth did not differ compared to controls 
(Ward et al., 2014). 
Possible mechanisms for the lack of sustained bone changes following Ca supplementation may 
be: 1) A remodelling transient (Heaney, 1994, Heaney et al., 1997, Parfitt, 2004); through a slowing 
of bone turnover due to increased Ca results in fewer bone sites undergoing resorption and more 
mineralised/mature bone being measured temporarily increasing BMD/BMC. When normal 
turnover resumes, an increased number of bone sites undergo resorption and the less mineralised 
immature bone would result in a lower BMD/BMC (Prentice et al., 2006); 2) Extra Ca is deposited 
on the endosteal surface, however, once the source of Ca is removed the effects are lost (Specker 
et al., 2004). Apposition on periosteal rather than endosteal surface would confer a greater bone 
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strength; 3) Method of supplementation; the maintenance of sustained bone changes have been 
observed where dairy sources of Ca were used (Specker, 1996, Cadogan et al., 1997, Eastell and 
Lambert, 2002, Prentice et al., 2006), however, these contain growth factors such as IGF-1 and 
protein so observed intervention effects might be due to increases in intakes of all of these factors 
(Prentice et al., 2006, Ward, 2012). 
 
 Bone densitometry and the estimation of bone strength and quality  
The aim of bone densitometry is to measure parameters that contribute to bone strength, to predict 
risk of low trauma fractures, to diagnose osteoporosis, and to differentially assess effects of growth, 
aging, disease, and treatment on these parameters (Baim et al., 2008). It is not possible to directly 
measure resistance to fracture load in-vivo as a measure of ultimate failure load would be required. 
Non-invasive X-ray based techniques measure the attenuation of X-ray beams of known energy 
through the body with one or multiple detectors measuring the beams’ energy loss on the opposite 
side. Figure 1.26 and Table 1.4 at the end of this chapter summarise the most common research 
techniques and their strengths and limitations. Tissues of varying densities such as bone, muscle, 
and fat cause the beam to attenuate to greater or lesser extents. Denser tissues such as bone lead 
to greater attenuation because they contain heavier elements such as calcium and phosphorus (Petit 
et al., 2005). In contrast soft tissues contain lighter elements, such as carbon, hydrogen, oxygen, 
and nitrogen, which cause little attenuation compared to bone (Petit et al., 2005). In the following 
sections methods to assess and estimate bone mineral density, mass, geometry, distribution, and 
strength will be described.  
 
1.5.1 Dual-Energy X-Ray Absorptiometry (DXA) 
Dual Energy X-Ray Absorptiometry (DXA, Figure 1.16) evaluates a 2D projection of a 3D object 
and as such is unable to measure the volume itself provides but provides an areal measure of bone 
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mineral density (aBMD, g/cm2). Two X-ray beams of differing photon energies are used to separate 
mineralised tissues (bone) from soft tissues (fat and muscle), low energy photons are attenuated by 
the fat and fat-free mass surrounding the bone whilst the high energy photons are attenuated by 
both bone and soft tissue. Each picture element (i.e. pixel) has a linear attenuation coefficient. The 
value of a single pixel is the sum of the mineral mass of the bone material between the X-ray source 
and the detector. The unit of this is expressed in g/cm2 of hydroxyapatite e.g. a pixel value of 0.5 
g/cm2 is the attenuation equivalent to a layer of 0.5 g of HA over a 1 cm x 1 cm area (Petit et al., 
2005). DXA cannot evaluate the distribution of bone mass within the bone envelope and is 
therefore size dependant i.e. for two bones of equal physical density but of different size the larger 
bone will be projected as denser than the smaller bone (Figure 1.17). DXA can only estimate 
cortical aBMD at sites where little trabecular bone is present, e.g. midshaft of the femur and radius.     
 
Figure 1.16 Dual-energy X-ray DXA scanner 
The location of x-ray source is highlighted in orange, with the yellow arrow showing the path of the beam to the 
scintillation detector located within the scanning arm. 
During scanning the scanner arm sweeps over the region of interest, with the X-ray beam passing 
through the subject in a posterior-anterior direction projected upwards to the scintillation detector, 
the collimator directs the X-ray beams in the direction of the participant reducing radiation scatter 
and improving image resolution. Early devices used highly collimated beam of X-rays (pencil 
beams), with a single detector that moved in a raster pattern (thin parallel lines across the subject). 
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Older pencil beam systems produced an image with minimal magnification but with long scan times 
(whole body 10-20 mins) (Cullum et al., 1989, Mazess et al., 1989). Newer techniques use fan (linear 
array detector) beams (Boudousq et al., 2003). Fan beam systems use a slit collimator to generate a 
beam that diverges in two directions with a linear array of detectors (Boudousq et al., 2003). 
Total aBMD can be obtained for the whole body and particular regions of interest in axial and 
peripheral skeleton (Table 1.1)(Ward, 2012). DXA measurements of aBMD and BMC have been 
shown to be related to fracture risk in populations at high risk of fracture (Marshall et al., 1996, 
Goulding et al., 2000, Clark et al., 2006). Clinically osteoporosis is defined as a DXA T- score of -
2.5 SD below the average score of young healthy adults in the reference population. Osteopaenia 
is diagnosed as a T-score of between -1 and -2.5 SD compared to peak bone mass (Kanis et al., 
1994). 
 
Figure 1.17  A comparison of physical density vs areal bone mineral density (aBMD).  
Both bones have the same physical density, however, the larger bone appears denser when projected on to a 
screen. The reason is that it absorbs more radiation because of the longer path length of the radiation beam 
through the bone. Source: Rauch and Schoenau (2002) 
 
aBMD is used as a predictor of fracture risk and osteoporosis within the FRAX® tool. More 
recently other DXA derived parameters such as Trabecular Bone Scone (TBS) have also been 
included in FRAX as it may improve FRAX® prediction accuracy for major osteoporotic fractures 
(Iki et al., 2015). Despite the role of DXA as the clinical gold standard for the measurement of 
BMD, clinically not all who fracture have a low aBMD or BMC, studies have revealed that in some 
populations i.e. the obese, those who fracture do not have a low aBMD (Compston, 2013, Leslie 
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et al., 2014, Premaor et al., 2014). Also not all those with a low aBMD or BMC fracture (Schuit et 
al., 2004). Research in females from The Gambia and China found that though low in comparison 
with an age-matched UK population, these populations are known to have lower fracture risk 
(Aspray et al., 1996, Yan et al., 2004). Although aBMD accounts for approximately 60–70% of 
bone strength (Ammann and Rizzoli, 2003) more than half of fragility fractures occur at a T-Score 
not classified as osteoporotic (Schuit et al., 2004).  
Although DXA measures of aBMD or BMC are strong predictors of fracture risk in older people 
and children in populations at high risk of osteoporosis they may be of limited value in different 
populations and at different stages of the lifecourse (Prentice et al., 2006). While BMC provides 
information about the amount of mineral within the measured area of the skeleton, bone strength 
is also determined by factors that DXA cannot measure (i.e. bone shape, geometry, and loading 
conditions) (Slemenda et al., 1996, Currey, 1999, Schoenau and Fricke, 2008, Nikander et al., 2010). 
This view is supported by the International Society for Clinical Densitometry (ISCD) which has 
stated that the inclusion and measurement of additional parameters that, together with aBMD may 
better account for bone strength improve fracture predication (Simonelli et al., 2008, Zemel et al., 
2008). Also there are issues in large or obese subjects as the lean and fat tissues have a higher X-
ray attenuation than in a thin subject leading to an over estimation of aBMD and bone size due to 
the large projected area, this may be accompanied by poor image quality with blurred bone edges 
(Brownbill and Ilich, 2005, Silver et al., 2010). 
Table 1.1 Common bone parameters that can be assessed by Dual-Energy X-ray Absorptiometry (DXA) 
1.5.2 Quantitative Computed Tomography (QCT)  
Quantitative Computed Tomography (QCT) is a 3D technology that provides detail beyond DXA 
measured BMD or BMC (Engelke et al., 2008), that are size-independent measures of volumetric 
Bone mineral content (BMC, g/cm)  Mineral mass component of bone (hydroxyapatite), does not 
include the mass of bone’s organic components  
Bone area (BA, cm2) Projected area of the bone onto the image plane 




BMD (vBMD) (g/cm3) for both trabecular and cortical compartments (Ferretti, 1999). The 
accuracy of measurement by standard clinical QCT methods are limited by resolution of the 
technique (Ward et al., 2005a), and while microcomputed tomography (µCT) is the gold standard 
for bone microstructure, it is invasive requiring a bone biopsy (Krause et al., 2014). In contrast 
QCT is relatively non-invasive but is expensive, time intensive, and involves a higher exposure to 
ionising radiation than DXA. 
 
1.5.3 Peripheral QCT 
pQCT scanners allow for the non-invasive measurement of parameters of bone strength in the 
appendicular skeleton (Table 1.2) (Grampp et al., 1997, Laib et al., 1997, Ferretti, 1999) and involve 
low exposure to ionising radiation with quicker scan durations than clinical axial QCT as they only 
measure at peripheral sites. Single-slice conventional pQCT scanners operate on a rotate translate 
basis, during scanning, the forearm or lower-leg is placed into the gantry and the frame rotates the 
X-ray tube and detector around the limb. A fan beam generates a 2D cross-sectional CT slice (1-2 
mm thick) of the limb with a resolution of 0.2 – 0.8 mm (Ulrich et al., 1999), measures are based 
on linear X-ray absorption coefficients of the mineralised and unmineralised tissues. This 
attenuation can be expressed using the Hounsfield scale which is a linear transformation of the 
original linear attenuation coefficient measurement. The Hounsfield scale is defined as the 
attenuation value of the X-ray beam in a given voxel, minus the attenuation of water, divided by 
the attenuation of water, multiplied by 1000 (Kamalian et al., 2016). While pQCT resolution is far 
poorer than that of ex-vivo μCT systems and newer in-vivo HRpQCT scanners, it offers a non-
invasive relatively inexpensive way to provide useful information in addition to BMD such as 




In addition, to mineralised tissue (material), trabecular and cortical bone contain unmineralised soft 
tissues (Ferretti, 1999, Ward et al., 2005a). pQCT estimates only the mineral portion of bone and 
does not account for the material properties determined by the unmeasured collagen (Petit et al., 
2005) (Figure 1.3). As vBMD represents the amount of mineral averaged over the volume, and 
analysed regions also include unmineralised soft tissue, the tissue BMD is always lower than the 
material BMD. In the trabecular compartment, vBMD is mainly determined by the thickness of 
trabeculae and the average spacing between them, although it is also influenced by trabecular tissue 
mineralization (Petit et al., 2005). In addition as the trabecular compartment contains bone marrow, 
unlike the cortical compartment, trabecular vBMD is lower than cortical vBMD, despite having a 
similar, though not identical, material BMD (Petit et al., 2005). Cortical vBMD is determined by 
the number and average size of osteonal canals (porosity) and the mineralised tissue density 
(Figures 1.18 & 1.19). At cortical-rich sites the resolution of single-slice pQCT is not high enough 




                     
Figure 1.18 Contouring and thresholding of pQCT slices to obtain volumetric bone mineral density outcomes and body composition data. 
pQCT scan slice at 4%, 14%, 38% and 66% tibia are displayed to the left, analysis of the region of interest (ROI) for each slice is shown to its right, with its density profile on the far right. 
At the 66% slice a muscle smoothing filter has been applied, from this slice muscle and bone area data are obtained. At the 66% site a total area and bone area ROI are also applied, 
these are similar to the muscle and bone ROI but different thresholds are applied. Data from these 3 ROIs at the 66% are used to subsequently generate (through subtraction) measures 
of cross-sectional muscle and fat area. Muscle density parameters can be calculated. 
45 
 
Table 1.2  Parameters of bone density, mass, geometry, distribution and strength as obtained by single slice pQCT. 
 
 
Parameters of bone mineral 
Total vBMD (mg/cm3) Total BMC divided by total CSA 
Total BMC (mg/mm) Mass of mineral per unit of axial bone length  
Trabecular vBMD (mg/cm3) Mean vBMD of 45% of the total CSA  
Cortical subcortical vBMD (mg/cm3) Mean vBMD of the remaining 55% not included in trabecular vBMD 
Cortical vBMD (mg/cm3) Determined by application of a threshold of 710 mm/mg3 to the scan image  
Cortical content (BMC) (mg/mm) Total BMC minus Trabecular BMC. 
Parameters of bone geometry 
Total CSA (mm2) The surface area of the whole bone cross-section, including cortical and trabecular bone. This is directly measured. 
Trabecular CSA (mm2) Usually measured as 45% central area of the total CSA. Depends on the peel mode settings. 
Cortical CSA (mm2) The surface area of the cortical bone cross-section, equivalent to total CSA minus the cross-sectional size of the marrow cavity. 
Cortical thickness (mm) The average thickness of the cortical shell. 
Marrow CSA (mm2) Total CSA minus cortical shell (i.e. trabecular and bone marrow). 
Periosteal circumference (mm) The outer diameter of bone: mathematically derived from total CSA by assuming total CSA is circular. PC = (Cross-sectional area / π)½ 
Endosteal circumference (mm) The inner diameter of bone: mathematically derived from trabecular CSA. EC = (Trabecular bone area / π)½ 
CSMI (mm4) Taken with reference to the "neutral axis" resulting from given bending conditions: i.e. resistance to torsion   
Polar moment of inertia (mm4) The sum of the bone-filled voxel areas multiplied by the square of this distance for each voxel. 
Section modulus (mm3) The ratio between the polar moment of inertia and the maximal distance of a bone-filled voxel from the centre 
SSI (mm4) Represents the distribution of bone from the diaphyseal axis, weighted by density  (i.e. density-weighted polar section modulus) 
Body composition 
Muscle CSA (mm2) Used as a surrogate of muscle force, determined at the widest CSA of the limb. Bone area is subtracted from whole image area 
Muscle density (mg/cm3) Muscle density derived by dividing total muscle mass by MCSA   
Subcutaneous Fat (mm2) Bone mass and muscle mass subtracted from whole image to derive subcutaneous fat mass.  




Figure 1.19 Basic schematic of parameters of bone area, mass, and density as obtained by single-slice pQCT 
The examples in the top pane are at the 4% distal radius a site rich in trabecular bone, and below the 33% proximal 
radius a site containing almost exclusively cortical bone. Equivalent sites are measured at the tibia, however, pQCT 
can obtain data from any user defined site along the radius or tibia. Source Ó Breasail 2018 
 
Single slice pQCT methods used at different research centres may vary in the selection of site for 
scanning, selection of thresholds for analysis, and the use of manufacturer or third party software 
for scan analysis these factors can make it difficult to directly compare studies in the literature. 
There are no official guidelines for using pQCT clinically, it is therefore difficult to compare 
reference datasets acquired under different device settings and at different regions of interest 




axial osteoporotic fracture sites such as the spine or hip. Consistent positioning is vital for 
longitudinal measurements, inaccurate accurate positioning will mean that the site of interest is 
incorrect and can result in large errors, especially in trabecular bone (Marjanovic et al., 2009). 
Participant movement can result movement artefacts, good quality scans require the participant to 
remain still throughout the procedure, which can be difficult for the very young, elderly, groups 
with learning difficulties or involuntary body movements. Scan times are dependent on the number 
of sites being measured, each individual CT slice takes approximately 1 minute, as typically 3-4 sites 
are measured along the tibia length (total scan time = ~5 minutes) and 3 sites along the radius (total 
scan time = 3 minutes). However, scan acquisition can be time intensive as in addition to scanning 
time, time is spent to ensure the participant is correctly positioned in the scanner. 
In images acquired by pQCT the 2D pixels correspond to 3D volume-elements (voxels) that extend 
through the slice thickness (2 mm) of the cross-section, like a grid (Figure 1.20) (Hangartner and 
Gilsanz, 1996). The accurate measurement of bone by pQCT (and all other techniques) is limited 
by voxel size, if a voxel contains a mixture of tissues these attenuate the x-rays to different extents 
and average attenuation of the voxel will be lower than that of true bone and the bone within these 
voxels will not be counted. This is referred to as partial volume effect (PVE) and it is very 
problematic when measuring small bones or bones with thin cortices (<2.5 mm) which will have a 
greater proportion of voxels that are close to the bone edge and will consequently appear to have 




Figure 1.20  Partial volume effect (PVE) and the role of thresholds in pQCT imaging  
 
(A) Partial volume effect (PVE) explained with pQCT radius scans and schematic diagrams. At the bone boundary due structures that cover only part of a pixel will be represented at that 
location with a density value that is an average of all the densities of the various materials covering that pixel (right). An example of why cortical vBMD is not analysed at the 4% distal 
radius due to the large number of voxels that are partially filled much of the cortex is not found on analysis (above). When cortical thickness is greater, the relative influence of these 
partially filled voxels becomes smaller. PVE is a limitation of both pQCT and HR-pQCT imaging. Adapted from (Schoenau et al., 2002) and (Hangartner, 2007) (B) Appropriate threshold 
selection to accurately determine cortical volumetric density and bone geometry. The hatched area denotes where density is maximal and the dotted area where the partial-volume 




To segment bone from the surrounding soft tissues, specific thresholds of attenuation are selected. 
Figure 1.20 based on work by Hangartner and colleagues shows the varying density across the 
actual bone boundary (superimposed pQCT bone scan), density increases from the periosteum 
towards the medullary cavity to its maximal cortical value and then decreases again as it crosses the 
bone boundary (Ward et al., 2005a, Hangartner, 2007). PVE will influence the accurate contouring 
and segmentation of the bone from the surrounding soft tissues as the edge voxels contain both 
bone and soft tissue, with the subsequent measured density being an average of these two tissues. 
Thus the error in the final density depends on the proportion of values used in the averaging 
process that suffer from PVE (Hangartner, 2007). Altering the threshold at which scans are 
analysed allows for the selection of only voxels above a user defined threshold, which is optimised 
to ensure that tissues of interest can be measured (Figure 1.20) (Ward et al., 2005a). The analysis 
of cortical bone parameters with pQCT (Figure 1.20) requires specific attenuation thresholds in 
order to analyse the image appropriately for the density or geometry based outcome measures 
(Ward et al., 2005a). Thresholds have a significant effect on the assessment of these parameters 
and selecting an optimum threshold for cortical thickness is based upon full width at half maximum 
(FWHM) of the difference between the densities of cortical bone and immediately adjacent tissues 
(Hangartner and Gilsanz, 1996). Whereas the ideal threshold to accurately obtain cortical vBMD 
is the peak of the density profile across the cortex, however if the cortical width is not great enough 
this peak is artificially lowered due to PVE (Hangartner and Gilsanz, 1996, Ward et al., 2005a). 
  
1.5.4 High Resolution-pQCT  
HRpQCT allows for the simultaneous measurement of vBMD and microarchitecture (Table 1.3, 
Figure 1.21) at the distal radius and tibia with an isotropic voxel size of 82 μm (largest trabeculae 
are ~100 μm). This is much greater than that of conventional pQCT (0.2 – 0.5 mm) but still far 
below that of ex-vivo μCT (Krause et al., 2014). HRpQCT has been validated against μCT 
reporting moderate to high correlation coefficients in individuals without a known metabolic bone 
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disorder or only slightly reduced bone quality (Burghardt et al., 2007, MacNeil and Boyd, 2008, Liu 
et al., 2010). Krause et al. (2014) compared the accuracy of in-vivo HRpQCT vs μCT in cadaveric 
ex-vivo samples from postmenopausal females (n=34) with osteoporosis finding HRpQCT 
provides acceptable in-vivo accuracy for bone volume (BV/TV). The major difference between 
these two techniques is a matter of image resolution; modern µCT systems can generate ex-vivo 
images with a voxel size as low as 0.5 μm with a spatial resolution of less than 2 μm. This greatly 
exceeds the standard in-vivo imaging resolution of both XtremeCTI and XtremeCTII scanners 
(60.7 μm) (Tjong et al., 2012, Manske et al., 2017). The resolution influences how HR-pQCT 
assesses the trabecular compartment. As images are of lower resolution, only trabecular number is 
directly measured and thus an indirect analysis method is used for standard clinical analysis. The 
other parameters, such as trabecular thickness and trabecular separation, are derived using various 
assumptions (Laib et al., 1998, Laib and Ruegsegger, 1999, Tjong et al., 2012, Cheung et al., 2013). 
Recent improvements in HRpQCT technology have improved the measurement of trabecular 
thickness (Agarwal et al., 2016, Manske et al., 2017) and cortical porosity (Agarwal et al., 2016) 
while there is high agreement between the XtremeCTI and XtremeCTII for parameters of vBMD 
(Agarwal et al., 2016, Manske et al., 2017). 
              
Figure 1.21 HRpQCT tibia scans from pre-menopausal and post-menopausal women 
HRpQCT scans at the tibia highlighting age-related changes in the appendicular skeleton. Note the healthy 
trabecular structure seen left compared to the thinner trabecular structures right. Additionally the greater porosity 




The ability to assess trabecular microarchitecture is a major benefit of HRpQCT imaging over 
other in-vivo bone densitometry techniques. While conventional pQCT can provide trabecular 
vBMD measures, it lacks the resolution to measure the spatial distribution of trabeculae within the 
compartment. Additionally HRpQCT measures the entire trabecular compartment within the 
acquired volume of interest (VOI), while conventional pQCT trabecular vBMD is acquired only 
from the inner 45% of the CSA. Burghardt et al. (2010) developed a cortical imaging script to 
provide improved measures of cortical density and cortical microarchitecture such as cortical 
thickness and cortical porosity. As with the standard analysis protocol a semi-automatic contour 
algorithm locates the periosteal surface with an additional contour placed on the endocortical 
surface. This process consists of three distinct stages to mask the bone structure to define the 
cortical bone compartment:  1) Segmentation of the cortical bone compartment – cortical image; 
2) Identification of Haversian canals – porosity image; 3) combination of the segmented cortical 
bone and porosity images to generate a refined cortical compartment region (Figure 1.22). 
 
Figure 1.22 Diagram illustrating the additional cortical analysis of Burghardt and colleagues  
End result of the additional cortical analysis as described in Burghardt et al. (2010). A, above shows the radius both 
at the most distal and most proximal slice and the corresponding 3 dimensional visualisation obtained following 
the analysis. B, tibia shows the corresponding analysis from the tibia. Cortical porosity is illustrated by the red. 
 
The limitations of HRpQCT overlap considerably with other pQCT techniques such as: sensitivity 
to participant movement, only scanning the distal regions of the peripheral skeleton (pQCT can be 
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used at the diaphysis and metaphysis), difficulty in positioning for longitudinal measurements, the 
indirect calculation of parameters (i.e. trabecular thickness), and PVE (Figure 1.20). HRpQCT, at 
present does not provide any body composition data as there are no imaging scripts available to 
assess soft-tissue. Limitations unique to HRpQCT compared to conventional pQCT include ‘ring 
artefacts’ which are prominent in third generation CT scanners that use multiple detectors. Ring 
artefacts occur if a detector is out of calibration when it provides a consistently inaccurate reading 
at each angular position forming a ring (Figure 1.23). 
As with all CT techniques beam-hardening negatively effects HRpQCT imaging through distortion 
causing the edges of the bone to appear brighter than the centre, even if the material is the same 
throughout. This is the result of the preferential attenuation of low-energy radiation, which 
“hardens” the energy spectrum of the beam as it passes through the limb, shifting the energy 
spectrum towards higher energy photons (Sekhon et al., 2009). vBMD varies between the cortical 
and trabecular compartments. Therefore it is difficult to differentiate between beam hardening 
artefacts and actual material variations (Barrett and Keat, 2004, Sekhon et al., 2009).  
Further issues that are encountered during scan analysis relate to the contouring of the bone edges. 
The HRpQCT software applies a semi-automated contour algorithm to select the outer cortical 
edge of the whole bone. Contouring time is reduced by using these algorithms. However, the 
algorithm may attach contours to unwanted regions and as such the operator must correct these 
errors. In participants with thin porous cortices (<2 mm) the automated contouring will often 
select trabecular over adjacent cortical pores (Buie et al., 2007). The operator is required to 
subjectively verify each slice to ensure that the correct contour has been selected and if not the 
operator is required to amend the contour. This process is time consuming and subjective and can 
introduce further error in both precision and bias. To reduce this, all scans should ideally be 





Figure 1.23 Ring artefacts on HRpQCT scans and a schematic explanation of how these artefacts occur: 
Ring artefact (highlighted, left) present on a HRpQCT forearm scan to the left of the mouse pointer, schematic 





Figure 1.24  The junction of the trabecular and cortical compartments is difficult to measure even with high-
resolution in-vivo scanning techniques. 
At the endocortical trabecular junction it can be 
difficult to define where one compartment ends 




Table 1.3 HRpQCT parameters from standard analysis and additional cortical analysis  
 
 
Standard analysis: Parameters of bone mineral 
Total vBMD  (D100, mg/cm3) Represents both trabecular and cortical compartments and quantified based on the periosteal segmentation. i.e. mean value of all voxels 
within the whole bone. 
Cortical vBMD (mg/cm3) Whole bone minus trabecular compartment and is a direct measure 
Trabecular bone volume to tissue volume (BV/TV) Derived from trabecular density assuming fully mineralised bone to have a mineral density of 1.2 g HA/cm3  
Standard analysis: Parameters of bone geometry 
Total bone area  (Tt.Ar, mm2) Mean total area defined by the imaging contours of the middle 104 slices analysed. Tt.Ar includes all bone tissue and marrow contained within 
the periosteal envelope. 
Cortical area (CtAr, mm2) Tt.Ar minus trabecular area. 
Trabecular area (Tb.Ar, mm2) Tt.Ar minus cortical area. 
Standard analysis: Parameters of bone structure 
Trabecular number  (Tb.N, mm-1) The inverse of the mean spacing of the mid-axes. Does not depend on a priori assumptions regarding the plate- or rod-like nature of the 
underlying structure. 
Trabecular thickness (Tb.Th, mm) Derived from BV/TV and TbN using standard methods from histomorphometry. TbTh = (BV/TV) /TbN 
Trabecular separation  (Tb.Sp, mm) Derived from BV/TV and TbN using standard methods from histomorphometry. TbSp = 1 - BV/TV)/TbN 
Cortical thickness  (Ct.Th, mm) Mean cortical volume divided by the outer bone surface. 
Additional cortical analysis: Parameters of bone mineral 
Cortical bone mineral density (Ct.BMD, mg/cm3) Mean mineralisation of the cortical volume of interest. 
Cortical tissue mineral density (Ct.TMD, mg/cm3) Mean mineralization of the segmented cortical bone voxels after exclusion of pores.  
Cortical total volume (Ct.TV, mm3) The volume of all voxels (i.e. bone and pore) contained within the cortical volume of interest. 
Cortical bone volume (Ct.BV, mm3) The volume of all bone voxels within the cortical volume of interest. 
Additional cortical analysis: Parameters of bone geometry 
Total bone area (Tt.Ar, mm2) The average cross-sectional area of the whole bone circumscribed by the periosteal contour. 
Cortical bone area (Ct.Ar, mm2) The average cross-sectional area of the cortical compartment between the periosteal and endosteal contours. 
Trabecular bone area (Tb.Ar, mm2) The average cross-sectional area of the trabecular compartment circumscribed by the endosteal contour. 
Additional cortical analysis : Parameters of bone structure 
Cortical thickness (Ct.Th, mm) Mean cortical thickness 
Cortical pore volume (Ct.Po.V, mm3) Direct voxel-based measure of the volume of the intracortical pore space. 




1.5.5 Non X-ray based techniques to measure bone mineral  
Quantitative Ultrasound (QUS) is a method based on the transmission of a sound wave through 
bone, energy from the sound wave (frequency 20 kHz to 100 MHz) propagates though the bone 
tissue with some of this energy transferred to the bone tissue, through attenuation (Gluer et al., 
2004). The shape, intensity, and speed of the sound wave are quantified by the receivers as speed 
of sound (SOS) and broadband ultrasound attenuation (BUA). SOS, BUA and stiffness index BMD 
equivalent (SI, a linear combination of BUA and SOS) show moderate correlations with DXA in 
some studies (Clo et al., 2015) but not in others (Laskey and Prentice, 2004). QUS is used at 
peripheral sites which have little soft tissue (Figure 1.25) (Baroncelli, 2008). However, in the past 
many manufacturers have produced these devices and there are difficulties in comparing studies 
without cross-calibration. A multicentre study by Gluer and colleagues tested five different 
commercially available QUS devices tested and found significant age-adjusted differences between 
subjects with and without vertebral fracture (i.e. 20% height reduction). They also claimed to show 
QUS of the calcaneus worked comparatively well as central DXA for the identification of women 
at high risk for prevalent osteoporotic vertebral fractures (Gluer et al., 2004). However, in 
conclusion they cautioned that the high correlation between QUS methods was due to rigorous 
quality assurance measures that should also be applied in clinical practice (Gluer et al., 2004). QUS 
is a non-invasive, safe, and radiation free modality which is easy to use (Guglielmi et al., 2009), in 
addition to being inexpensive and portable. This has allowed for data to be collected in large 
reference populations. However, despite the advantages of QUS there are a number of major 
limitations. They are sensitive to temperature change. Some QUS techniques that measure the 
calcaneus use a fixed sized foot well as such participant foot size may affect the region of the bone 
being observed. In conditions where oedema is common such as pregnancy, additional soft tissue 
may interfere with the attenuation perhaps leading to erroneous measures at the calcaneus and 
phalanges. Although today very few manufacturers continue to produce and market QUS devices, 
historically they have been widely used by many studies in pregnancy as they are non-ionising and 
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have allowed for the collection of QUS data from large numbers of pregnant women at multiple 
time points across pregnancy. As such QUS warrants a brief mention in this chapter and data from 
studies during pregnancy with be discussed in the next chapter. 
 
Figure 1.25 Schematic showing qualitative ultrasound (QUS) devices and their respective scan sites. 
QUS devices (probes: light blue, transducers: red), X-ray films left used to represent the sites of measurement, and 
the approximate ROI (yellow box). The yellow arrows indicate the principal pathways of the ultrasound waves from 
the emitter transducer(s) to the receiving transducer(s). Below Hologic Sahara (Os Calcis) and miniOmnisense 







Figure 1.26 Overview of the interrelated biological determinants of bone stiffness and strength and the available techniques to measure bone and muscle. 
The production of anisotropy (different stiffness / strength in different directions) at tissue and organ levels of structural complexity of bones derived from the material and geometric 
properties, respectively, is shown. The ability of some current methodologies (DXA, QCT, and QUS) to determine some suitable indicators of those properties is also indicated. Adapted 
from Cointry et al. (2004)  
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Table 1.4 Summary of the primary advantages and limitations of main x-ray modalities used in bone mineral research along with the exposure to ionising radiation from standard 
imaging investigations. Typical precision estimates are also given. 
Advantages Limitations Radiation Exposure  Precision  
DXA 
Rapid scan acquisition  
Low cost  
Low radiation dose 
High precision  
Clinical gold standard  
Flexibility – can assess the total body, lumbar spine, forearm, 
femoral neck and body composition (lean and fat mass). 
Size dependent measurements 
Sensitivity to body composition changes 
Software and reference data changes. 
Unable to quantify trabecular and cortical 
bone compartments separately  
whole body <1.0µSv,  
hip scan         3.1µSv,  
lateral spine  12.09µSv 
AP spine         3.37µSv 
AP spine: 1-2%  
 
Hip:  2-3%  
pQCT 
Size independent  
Low radiation 
Can quantify cortical and trabecular bone compartments 
Can assess bone geometry and shape 
Can assess indices of bone strength 
Can assess fat and muscle 
Low radiation dose 
Low cost 
Relatively long acquisition time 
Peripheral sites only 
Sensitive to participant movement 
Research tool – little clinical use 
Less reference data vs DXA 
Imaging artefacts  
Partial Volume Effect. 
Reproducibility of scan location. 
<1.6 μSv per scan  Radius: 0.9– 5.7% 
 





Can quantify cortical and trabecular bone compartments 
Can assess bone geometry and shape 
Can assess indices of bone strength 
Very detailed images due to high resolution Can image the 
trabecular bone structure 
Relatively long acquisition time 
Peripheral sites only 
Sensitive to participant movement 
Research tool – little clinical use 
Less reference data vs DXA 
Imaging artefacts. 
Partial Volume Effect 
High cost and maintenance 
<3 μSv per scan  Radius: 1.1 – 12.7 %  
 
Tibia:  0.2 – 5.2 % 
 
DXA = dual-energy x-ray absorptiometry ,pQCT = peripheral qualitative computed tomography , HR-pQCT = high-resolution peripheral qualitative computed tomography, AP= anteroposterior 
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2 Literature Review: Pregnancy-Induced Bone Mineral Changes 
in the Maternal Skeleton  
 Introduction  
The new-born skeleton contains 20–30 g calcium, 16 g phosphorus, 750 mg magnesium and 50 
mg zinc, this represents 98%, 80%, 60% and 30%, respectively, of total body stores (Givens and 
Macy, 1933, Prentice, 1994b, Prentice and Bates, 1994). Very little of this fetal mineral accrual 
occurs before mid-pregnancy; Ca accretion increases thereafter, peaking in the third trimester 
(Prentice, 2000a). The total Ca accretion rate of the fetus increases from approximately 50 mg/day 
at 20 weeks to approximately 330 mg/day at 35 weeks (Forbes, 1976). As pregnancy and lactation 
place increased pressure on the maternal mineral economy to supply these essential nutrients, there 
needs to be potential biological strategies that allow the mother to meet these extra nutritional 
demands of pregnancy and later lactation (Prentice, 1994b, Prentice, 2000a, Prentice, 2000b). 
Possibilities include increases in mineral intake, physiological adaptations via increased 
gastrointestinal absorption and decreased urinary/faecal mineral excretion, and/or mobilisation of 
mineral from tissue stores (Kalkwarf and Specker, 1995, Prentice, 2003, Olausson et al., 2012). 
This final possibility has been well documented in lactation (Laskey and Prentice, 1997, Laskey and 
Prentice, 1999, Moller et al., 2012, Brembeck et al., 2014) but as there are few and conflicting 
densitometry and bone turnover data in pregnancy, questions remain as to whether mineral 
mobilisation from the maternal reserves occurs, and, if so, its possible magnitude. Although 
pregnancy is not considered a risk factor for osteoporosis (Kalkwarf and Specker, 1995) if 
mobilisation occurs and is not restored after pregnancy, some individuals and populations may be 
more vulnerable and subsequently at increased risk of fracture in later life.  
It helps to contextualise the potential for increased risks of bone mineral mobilisation during 
pregnancy for women at different ages by considering the changes in bone mass through the 
lifecourse (Figure 1.8). Framing the question as such we can consider whether: 1) mobilisation 
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influences PBM attainment in the still-growing skeleton (i.e. adolescent pregnancies); 2) future 
skeletal health is affected in women who become pregnant after PBM and at the start of skeletal 
decline in midlife; 3) sufficient time is available to fully replenish any mobilised mineral prior to the 
onset of menopause. These final two points are of growing relevance in 2016 because 54% of live 
births in the UK were to women aged 30 years and older (ONS, 2016), while the latest ONS data 
shows that births to women aged ≥40 years are at their highest number since 1949 (ONS, 2017). 
There is conflicting evidence about whether pregnancy is associated with changes in bone, from 
studies using a variety of outcome measures, including circulating hormone levels, bone turnover 
markers (BTM), bone histomorphology (via bone biopsies), QUS, and a handful of studies using 
DXA and pQCT. Limitations of the available technologies for the direct measurement of maternal 
bone, such as the invasiveness of bone biopsies and the concerns over the use of ionising radiation 
during pregnancy, make it challenging to quantify maternal bone mobilisation during pregnancy.  
The following sections present a review of the literature to address these points. Pubmed was 
searched using the keywords pregnancy AND Bone to identify papers that may be relevant, these 
were filtered to only include those carried out in humans. As well as original research, reviews and 
systematic reviews of pregnancy/lactation and bone mineral metabolism were also consulted to 
help identify suitable papers for inclusion.  I chose to include only prospective studies prospective 
studies, as retrospective studies assessing bone mineral density in postmenopausal women are 
difficult to interpret due to factors affecting bone since pregnancy and the need to rely on 
participants recall of such variables as previous weight, diet and vitamin D status, hormonal 
contraceptives use, and intervening lactation and infant feeding practices (Olausson et al., 2012). 
While osteoporosis and fractures in pregnancy can occur rarely in some women (Dunne et al., 1993, 
Herath et al., 2017, Laroche et al., 2017), there are no data to suggest that osteoporosis of pregnancy 
is either an exaggerated metabolic response to pregnancy or the result of dietary deficiencies 
(Prentice, 2000a). The fact that osteoporosis can occur in pregnant women cannot be taken as 
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evidence that bone mineral loss is a necessary corollary of normal pregnancy (Prentice, 2000a); for 
this reason I have not included literature relating to osteoporosis during pregnancy in this review.  
 
 Normal calcium metabolism and pregnancy-related adaptations  
Ca metabolism is tightly regulated, even in cases of dietary Ca deficiency circulating levels of serum 
ionised Ca are maintained within a narrow normal range. The reason for such tight regulation is 
that Ca2+ ions act as an important electrolyte in many body systems and are vital to the regulation 
of muscles contraction, nerve conduction, and the clotting of blood. For these reasons the 
consequences of serum Ca being too low (hypocalcaemia) or too high (hypercalcaemia) can be life 
threatening and the maintenance of adequate levels of blood ionised Ca (1.1–1.3 mM) is vital. The 
skeleton at maturity contains approximately 1 kg Ca, of which more than 99% is found in within 
bone and teeth. This Ca stored in the skeleton can be released into the plasma when required to 
supply the body with Ca ions required by the other body systems. 
Although in my review and PhD research I have focussed predominantly on methods used to 
assess whether bone mineral changes occur in the maternal skeleton during pregnancy, I have also 
provided a brief summary of normal Ca homeostasis and a consideration of how metabolic changes 
may initiate bone mineral changes during pregnancy. This tightly regulated metabolic pathway is 
controlled by a number of hormones including parathyroid hormone (PTH), calcitonin, and 1,25-
dihydroxyvitamin D (1,25(OH)2D) metabolically active form of vitamin D), and fibroblast factor 
23 (FGF23) which permit serum calcium and phosphate to be maintained within very narrow limits 
over a wide range of dietary Ca intakes (Figure 2.1). PTH is one of the key players in the regulation 
of circulating Ca levels, in response to reductions in ionised Ca it can: 1) promote bone resorption 
and releasing Ca from the skeleton; 2) reduce urinary Ca losses and increase phosphate excretion; 
3) enhance intestinal Ca absorption (indirectly via renal 1,25(OH) 2 vitamin D production). 
62 
 
Subsequent increases in blood ionised Ca and the active form of vitamin D contribute to the 
negative feedback inhibition of PTH secretion, while serum phosphate increases PTH secretion. 
 
Figure 2.1  Relationships between calcium, phosphate and their regulatory hormones. 
Simplified overview of the relationships between Ca2+ and Pi and their regulatory hormones, PTH, FGF23, and 
1,25(OH)2 vitamin D are displayed above as a network of endocrine feedback loops that govern mineral 
homeostasis. The effect of calcium to increase serum FGF23 levels, a low Pi level to increase serum 1,25(OH)2D, 
and a high Pi level to decrease serum 1,25(OH)2D is not shown. FGF23, fibroblast growth factor 23; PTH, 
parathyroid hormone. Source: Silver and Naveh-Many (2009) 
 
While the actions of PTH and 1,25(OH)2D work together to increase blood Ca levels, calcitonin 
(produced in the C glands of the thyroid), is a hypocalcaemic hormone which reduces plasma Ca 
(Figure 2.1). Compared to the other calciotropic hormones calcitonin is relatively poorly 
understood, its primary action being the inhibition of osteoclast activity (Friedman and Raisz, 1965, 
Chambers et al., 1984, Samura et al., 2000). Interestingly calcitonin is produced in large amounts in 
the mammary gland and in the pituitary gland, which has fuelled speculation of a potential role in 
protecting the maternal skeleton during reproduction (Miller, 2006, Davey and Findlay, 2013). It is 
thought that during pregnancy, calcitonin may have a role in promoting renal Ca excretion (Kovacs, 
2001) and in protecting the maternal skeleton from excessive resorption (Stevenson et al., 1979) 
though at present the evidence base is insufficient. Finally, FGF23 is another hormone that 
contributes to the regulation of calcium and phosphate homeostasis by promoting renal phosphate 
excretion, which in turn reduces the circulating levels of 1,25(OH)2D, thus diminishing intestinal 
Ca absorption (Figure 2.1). 
In non-pregnant, non-lactating (NPNL) women, the absorption of Ca from dietary sources 
depends on many intrinsic and extrinsic factors. Efficiency of intestinal absorption of Ca is 
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important, active transport of Ca occurs in the duodenum and proximal jejunum, with passive 
absorption in the distal jejunum and ileum accounting for the majority of Ca absorption (Diaz de 
Barboza et al., 2015). As such, conditions (coeliac disease, Crohn’s disease, irritable bowel 
syndrome) that afflict the gut can result in intestinal Ca malabsorption (Melvin et al., 1970, Walters, 
1994). The production of sufficient gastric acid also has a role in Ca absorption (Kopic and Geibel, 
2013). While exogenous factors such as vitamin D (dietary or skin synthesis after UVB exposure) 
and dietary components can enhance or inhibit Ca absorption (Heaney and Skillman, 1964, Heaney 
and Skillman, 1971, Heaney, 1990, Heaney et al., 2001, Rafferty and Heaney, 2008, Heaney, 2013). 
Ca is excreted through faeces, urine and sweat (Heaney and Recker, 1994). 
 
 Changes in Ca metabolism and calciotropic hormones during pregnancy  
Data from longitudinal studies across pregnancy demonstrate that total Ca plasma concentration 
(i.e. both ionised and protein(albumin)-bound) decreases during pregnancy versus pre-pregnancy 
or early pregnancy (Ritchie et al., 1998, Black et al., 2000, Ulrich et al., 2003, Wisser et al., 2005). 
However, this is likely to be due to the expansion of the intravascular volume, as indicated by the 
decrease of plasma albumin (Pitkin and Gebhardt, 1977, Black et al., 2000). Ionised Ca, the tightly 
regulated fraction in circulation, remains unchanged between early and late pregnancy (Pitkin et al., 
1979, Seki et al., 1991, Dahlman et al., 1994, Wisser et al., 2005). Between individuals there is large 
variability in PTH concentrations during early gestation (Hemmingway et al., 2018a). Within 
individuals, PTH concentration has been reported to be unchanged (Ritchie et al., 1998, Casanueva 
et al., 2004), or significantly decreased across pregnancy (Black et al., 2000, Naylor et al., 2000). 
Studies have reported 25-hydroxyvitamin D (25(OH)D) levels remain stable during pregnancy 
(Brooke et al., 1980, Ritchie et al., 1998, Hollis et al., 2011, Roth et al., 2013, Wagner et al., 2013) 
or slightly increased (Morley et al., 2006). Increases in plasma 1,25(OH)2D relative to NPNL 
controls have been reported in early pregnancy, with further increases in 1,25(OH)2D observed by 
the 3rd trimester. Increased concentrations of 1,25(OH)2D reported from cross- sectional studies 
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can be several-fold greater than pre- and early-pregnancy levels (Fleischman et al., 1980, Whitehead 
et al., 1981, Bikle et al., 1984, Moller et al., 2013). Vitamin D Binding Protein (DBP) and 
concentrations of free 25(OH)D and 1,25(OH)2D (regarded as the biologically active forms) also 
increase during the same period (Bikle et al., 1984, Seki et al., 1991, Ardawi et al., 1997, Ritchie et 
al., 1998), although it is not until late pregnancy that the proportion of free to bound 1,25(OH)2D 
increases. However, it is possible that free 1,25(OH)2D may be raised across gestation but only 
detectable in the third trimester due to the decreases in albumin (Kovacs, 2016). The importance 
of adequate calcium and vitamin D intake to maternal and fetal health is known, though research 
is emerging to suggest that maternal calcium metabolic stress rather than low calcium intake or 
insufficient vitamin D alone has an adverse influence on fetal growth (Scholl et al., 2014), however, 
further evidence for this is needed. The role of calcitonin during pregnancy is not fully determined 
(see section 2.2), findings from observational studies have varied widely reporting unchanged 
concentrations during gestation compares to postpartum levels (Ritchie et al., 1998, Wisser et al., 
2005), or longitudinal measures at multiple points across pregnancy (Pitkin et al., 1979, Cruikshank 
et al., 1980, Seki et al., 1991). Conversely some studies have found several-fold increases from early 
to late pregnancy compared to non-pregnant values (Samaan et al., 1975, Hillyard et al., 1978, 
Stevenson et al., 1979, Kovarik et al., 1980, Silva et al., 1981, Whitehead et al., 1981, Woloszczuk 
et al., 1981, Dahlman et al., 1994, Ardawi et al., 1997). 
Figures 2.2 summarises how Ca metabolism in (i) early pregnancy and (ii) late pregnancy differ 
from NPNL women with hypothesised bone mineral changes highlighted. For context within the 
reproductive cycle of pregnancy and lactation, Figure 2.3 is an overview of changes occurring in 
the maternal skeleton during (iii) lactation and (iv) post-lactation. Large shifts in Ca homeostasis 
and bone mineral changes have been widely documented during these periods (iii & iv) with several 
comprehensive reviews available (Olausson et al., 2012, Kovacs, 2016). Briefly, mobilisation of 
maternal bone mineral has been documented consistently from trabecular-rich sites (Hayslip et al., 
1989, Sowers et al., 1993, Cross et al., 1995, Kolthoff et al., 1998, Laskey and Prentice, 1999, Polatti 
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et al., 1999, Akesson et al., 2004, Pearson et al., 2004), with repletion documented at several skeletal 
sites following the cessation of lactation (Laskey and Prentice, 1999, Polatti et al., 1999, Akesson 
et al., 2004) and the resumption of menses (Holmberg-Marttila et al., 2000). Recent HRpQCT data 
suggest potential lasting reorganisation of trabecular and cortical microarchitecture up to 5 years 




Figure 2.2 Summary of known and possible changes in maternal calcium homoeostasis during early gestation.  
Thicker arrows denote increases from NPNL, while dashed lines denote decreases from NPNL, lighter arrows denote few data or conflicting evidence for mechanisms of change. During 
early pregnancy calcium absorption from the small intestine increases, urinary excretion also increases. Limited data suggest some changes may occur in the maternal skeleton however 
data are few and inconsistent. See Tables 2.2 & 2.3 for data summarised here. The schematic was prepared with the use of images from Servier Medical Art through Creative Commons 




Figure 2.3 Summary of differences in calcium flux during lactation and the period following weaning compared with non-pregnant non-lactating women (NPNL).  
Thicker arrows denote increases from NPNL, while dashed lines denote decreases from NPNL.. The well-documented changes in maternal bone mineral during lactation are supported 
by biochemical data. Data from DXA for the most part support a trend towards repletion, near total repletion or as in several studies higher aBMD at the spine (depending of course on 
the baseline). However, HRpQCT data may indicate lasting adaptations in bone microstructure despite the repletion of mobilised bone mineral. The schematic was prepared with the 
use of images from Servier Medical Art through Creative Commons Attribution 3.0
68 
 
2.3.1 Bone turnover markers during pregnancy  
Bone turnover markers (BTM) are a useful method of indirectly investigating mineral changes in 
the skeleton. BTMs reflect mainly osteoblast (formation) or osteoclast (resorption) activity rather 
than osteocyte function (Table 2.1). Changes in BTM are measurable closer to the initiation of 
changes in bone formation and resorption than the physiological manifestations of such events 
observed through changes in BMD (Vasikaran et al., 2011). BTM levels reflect global skeletal 
turnover and cannot distinguish the metabolic activity of the trabecular or cortical bone 
compartments (Chapurlat and Confavreux, 2016). A number of studies have used BTMs alone or 
alongside densitometry in pregnant women, however appropriate BTM selection is crucial, as some 
historically widely-used BTMs have inadequate bone specificity or may enter or leave the maternal 
circulation from/to the placenta, fetus, or other tissues (e.g. mammary gland). (Chapurlat and 
Confavreux, 2016). This is discussed in more detail in sections 2.3.1.2 and 2.3.1.3. Other limitations 
of BTMs such as haemodilution which is common (but not confined to) in early pregnancy, and 
while BTMs are known to have diurnal variation in NPNL there are few data from across 
pregnancy. Haemodilation can be overcome to some extent through correcting for albumin (Kaur 
et al., 2003a). 
Collagen type 1 comprises 90% of the total protein in our skeletons making collagen formation or 
degradation products useful as BTMs. Early techniques measuring hydroxyproline required dietary 
restriction (i.e. meat and other collagen-containing foods). Newer collagen derived BTM used to 
assess bone formation and resorption are more robust as their secretion is not influenced by diet 
and they are produced by the metabolism of mature collagen and are secreted without being re-
utilised in collagen formation (Black et al., 2000). These include: cross-linked telopeptides of type 
I collagen (DPD) and pyridinoline (PYD), are measured in urine, while both NTx and CTx may be 
measured in either urine or blood (Olausson et al., 2012) all 4 have been widely to investigate bone 
turnover in pregnancy (Table 2.2). DPD is more specific for bone resorption than PYD, but neither 
is absolutely bone-specific (Yamaga et al., 1997). BTMs used to assess formation include products 
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of osteoblastic synthesis of new bone matrix, such as N and C-propeptides of type I collagen 
(P1NP and P1CP respectively) these are released when collagen type I collagen is synthesised (Black 
et al., 2000, Olausson et al., 2012). Proteins involved in osteoblast function such as alkaline 
phosphatase (BAP is produced by osteoblasts and reflects osteoblast activity, while only a fraction 
of TAP be reflective of osteoblast activity) and serum osteocalcin (OC) have also been widely used 
(also see sections 2.3.1.2 and 2.3.1.3). 
Table 2.1 Commonly used bone turnover markers (BTM) of bone formation and resorption  
 
Formation markers (i.e. osteoblast activity) Resorption markers (i.e. osteoclast activity) 
Total Alkaline Phosphatase  (TAP) in serum C – Terminal Crosslinks (CTX)* in serum and urine 
Bone Specific Alkaline Phosphatase (BAP) in serum N – Terminal Crosslinks  in serum and urine (NTx) 
Osteocalcin (OC) in serum Free Crosslinks: pyridinoline (PYD) and 
deoxypyridinoline  (DPD) in urine 
N - propeptides of type I collagen (P1NP)*  in serum Telopeptide of type 1 collagen  (ICTP) in serum 
C-propeptides of type I collagen (P1CP) in serum  
* International Osteoporosis Foundation (IOF) recommended reference markers for clinical trials 
 
As the inconsistent use of the various BTMs makes it difficult to directly compare studies, the 
International Osteoporosis Foundation (IOF) has recently recommended particular reference 
BTMs to be reported in all clinical trials to ensure that outcome measures are comparable between 
studies. These are C-terminal telopeptide of type 1 collagen (CTx) for bone resorption, and 
procollagen type 1 N propeptide (P1NP) for bone formation (Vasikaran et al., 2011). A detailed 
review of the evidence for collagen-derived BTM, Alk phos and OC follows in sections 2.3.1.1, 
2.3.1.2 and 2.3.1.3. In general there appears to be an increase in resorption markers throughout 
pregnancy (highest levels in late-pregnancy) while evidence for formation markers is much more 
conflicting with some indications of potential increases in late pregnancy. 
70 
 
Table 2.2  Summary of studies using biomarkers of bone resorption across gestation. 
 
Authors Country, n Age* Controls T1 T2 T 3 PP 
Cross-linked telopeptides of type I collagen  C-Terminal (CTx) 
Yamaga et al. (1997) Japan (n=230) P: 28.9 (3.4) 
NP: 26.2 (2.5) 
P-FU: 28.1 (2.7) 
18 NP - - ↑ vs NP - 
Naylor et al. (2000) UK (n=16) 29 (20–36) Pre-preg - ↑ ↑ ↓ 
Kaur et al. (2003a)  UK (n=41) 31 (5.0, Pre-preg ↓* - ↑ ↑ 
Haliloglu et al. (2011) Turkey (n=60) P: 28.1 (3.7) 
NPNL: 29.2 (4.2) 
NPNL - ↑ vs NPNL ↑ vs NPNL ↑ vs NPNL 
Cross-linked telopeptides of type I collagen N-Terminal (NTx) 
Akesson et al. (2004)  Sweden (n=254) 31 (20–45) NA - - ↑ vs T1 ↑ vs T1 
Moller et al. (2013) Denmark ( n=153) 29 (25–35) NPNL & Pre-Preg ↑ ↑ ↑ ↑ 
Ulrich et al. (2003)  USA (n=15) 32.7±3.4 NP & Pre-Preg - - ↑ vs Prepreg ↑ vs Prepreg 
Naylor et al. (2000)  see above 29 (20–36) Pre-preg    ↓ 
Ettinger et al. (2014)  Mexico (n=563) 26 NA - ↑ vs T1 ↑ vs T2 ↓ vs T3 
Yamaga et al. (1997)  see above see above NP - ↑ vs NP ↑ vs NP ↑ vs NP 
Black et al. (2000)  USA (n=10) 30 (23–40) Pre-preg ↑ ↑ ↑  
Telopeptide of type 1 collagen  (ICP) 
Ulrich et al. (2003)  See above 32.7 (3.4) NP & Pre-Preg - - ↑ ↑ 
Free Crosslinks: pyridinoline (PYD) and deoxypyridinoline  (DPD) 
Yamaga et al. (1996)  Japan (n=18) 27.5 (3.2) NA - ↑ vs 5 wks ↑ vs 5 wks ↑6 mo BF 
Yamaga et al. (1997)  see above see above NP - - Both ↑ Both ↑ 
Black et al. (2000) (both) see above see above Pre-preg ↑ ↑ ↑  
Naylor et al. (2000) (both) see above see above Pre-preg - - Both ↑ Pyd ↑ 
Yoon et al. (2000)  South Korea (n=41) 30 (0.9) 
29.5 (0.7) 
NPNL ↑ vs NPNL ↑  vs NPNL ↑  vs NPNL + 8wks ↑  vs NPNL, 8 wks 
Ritchie et al. (1998)   USA (n=14) 29.4 ± 2.3 Pre-preg - - ↑ vs T1 ↑ vs T1 
Wisser et al. (2005) Switzerland (n=43) 28.4 (0) 
NP 34.0 (4.7)) 
NP - - ↑ Vs T1 - 
Cross et al. (1995)  USA, ( n=10) 28.4 ± 1.0 NPNL/Pre-Preg - Vs NPNL - Vs NPNL ↑ Vs NPNL ↑ Vs NPNL 
Paoletti et al. (2003)  Italy (n=44) 27.6±2.1, 
NPNL 28.2±1.8 
NPNL both ↑ vs NPNL both ↑ vs NPNL both ↑ vs NPNL both ↑ vs NPNL 
Statistically significant increase or decreases in each marker are indicated by arrows. Where possible it is reported whether a control group was recruited or whether women had pre-pregnancy baseline data from which 
the differences are expressed. Post-partum data are shown only when considered relevant and not beyond 6 months postpartum. *range given if mean (SD) not available,  T1 = 1st trimester, T2 = 2nd trimester, T3 = 3rd 
trimester, PP = postpartum, NP = non-pregnant, NPNL = non-pregnant non-lactating, BF = breastfeeding 
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Table 2.3 Summary of studies using biomarkers of bone formation across gestation. 
Authors Country, n Age * Controls T1 T2 T3 PP 
Procollagen type 1 N Propeptide (P1NP) 
Naylor et al. (2000) UK (n=16) 29 (20–36) Pre-preg - - ↑ - 
Kaur et al. (2003a)  UK (n=41) 31 (5.0) Pre-preg ↓* ↓* ↑ ↑ 
Procollagen type 1 C Propeptide (P1CP) 
Naylor et al. (2000)  See above 29 (20–36) Pre-preg - - ↑ - 
Black et al. (2000)  USA (n=10) 30 (23–40) Pre-preg - - ↑  
Cross et al. (1995) USA (n=10) 28.4 ± 1.0 NPNL/Pre-Preg ↓ Vs NPNL ↓ Vs NPNL ↑ Vs NPNL Vs NPNL 
Bone-specific Alkaline Phosphatase (BAP) 
Naylor et al. (2000) See above See above Pre-preg - - ↑ - 




NP - - ↑ 
Vs T1 
 
Ulrich et al. (2003)  USA (n=15) 32.7±3.4 NP & Pre-Preg ↓ - ↑ ↑ 
Black et al. (2000) See above See above Pre-preg - - ↑  
Cross et al. (1995) See above See above NPNL/Pre-Preg - Vs NPNL - Vs NPNL ↑ Vs NPNL ↑ Vs NPNL 
Rodin et al. (1989)  (n=80) 20-36 NP  ↑ ↑ - 
Total  Alkaline Phosphatase (TAP) 
Ulrich et al. (2003) See above See above NP & Pre-Preg - - ↑ ↑ 
Yamaga et al. (1996)  Japan (n=18) 27.5 (3.2)  - - ↑ vs 5 wks ↑ until 6mo PP 




NP ↑ ↑ ↑ ↑ 
Black et al. (2000) See above 30 (23–40) Pre-preg - - ↑  
Rodin et al. (1989)  See above 20-36 NP - ↑ ↑ - 
Dahlman et al. (1994)  Sweden (n=24) Abstract only N/A ↑ ↑ ↑ ↓ vs T3, ↑ vs T1 
Significant increase or decreases in each marker are indicated by arrows. Where possible it is reported whether a control group was recruited or whether women had pre-pregnancy baseline data from which the differences 
are expressed. Post-partum data are shown only when considered relevant and not beyond 6 months postpartum.*range given if mean (SD) not available,  T1 = 1st trimester, T2 = 2nd trimester, T3 = 3rd trimester, PP = 
postpartum, NP = non-pregnant, NPNL = non-pregnant non-lactating, BF = breastfeeding 
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Table 2.3 (continued). 
 
 
Authors Country, n Age * Controls T1 T2 T3 PP 
Osteocalcin (OC) 
Akesson et al. (2004)  Sweden (n=254) 31 (20–45) NP - - ↑ ↑ 
Ulrich et al. (2003) See above 32.7±3.4 NP & Pre-Preg ↓ - ↑ ↑ 
Moller et al. (2013)  Denmark (n=153) 29 (25–35) 
Age matched 
NPNL& Pre-Preg ↓ ↓ - ↑ 
More et al. (2001)  Hungary (n=-38) 26 (19–36) Pre-Preg  - ↑ ↑ 
Ainy et al. (2006)  Iran (n=95) 26.2 (5) 
NP 24.1 (5.3) 
NP - ↓ ↓  
Sowers et al. (2001)  USA (n=962) 21.0 (0.17) 
NP 19.6 (0.6) 
 - ↓ -  
Naylor et al. (2000) See above 29 (20–36) Pre-preg ↓ - ↓ ↑ 
Yoon et al. (2000)  South Korea (n=41) 30 (0.9) 
NPNL  29.5 (0.7) 
NPNL - ↓ Vs NPNL 
↓ Vs  8wks 
- Vs NPNL 
↓ vs 8wks 
↑ vs NPNL ↑ 
vs  8wks 
Paoletti et al. (2003)  Italy (n=44) 27.6±2.1 
NPNL 28.2±1.8 
NPNL - - ↓ vs 18 wks, 
pre-preg, NPNL 
- 
Wisser et al. (2005)  See above 28.4 (0) 
NP 34.0 (4.7) 
NP ↓$ - ↑ Vs T 1  
Ardawi et al. (1997)  See above 26:8 (5:8) 
NPNL 27.8 (5.3) 
NPNL ↓ ↓ ↑ ↑ 
Cross et al. (1995) See above 28.4 (1.0) NPNL/Pre-Preg ↓  Vs NPNL ↓ Vs NPNL ↓ Vs NPNL Vs NPNL 
Seki et al. (1991)  Japan (n=20) Abstract only  low ↓ ↑  
Ritchie et al. (1998)  USA (n=14) 29.4 ± 2.3 Pre-preg ↓vs PrePreg ↓ vs PrePreg ↓ vs PrePreg ↑ vs T1 – T3 
Significant increase or decreases in each marker are indicated by arrows. Where possible it is reported whether a control group was recruited or whether women had pre-pregnancy baseline data from which the 
differences are expressed. Post-partum data are shown only when considered relevant and not beyond 6 months postpartum.*range given if mean (SD) not available,  T1 = 1st trimester, T2 = 2nd trimester, T3 = 3rd 
trimester, PP = postpartum, NP = non-pregnant, NPNL = non-pregnant non-lactating, BF = breastfeeding 
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2.3.1.1 Collagen-derived markers of bone resorption during pregnancy  
Many studies have used pyridinium crosslinks (DPD and PYD) to investigate maternal bone 
mineral resorption. Despite conflicting results in early pregnancy (vs NPNL/pre-pregnancy values) 
consistent increases in these markers into the third trimester and during lactation are reported 
(Table 2.2) (Yamaga et al., 1996, Ritchie et al., 1998, Black et al., 2000, Naylor et al., 2000, Yoon et 
al., 2000, Black et al., 2003, Paoletti et al., 2003, Wisser et al., 2005). Yamaga and colleagues 
performed longitudinal measurements of urinary CTx at 5-9, 28-31 and 36-39 weeks of gestation 
and reported similar changes observed in CTx to their previous work with PYD and DPD (Yamaga 
et al., 1996), CTx and NTx were reported to increase significantly in the 3rd trimester of pregnancy 
and remained high during puerperium compared with non- pregnant or early pregnancy measures 
(p<0.05). Several other studies have also reported a similar trend. Naylor et al. (2000) in a 
comprehensive study, investigated a wide range of biomarkers during pregnancy finding of both 
CTx and NTx to be elevated by 36 weeks of pregnancy levels in addition to DPD and PYD 
(p<0.05). They also measured insulin-like growth factor-I (IGF1) and suggested it may be 
implicated for the increased bone turnover in pregnancy as IGF1 levels were significantly correlated 
with the change in BTMs at 36 weeks (Naylor et al., 2000). Haliloglu et al. (2011) reported 
significant differences in CTx between 30 NP controls and 30 pregnant women in the second 
(p<0.05) and third trimesters (p<0.05) of pregnancy. 
Kaur et al. (2003a) also followed up women from pre-pregnancy to post-partum and in contrast to 
several of the above studies found early pregnancy decreases in CTx. These differences were likely 
to due to haemodilation and were attenuated when corrected for albumin, like other studies 
reported a significant increase in CTx by week 36 of pregnancy (Kaur et al., 2003a). Black et al. 
(2000) followed up 10 women aged 23-40 years from pre-pregnancy taking serial measures at each 
trimester, finding NTx increased throughout pregnancy. Ulrich et al. (2003) also reported 
significant increases in NTx during pregnancy during the third trimester compared to pre-
pregnancy values, postpartum NTx declined but remained significantly above baseline. A large 
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study of Swedish pregnant women reported a significant increase in NTx from the first trimester 
(mean 12 weeks) to the late third trimester (mean 37 weeks), compared to the late 3rd trimester 
NTx decreased puerperium (mean 3 days) before increasing again during lactation (Akesson et al., 
2004). A comprehensive Danish study of women planning to conceive aged 25-35 years (n=153) 
of whom 92 conceived measured NTx and ICTP from pre- pregnancy through pregnancy (week 
11 ± 2, 22 ± 1 and 35 ± 2) and into lactation. In this study those who did not conceive acted as 
NPNL in addition to the pre-pregnancy data available from all those who became pregnant. They 
reported that urinary NTx increased significantly as a function of time (p<0.001) rising from early 
pregnancy and remaining elevated throughout pregnancy compared to pre-pregnancy levels and to 
52 non-pregnant, age-matched control (p<0.001). ICTP was also found to rise significantly by the 
third trimester of pregnancy (Moller et al., 2013).  
2.3.1.2 TAP and BAP as markers of formation during pregnancy  
Alkaline phosphatase (AP) reflects osteoblast function, many studies have used total alkaline 
phosphatase (TAP) as a marker of bone formation during pregnancy finding for the most part that 
TAP increases throughout pregnancy particularly in the third trimester (Rodin et al., 1989, 
Dahlman et al., 1994, Ardawi et al., 1997, Black et al., 2000, Ulrich et al., 2003) and remains elevated 
from early pregnancy levels into lactation (Dahlman et al., 1994, Ardawi et al., 1997, Ulrich et al., 
2003). However, caution is required when interpreting TAP as alkaline phosphatase is also derived 
from extra-skeletal sources and, in pregnancy the placenta produces an isoenzyme that is excreted 
into the maternal circulation. The use of bone-specific assays of alkaline phosphatase is essential 
because, unlike TAP, most studies that have measured bone-specific AP (BAP) have reported little 
significant change until late pregnancy when values are significantly higher than in pre-pregnancy, 
NPNL, or the first trimester (Table 2.3). However, Ulrich et al. (2003) reported first trimester 
decreases compared to pre- pregnancy but this may have been as a result of haemodilution. Naylor 
et al. (2000) reported that levels of BAP increased (p<0.05 vs pre-pregnancy levels) by 36 weeks of 
pregnancy. Moller et al. (2013) also found that BAP increased as a function of time, in early 
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pregnancy they were lower than in controls (p<0.001), however, in late pregnancy they had 
surpassed control levels. 
2.3.1.3 Collagen-derived markers of bone formation during pregnancy 
Relatively few studies have used P1NP or P1CP during pregnancy, Naylor et al. (2000) reported 
that levels of P1CP, and P1NP increased (p<0.05 vs prepregnancy) by 36 weeks of pregnancy. 
Both Kaur et al. (2003a) and Cross et al. (1995) reported reduced P1NP from prepregnancy. This, 
however, was likely to have been due to haemodilation because the authors reported that correcting 
for albumin removed this apparent early pregnancy reduction, similar to the finding of Naylor et 
al. (2000) P1NP was reported to be significantly to be elevated at 36 weeks of gestation. Other 
studies have also found late pregnancy increases in P1CP (Cross et al., 1995, Black et al., 2000), 
although one of these studies reported decreases during early pregnancy compared to NPNL 
controls (Cross et al., 1995). 
2.3.1.4 Osteocalcin (OC) as a Marker of Bone Formation during Pregnancy  
OC has been widely used as a marker of bone formation in pregnancy (Rodin et al., 1989, Seki et 
al., 1991, Ardawi et al., 1997, Ritchie et al., 1998, Naylor et al., 2000, Sowers et al., 2000, Yoon et 
al., 2000, More et al., 2001, Paoletti et al., 2003, Ulrich et al., 2003, Akesson et al., 2004, Wisser et 
al., 2005, Ainy et al., 2006, Moller et al., 2013, Ettinger et al., 2014). These studies have suggested 
that OC is reduced in early pregnancy which also may be attributable to haemodilation. Data are 
inconstant in late pregnancy with a number of these studies reporting increases (Ardawi et al., 1997, 
More et al., 2001, Ulrich et al., 2003, Akesson et al., 2004, Wisser et al., 2005) and others reporting 
decreases in OC (Ritchie et al., 1998, Naylor et al., 2000, Yoon et al., 2000). Many studies have 
historically used OC as a formation marker (Ardawi et al., 1997, Naylor et al., 2000, Paoletti et al., 
2003, Akesson et al., 2004, Wisser et al., 2005, Moller et al., 2013) with several accrediting rising 
OC levels during pregnancy to formation. Late pregnancy increases in OC may need to be 
interpreted with some caution as they may stem from OC secreted by osteocytes trapped within 
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the bone matrix released due to the resorption. Although increases in P1NP and P1CP in late 
gestation cannot be discounted as easily.  
 
  Estimating changes in maternal bone mineral during pregnancy 
2.4.1 Direct measurements of maternal bone mineral during pregnancy  
Directly measuring changes in maternal bone mineral during pregnancy is invasive as it would 
involve taking of bone biopsies which are painful. Only one study to date has measured bone 
histomorphology during pregnancy with bone biopsies from the iliac crest a common biopsy site 
rich in trabecular bone (Figure 2.4). Purdie et al. (1988) used a cross-sectional study design with 
iliac crest biopsies from 1) women planning elective 1st trimester terminations (n=15), 2) women 
with scheduled 3rd trimester C-sections (n = 13), 3) non-pregnant women (n=40: living n=14; 
cadaveric n=26). From these samples the authors suggested that changes in maternal trabecular 
bone take place in early pregnancy (Purdie et al., 1988, Shahtaheri et al., 1999). However, their 
sample was limited by poor age-matching between the groups (1: 22.4 ± 3.0 years; 2: 25.1 ± 5.0; 3: 
32.6 ±8.1 years).  
 
Figure 2.4  Potential pregnancy-induced change in trabecular architectural variables of trans-iliac bone biopsies. 
  
Photomicrographs (top) and stylised drawings derived from trabecular architectural variables of trans-iliac bone 
biopsies of potential modification induced by pregnancy in trabecular bone. Cross-sectional bone biopsies from: (A) 
Non-pregnant woman with interconnected trabecular network; (B) early pregnancy where there is less bone and 
thinner, less connected trabeculae; (C) late pregnancy where the bone volume is restored by more numerous finer 
struts. Study limitations are noted above. Source: Shahtaheri et al. (1999)  
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2.4.2 DXA and pregnancy-induced changes in aBMD 
Much of what we know about bone changes during pregnancy comes from techniques that measure 
areal BMD (aBMD) before pregnancy and again shortly after term, capturing the cumulative effect 
of pregnancy and the early post-partum period. Earlier studies used single photon absorptiometry 
(SPA) and later dual photon absorptiometry (DPA) and more recently studies with similar 
longitudinal designs to the earlier literature have used DXA (Drinkwater and Chesnut, 1991, 
Sowers et al., 1991, Holmberg-Marttila et al., 1999, Black et al., 2000, Naylor et al., 2000, More et 
al., 2001, Butte et al., 2003, Fiore et al., 2003, Kaur et al., 2003b, Ulrich et al., 2003, Pearson et al., 
2004, Olausson et al., 2008, Moller et al., 2012). The primary limitation of DXA is that it cannot 
be used to measure common clinical sites in the axial skeleton due to the position of the fetus 
obstructing clear imaging of the lumbar spine and concerns over ionising radiation exposure in 
utero. A further limitation of DXA is that it lacks sensitivity because it measures a two dimensional 
projection of bone and cannot separate bone compartments. 
A number of these studies show statistically significant decreases in whole body, lumbar spine (L1-
L4), total hip, trochanter, femoral neck, and radial aBMD (Table 2.4). There are few longitudinal 
DXA data on the effect of pregnancy in LMIC, although a number of studies based in the USA 
have included ethnically varied populations. However, the main difficulty with many of the studies 
discussed in the period ‘shortly postpartum’ when the follow scans were obtained it is not specified 
clearly whether the mothers were exclusively breast-feeding or not. With rapid mobilisation 
occurring in the early stages of lactation, this is an important consideration when trying to attribute 




Table 2.4. Mean change (%) using DXA, DPA, and SPA in healthy women pre-pregnancy (PRE) to postpartum (POST) at different sites. Adapted from Olausson et al.2012  
 















Moller et al. (2012) ‡ Denmark, Healthy (n=153) DXA:  aBMD <15 days PP 29 median Yes (52) -2.4 -1.8 -3.2 NA NA RW -4.2 
Olausson et al. (2008) ‡ UK, Healthy (n=114) DXA: BA 
adjusted BMC 
PRE <13mo (median 5mo) 
POST 15±5d (10–21d) 
31.7 (3.7) Yes (84) -1.7*** -2.6*** -2.2*** -3.7*** -1.4* RW -0.08 
RS -0.94 NS 
Pearson et al. (2004)‡ UK, Healthy (n=60) DXA: aBMD PRE <16mo 
POST 2wks  (median 8d) 
30.9 (4.5) No NA -1.5** -1.2* -3.9*** 0 NS NA 
Kaur et al. (2003b)‡ UK, Healthy (n=76) DXA: aBMD PRE <13mo 
POST <2wks 
31 (5) Yes (30) NA -0.9 NS -1.2 NS -4.2 NS -0.7 NS NA 
Butte et al. (2003)§ 
 
USA, (n=63) DXA: BMC¶ PRE 179±184d 
POST 2wks 
31 (4) No -2.0 
-0.8 
-0.5* 
In women of pre-pregnant BMI, 19·8 kg/m2 
In women of pre-pregnant BMI, 19·8–26·0 kg/m2 
In women of pre-pregnant BMI, 26·0 kg/m2 
Fiore et al. (2003)‡ 
 
Italy, Healthy (n=16) D XA: aBMD ǁ PRE <90d 
POST 2wks 
21 - 35 No -13.4* -9.2* NA NA -7.8* NA 
Ulrich et al. (2003) ‡§ USA (n=30) 7 attending fertility 
clinics 
DXA: aBMD PRE <6 months 
POST <2 weeks 
32.7 (3.4) NPNL (15)  -3.4** 
 
1·8 NS -4.3*** -1.7 NS RS 1.3* 
 
More et al. (2003)§ Hungary, Healthy, (n=38) 1st 
pregnancy 
DXA:  aBMD PRE <3mo 
POST <6d 
26 (19–36) No NA -2.1*** NA NA NA RS, RW 
 -3.8*** 
Naylor et al. (2000)‡§ UK, Healthy (n=16) DXA: aBMD PRE <8mo (mean <3mo) 
POST <4wks (mean <2wks) 
29 (20–36) No <+1 -4.5*¶¶ NA NA NA NA 




PRE not defined 
POST 6 weeks 
30 (23–40) No  -2.0* ǁǁ -3.6* -4.8** -2.0* RS -4.2NS 
RW-3.1NS 
Holmberg-Marttila et al. 
(1999)§ 
Finland, Healthy (n=5) DXA: aBMD PRE <17wks 
POST ‘some days’ 
27 (2.6) No NA -2.8††† NA NA -0.4*††† RS -3.5*††† 




29.4 ( 2.3) No +0.5NS QCT NA NA NA NA 
Drinkwater and Chesnut 
(1991)‡ 




30 (0.5) Yes (25) NA -3.6 NS NA NA -2.4* RS -2.2* 
Sowers et al. (1991)§ USA, Healthy (n=32) DPA: aBMD PRE not defined 
POST <15d 
29.6 (3.6) Yes NA NA NA -1.2 NS +1.2 NS NA 
NPNL, non-pregnant, non-lactating; NBF, non-breast-feeding; BA, bone area; BMC, bone mineral content; RS, radius shaft; RW, radius wrist; aBMD, areal bone mineral density; QCT, quantitative computed tomography. 
Statistically significant: * P<0·05, ** P<0·01, *** P<0·001, NS, non-significant, as indicated in original papers.  
†All data are for measurements without correction for changes in body weight.  
‡ Bone mineral data taken from paper. § Bone mineral data derived from tables or figures in paper. 
ǁ Implausible values?  
¶Data adjusted for weight.   
ǁǁ Note: value of -3·5% cited in abstract is incorrect.   
¶¶Derived from the original paper by Olausson et al., 2012 from whole-body scan divided into sub regions.  
††† Given the small sample size, the original authors concluded that there is a tendency for a decrease in bone mineral status at the spine, but not at the femoral neck or radial shaft. 
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Sowers et al. (1991) followed up 32 pregnant women in US from preconception to within 15 days 
of giving birth, performing scans of the femoral head (i.e. femoral neck, trochanter, Ward’s triangle) 
with DPA (Lunar DP3 bone densitometer). This was a follow-up from a cross-sectional study of 
maximal bone mass in women aged 20-40 years allowing a large number of potential NPNL 
controls for age- (±3 years), height- (±3 cm), weight- (±3 kg), and parity- (±1) matching. No 
significant aBMD differences were observed between pregnant women compared to NPNL at any 
site. A longitudinal study in USA by Drinkwater and Chesnut (1991) used DPA (Ohio Nuclear 
Series 84) at 5 sites (lumbar spine Ll-L4, femoral neck, femoral shaft, tibia, and fibula) and SPA 
(Norland-Cameron Bone Analyzer, Model 178) at the forearm (10%, and 20% proximal from the 
ulnar styloid process) in 6 pregnant women and 25 non-pregnant women. Significant decreases in 
aBMD at the trabecular-rich femoral neck and at the cortical-rich radial shaft was reported in the 
pregnant women (Table 2.4, both p<0.05). However, aBMD of the tibia, a loadbearing bone, 
increased in both groups (both p<0.05). Pregnant women had an 8.2% increase in body weight 
during the course of their pregnancy while no increase in control group weight was reported, which 
may have partly explained the increase in aBMD in the tibia. (Drinkwater and Chesnut, 1991). 
Holmberg-Marttila et al. (1999) obtained DXA scans from 5 pregnant Finnish women from before 
pregnancy until up to a year postpartum, reported a tendency for a decrease in bone mineral status 
at the spine, but not the femoral neck or radial shaft shortly postpartum. Ritchie et al. (1998) 
performed repeated DXA (DPX, Lunar Radiation Corporation, WI) and QCT (model 9800, 
General Electric, Milwaukee) measures on 13 US women from pregnancy to postpartum, collecting 
BTMs and other biochemistry also (Tables 2.2 & 2.3). No statistically significant changes were 
observed by DXA or QCT from baseline to shortly postpartum. 
One of the most comprehensive studies in the literature was conducted by Naylor et al. (2000) who 
studied 16 women longitudinally in the UK, with DXA (DPX, Lunar Radiation Corporation, WI) 
measurements pre-pregnancy and postpartum and supported by biochemistry and BTMs collected 
at baseline, 16, 26, and 36 weeks of pregnancy, and 2 weeks postpartum. They reported 
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 aBMD decreases at trabecular rich axial sites of the spine (p<0.01) and pelvis (p<0.05). Total- 
body scans were divided into sub-regions for analysis of different body sites reporting increases in 
aBMD at sites where cortical bone predominates in the appendicular skeleton (arms (p<0.05), legs 
(p<0.01)). Biochemistry and BTM data supported the densitometry data indicating that elevated 
bone turnover may explain trabecular bone mobilisation during pregnancy at the lumbar spine 
(Tables 2.3 and 2.4). 
More et al. (2001) used DXA to measure changes in the maternal skeleton (n=38) from pre- 
pregnancy and throughout lactation until 12 months postpartum. This study recruited only first 
time mothers. Lumbar spine (L2–L4) and forearm scans (ultra-distal radius and one-third radius) 
were obtained. During pregnancy DXA was only performed at the forearm. Significant decreases 
between pre-pregnancy and <6 days postpartum were found at the lumbar spine, ultra-distal radius 
(trabecular site) and one-third radius (cortical site) (all p<0.001, Table 2.4). A study by Butte et al. 
(2003) to evaluate how changes in gestational weight and body composition affect infant birth 
weight and maternal fat retention after delivery collected DXA data in underweight, normal-weight 
and overweight US women. Significant differences in BMC were observed between BMI groups 
before pregnancy (p=0.001). After delivery maternal whole body aBMD had significantly decreased 
in each BMI category from pre-pregnancy (Table 2.4). 
Kaur et al. (2003b) explored longitudinal aBMD changes from pre-pregnancy to shortly 
postpartum in the same population on which they previously published BTM changes during 
gestation (Kaur et al., 2003a). DXA data were collected from 46 women who became pregnant and 
30 controls who did not conceive. Non-significant declines in aBMD were observed at the spine 
(L1–L4), total hip, femoral neck, and trochanter. However, a significant difference was seen at the 
trochanter between those who did and did not become pregnant (p<0.01). The same group 
subsequently reported that in 60 women measured from preconception to 2 weeks postpartum 
significant decreases in aBMD occurred at the lumbar spine (p<0.01), total hip (p<0.05) and 
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trochanter (p<0.001) while change at the femoral neck was not statistically significant (Kaur et al., 
2003b, Pearson et al., 2004)(Table 2.4). 
Two studies stand out in the literature due to their large sample size and large number of 
representative NPNL controls. Olausson et al. (2008) scanned 34 pregnant participants pre- 
pregnancy and at 2 weeks postpartum, 84 NPNL participants were also scanned with a similar time 
difference between visits. BA-corrected BMC in this study was used to allow for the known 
relationship between BMC and scanned bone area (BA) that is not fully accounted for in the 
measure of aBMD (Dibba et al., 1999, Olausson et al., 2008). Pregnant participants had statistically 
significant decreases in BA-adjusted BMC for total body (p<0.001), spine (p<0.01), total hip 
(p<0.001), trochanter (p<0.001), femoral neck (p<0.05) (Table 2.4 below). However, the authors 
noted that there was considerable between-subject variation in bone change. These findings are 
supported by those of Moller et al. (2012) who obtained longitudinal DXA measures at the lumbar 
spine, hip and whole body from pre-pregnancy (with forearm scanned during pregnancy) and then 
in multiple time points during lactation, additionally 75 NPNL women were followed up 
concurrently. Compared with NPNL participants the pregnant women showed decreased aBMD 
at all sites 15 days after delivery (p<0.01) (Moller et al., 2012). Furthermore, aBMD measures were 
taken at the distal, one-third proximal, and total forearm during pregnancy with decreases reported 
(p<0.001) (Table 2.4). As noted above Moller et al. (2013) also measured BTMs during pregnancy 
finding that BAP was significantly lower in the pregnant women compared to NPNL while urinary 
NTx/Creatinine ratio was significantly higher (both p<0.05), adding further support to the 
possibility of skeletal changes occurring during pregnancy in this population (Moller et al., 2013). 
The largest significant mean change in maternal aBMD between pre-pregnancy and 2 weeks 
postpartum was reported by Fiore et al. (2003), (n=16). Significant decreases aBMD of total body 
(- 13.4%), the spine (-9.2%) and hip (-7.8% at the femoral neck and -9.2 % at Ward's triangle) were 
reported and while such changes appear implausibly large compared with other studies (perhaps 
suggesting technical problems), the same study obtained QUS data and showed a large BUA 
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decrease (-14.5%) concurrent to the DXA findings. Given that DXA and QUS typically have weak 
to moderate correlation, it is difficult to confirm the validity of these data and even in the context 
of mineral mobilisation during lactation these changes seem very large. 
Two additional studies found similar differences to those described above but were conducted in 
two slightly different groups of women that potentially differ from the general population. It is 
important to consider that an underlying hormonal problem can affect normal bone turnover and 
may confound pregnancy-induced bone mineral changes. Black et al. (2000) followed 10 patients 
attending recurrent (≥2 previous) miscarriage clinics. The authors reported oestrogen levels, 
thyroid function, follicle-stimulating hormone, and luteinising hormone were all normal in the 
study population. Significant decreases were found by 6 weeks postpartum at the spine, total hip, 
trochanter, and femoral neck. However with such a lengthy follow-up postpartum these data are 
highly confounded by lactation (p<0.05). Ulrich et al. (2003) recruited patients attending fertility 
clinics (n=7), some of whom were on treatment, and healthy, normally-menstruating women (n=8) 
planning a pregnancy through natural conception with no previous history of infertility. NPNL 
controls (n=15) were also recruited. By two weeks postpartum statistically significant decreases at 
the spine (p<0.01) and trochanter (p<0.001), while an increase was reported at the radial shaft 
(p<0.05). The authors did not investigate whether any differences could be found between the 
women with a history of fertility problems and those who did not (Ulrich et al., 2003). 
In summary, the fact that these studies have consistently shown decreases in trabecular-rich bone 
sites from preconception to shortly postpartum, with the women acting as their own controls or 
with an NPNL group scanned at concurrent time points, seems to support that maternal bone 
mineral is released from the maternal skeleton. However, these data unfortunately cannot tell us 
whether the changes observed occur during the pregnancy or occur in the immediate postpartum 
period because mineral is lost from the maternal skeleton at the onset of lactation. Despite this 
common limitation, these studies, especially those with accompanying measures of BTM, provide 
at present some of the best evidence for changes in maternal bone mineral during pregnancy. 
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Olausson and colleagues reported a decrease of approximately 2% in whole body aBMD which 
would equate to ~25 g of Ca being mobilised from the maternal skeleton, which, interestingly, is 
close to the approximate Ca content of the fetal skeleton at term (Olausson et al., 2008).   
2.4.2.1 DXA of the appendicular skeleton during pregnancy  
The second important body of densitometry data comes from studies that used DXA and its 
precursors to image the appendicular skeleton during pregnancy. There is some overlap with the 
studies listed in Table 2.4, however, several of these studies of the peripheral skeleton lack pre- 
pregnancy or postpartum data. Data discussed here are from forearm SPA, DPA, and DXA scans 
(Figure 2.5) and should not be confused with studies performing sub-regional analysis of whole 
body scans. Data are presented as change in aBMD, with data from forearm scans reported from 
the ultra-distal radius, one-third distal radius and/or the mid radius (radial shaft). The terminology 
used to describe these sites differs between studies but simply put the distal radius contains a 
relatively high proportion of trabecular bone and a thin cortex, progressing proximally the cortex 
thickens and the amount of trabecular bone diminishes greatly (Figure 2.6). Importantly, the distal 
radius is a common fracture site in later life 
The data are inconclusive with most studies finding no significant change across pregnancy (Table 
2.5). However, the findings of both Kolthoff et al. (1998) and Moller et al. (2012) in Danish women 
suggest changes could take place during pregnancy at the radius. Kolthoff et al. (1998) reported 
changes at the ultra-distal radius during pregnancy amounting to a 2% reduction in aBMD within 
2 weeks postpartum. Moller (Moller et al., 2012) also investigated several sites at the forearm (ultra- 
distal, proximal 1/3 distal forearm, and total forearm) during pregnancy. At the ultra-distal forearm, 
measurements performed during pregnancy showed a progressive aBMD reduction compared with 
the NPNL group (p<0.001). Total forearm aBMD was also reported to decline in late pregnancy 
however this is likely a reflection of the changes at the ultra-distal radius. This highlights the 
limitations of aBMD at the total forearm as measured by DXA because it is unable to distinguish 




Figure 2.5 DXA scan of the forearm, highlighting the regions of interest (ROI) that are analysed.  
 
pQCT scans are shown adjacent for context and to highlight the relative proportions of each type of bone at these 
sites.  The distal radius is a relatively trabecular-rich site (top right), while the 1/3 proximal radius, is a cortical-rich 
site (bottom right). The analysis of the total forearm ROI includes both these regions and as such is an admixture 
of both compartments.  
 
 
2.4.3 Peripheral QCT techniques and pregnancy-related changes in vBMD  
pQCT techniques provide measures and estimates of bone size, shape, mineral content, while 
HRpQCT additionally assesses cortical and trabecular microarchitecture. Furthermore the data 
acquired are not as size-dependant as aBMD from DXA, and provide a compartment-specific 
measures (i.e. cortical and trabecular bone) of density, mass, bone size, shape and distribution. 
Despite these advantages, to date only one study has used a pQCT technique (Densiscan 1000, 
Scanco Medical) in pregnancy (Wisser et al., 2005). Their method differs from the single slice 
systems discussed previously (see section 1.5.3) and was the precursor of the modern Scanco 
HRpQCT systems. The Densiscan had a voxel size of 0.3mm is similar to that of single-slice pQCT 
techniques, but rather than a single slice a stack of tomograms are acquired (slice thickness 1mm, 
interslice distance 1.5mm). In-keeping with single-slice pQCT the resolution of this technique is 
too low to make simultaneous measurements of trabecular and cortical bone: trabecular vBMD is 
obtained at the ultra-distal radius; cortical vBMD was measured closer to the bone diaphysis. 
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(Dambacher et al., 1998). The authors reported wide inter-individual variation in trabecular vBMD 
with significant decline between the 1st and 3rd trimesters (p<0.001). No significant changes were 
noted in the cortical compartment of the radius. Whilst no data have been published to date using 
single-slice pQCT or HR-pQCT in pregnancy, HRpQCT has recently been used in a number of 
studies during lactation where changes in trabecular and cortical microarchitecture in the 
appendicular skeleton are reported. These studies add to the already large body of literature of 
lactation related bone changes and are beginning to provide a better understanding of whether full 
repletion of lactation-mobilised bone mineral occurs (Brembeck et al., 2014, Bjornerem et al., 
2017).  
2.4.4 QUS to measure surrogates of BMD during pregnancy 
Qualitative Ultrasound (QUS) has been used to quantify changes in bone during pregnancy as it is 
non-invasive, non-ionising, and inexpensive. QUS is used at peripheral sites that have little soft 
tissue to interfere with attenuation such as the calcaneus, phalanges, tibia, and radius. Several 
studies suggest there are decreases in QUS measured SOS (speed of sound) and BUA (bone 
ultrasound attenuation) parameters of bone quality during pregnancy at the calcaneus and 
phalanges (Table 2.6) (Yamaga et al., 1996, Akesson et al., 2004, Javaid et al., 2005, To and Wong, 
2011, Kraemer et al., 2012, Hellmeyer et al., 2014, Whisner et al., 2014). However, Fiore et al. 
(2003) who also used DXA pre- and post-pregnancy (Section 2.4.2) used calcaneal QUS pre- 
pregnancy and at 16, 26, and 36 weeks of gestation and <2 weeks postpartum. They found no 
significant changes across pregnancy but reported a significant BUA decrease of 14.5% postpartum 
(Fiore et al., 2003). The lack of change during the pregnancy time points observed may suggest that 
if losses occur in gestation they may be quite late towards the second half of the 3rd trimester or 
postpartum. However, it may also be the case that perhaps the calcaneus is not truly representative 
of the changes occurring elsewhere in the skeleton. 
QUS parameters from the phalanges have been reported to progressively decrease from the first 
trimester into the second and third trimesters. Hellmeyer et al. (2006) reported AD-SOS (amplitude 
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dependant-SOS) was significantly lower in the second and third trimesters compared to the first 
(p≤0.001) and that bone transmission time (BTT) decreased significantly in second and third 
trimesters (p≤0.001). Della Martina et al. (2010) also reported a progressive decrease of BTT from 
the first to the third trimester, however, AD-SOS remained unchanged between the first and 
second trimester only dropping in late pregnancy. Pluskiewicz et al. (2004) performed in each 
trimester reporting significant differences between 1st and 2nd AD-SOS measurements (p<0.01), 2nd 
and 3rd, and 1st and 3rd (both p<0.001). A significant difference between 1st and 2nd trimester 
diameter (p<0.001) and 2nd and third trimester finger diameter (p<0.001), would indicate changing 
soft tissue composition at the scan site. Similarly, as oedema around the lower limbs is common 
during pregnancy, additional soft tissue may interfere with sound wave attenuation and resulting 
QUS data. While this may affect techniques that scan at the calcaneus or phalanges, techniques that 
scan the radius or tibia are less effected. An important caveat regarding the usefulness of QUS 
during pregnancy comes from the literature of bone mineral changes in lactation. During lactation, 
bone mineral mobilisation from the lumber spine was detected with DXA, but QUS did not find 
a concurrent change at the calcaneus in the same women (Laskey and Prentice, 2004). This cautions 
against extrapolating from QUS measures in the peripheral skeleton to those that may occur in the 
axial skeleton with DXA. 
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Table 2.5  Investigation of bone mineral changes in the maternal appendicular skeleton (radius) during pregnancy 




Authors Country, n Modality and measurement Pre-preg/NPNL T1 T 2 T3 PP 
Christiansen et al. (1976) Denmark, n=13 SPA: UD, One-third distal, RS No  - -  
Kent et al. (1993) Australia, n=37 SPA: UD, One-third distal, RS No  - -  
Cross et al. (1995) USA, n=10 SPA: UD, One-third distal NPNL - - -  
Kolthoff et al. (1998) Denmark, n=59 DXA: UD, One-third distal Yes  -  2% ↓ vs 18wks 
Black et al. (2000) USA, n=10 DXA: UD, One-third distal, RS Yes - - -  
More et al. (2001) Hungary, n=38 DXA: UD, One-third distal Yes  NS  ↓ at 1wk vs 6 mo 
Moller et al. (2012) Denmark, n=153 DXA: UD, RS NPNL progressive ↓ in UD BMD vs NPNL (p<0.001) 
Pre-preg = Pre-pregnancy,T1 = 1st trimester, T2 = 2nd trimester, T3 = 3rd trimester, PP = postpartum, DPA = Dual Photon Absorptiometry, DXA = Dual-energy X-ray Absorptiometry, SPA = Single Photon Absorptiometry, RS = 
radial shaft, UD = ultra-distal 
 
Author Country Site T1 T2 T3 PP 
 Hellmeyer et al. (2014) Germany, n=125 calcaneus - - ↓  
Whisner et al. (2014) USA, n = 156 calcaneus Significant ↓ in SOS, BUA, and QUI across pregnancy  
Kraemer et al. (2012) Germany,  n=200 calcaneus - - - Median ↓ SOS  vs T1 
Della Martina et al. (2010) Finland, n=59 phalanges - BTT ↓ BTT & AD-SOS↓ at term  
Hellmeyer et al. (2006) Germany,  n=60 phalanges - BTT & AD-SOS ↓ vs T1 BTT & AD-SOS ↓ vs T1  
Javaid et al. (2005) UK, n=307 calcaneus - - ↓ SOS & BUA vs early preg  
Akesson et al. (2004)  Sweden, n=254 calcaneus - - NS vs early preg Stiffness index ↓ vs T1 
Tanquilli et al. (2004) Italy, n=200 phalanges AD-SOS ↓ AD-SOS ↓ AD-SOS ↓  
Pluskiewicz et al. (2004) Poland, n=48 phalanges ↓ ↓ ↓ - 
 Fiore et al. (2003) Italy, n=16 calcaneus No significant change during pregnancy ↓ 
To et al. (2003)  China, n=780 calcaneus Significant ↓in simulated  BMD across pregnancy  
Yamaga et al. (1996)  Japan, n=18 calcaneus - - SOS ↓ vs T1  
Note BMD cannot be measured with QUS and simulated BMD is not a true measure of bone mineralisation. T1 = 1st trimester, T2 = 2nd trimester, T3 = 3rd trimester, PP = postpartum, QUS = qualitative ultrasound, BUA =bone 
ultrasound attenuation, SOS = speed of sound, AdSOS = amplitude dependant speed of sound, BMD = bone mineral density, BTT = Bone Transit Time 
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 Discussion and conclusions  
The evidence of pregnancy-induced maternal bone mineral mobilisation comes from studies using 
diverse techniques including bone turnover and biochemistry (section 2.3.1), bone densitometry 
and QUS (sections 2.4.2, 2.4.3 & 2.4.4), and bone histomorphology (section 2.4.1). When these 
data are carefully considered in the context of known pregnancy-induced adaptions in Ca 
homeostasis (section 2.3), there appears to be a reasonable case for pregnancy-induced maternal 
skeletal adaptation to satisfy at least a proportion of fetal Ca requirements. While few data at present 
support early-pregnancy bone mineral mineralisation when fetal Ca accrual and requirement are 
low (Purdie et al., 1988, Shahtaheri et al., 1999, Whisner et al., 2014), a strong case can be made for 
transient mineral mobilisation from the maternal skeletal reserves in late gestation when Ca transfer 
and accretion peak (section 2.3). Due to a lack of densitometry during pregnancy the primary 
question of this work remains unanswered: Is maternal bone mineral mobilised during pregnancy? 
If mobilisation does occur few data are available to explain from where in the maternal skeleton 
(axial vs appendicular sites; trabecular vs cortical compartment) this increased resorption happens 
due to the global nature of BTM and our present inability to make axial measures during pregnancy. 
Data presented in Table 2.4 reflect the cumulative effects of pregnancy and early-lactation, losses 
occur mostly at trabecular-rich skeletal sites, in-keeping with data from studies of breastfeeding. It 
is impossible to determine to what extent the initiation of lactation has confounded these data. The 
data presented in Tables 2.5 and 2.6 from peripheral DXA scans of the forearm and QUS of the 
calcaneus and phalanges during pregnancy are inconclusive, in part due to the limitations of the 
techniques used. Peripheral DXA scans provide an aBMD measurement without additional context 
of bone shape or mineral distribution, the inability to make independent measures of the respective 
bone compartments could potentially cloud any redistribution of mineral from one to the other. 
Interestingly Moller et al. (2012) reported significant progressive decreases in aBMD at the 
trabecular-rich distal radius (but not the radial shaft) during pregnancy, which is in keeping with 
the pattern from trabecular sites in Table 2.4. Body composition changes during pregnancy may 
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interfere with the precision and accuracy of QUS, while how well changes in QUS parameters 
reflect any changes in the axial skeleton is questionable. 
pQCT techniques although not widely used in the literature overcome a number of the limitations 
of DXA and QUS. Wisser et al. (2005) using an early pQCT modality (limited to measures of 
vBMD only) reported compartment-specific changes during pregnancy, with wide inter-individual 
variance found in trabecular vBMD without change in cortical vBMD. However, the cortical site 
scanned with this technique is still relatively distal and more accurate measures would be obtained 
if the cortex was measured at its thickest closer to the midshaft of the bone. Single-slice pQCT 
scanners can provide additional parameters beyond vBMD such as bone mass, geometry, 
distribution and strength at both trabecular- (distal) and cortical-rich (proximal) sites. Another 
advantage is that any site along the length of the bone can be selected for scanning. However, 
single-slice pQCT does not have sufficient resolution to detect changes in bone microstructure, 
such adaptations could occur without overt changes in vBMD. HRpQCT has been used to show 
changes in both cortical and trabecular compartments during lactation (Brembeck et al., 2014) and 
provides micro-architecture data such as trabecular thickness, number and separation in addition 
to cortical thickness and porosity. 
There is a genuine need to establish whether maternal skeletal adaptations occur across gestation. 
Ca is a vital mineral to bone health and were pregnancy to temporarily disrupt maternal reserves it 
is important to understand to what extent it may happen. Pregnancy and lactation are not 
considered risk factures for osteoporosis, and lactation associated maternal bone mineral 
mobilisation has been repeatedly found to be mostly transient in nature (Laskey and Prentice, 1999, 
Olausson et al., 2008, Laskey et al., 2011, Moller et al., 2012), however, a recent study which 
followed up women over five years has hinted towards the possibility of lasting skeletal micro- 
architectural adaptations following lactation (Bjornerem et al., 2017). In the context of maintaining 
optimal bone health across the lifecourse, if changes occur as a result of pregnancy and indeed 
lactation, the replenishment of any mineral mobilised from the maternal skeletal reserves prior to 
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reaching menopause may be important for bone health in later life. The majority of studies 
described above recruited women in their 20’s – 30’s, there are limited data on reproduction and 
bone health during adolescence and no studies have specifically focused on women who conceive 
at an advanced maternal age (>35 years). In 2016 54% of all live births in England and Wales were 
to women aged >30 years. It is likely that the proportion of women having pregnancy later in life 
will continue to rise in the future. In addition to this age-bias, the majority of studies are in: 
a) High income counties (HIC); 
b) Women of European ancestry; 
c) Populations with habitually high Ca intakes. 
Consequently most of the studies cited above are from Europe, North America, and Japan, with 
few data available are available from LMIC in Africa and Asia. Whatever the barriers to such studies 
being conducted the result is an almost complete lack of data of bone mineral homeostasis during 
pregnancy and lactation in populations of different ethnicities and with low habitual Ca intakes. 
Given our knowledge of ethnic differences in BMD, bone geometry and other bone structural 
parameters, we cannot confidently apply findings from HIC countries with populations of 
predominantly European ancestry to other ethnic groups. With the available data also primarily 
drawn from Ca replete populations, we do not know if fetal demand for Ca places mothers with a 
habitually low Ca intake under increased pressure during pregnancy.  
 
 Thesis objectives 
The overarching aim of my PhD research was to determine whether a maternal skeleton response 
resulting in the mobilisation of bone mineral occurs during pregnancy, using non-invasive pQCT 
(single slice- and HRpQCT) techniques. Both studies presented in this thesis are formed around a 
shared primary research question: is bone mineral mobilised from the maternal skeleton between 
early- and late pregnancy? Each study also aims to contribute towards bridging some of the major 
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research gaps highlighted in the above discussion. The ENID Bone Study presented in chapters 3 
and 4 is from a Sub-Saharan subsistence farming community in The Gambia, a LMIC resource-
poor country with a notably low habitual Ca intake.  The Pregnancy and Bone study (PABS) was 
conducted in Cambridge, UK and focused on women aged 30-45 years to explore mineral 
adaptations in pregnancy in women with a higher maternal age than found in the majority of the 
available literature.  
 
2.6.1 Primary thesis objective 
This primary objective of this research was to characterise whether changes occur in the maternal 
appendicular skeleton by measuring total and trabecular vBMD with pQCT (in both the Gambian 
and Cambridge studies), and HRpQCT (in our Cambridge cohort). HRpQCT also allowed for the 
investigation of change in trabecular microarchitecture during pregnancy at the distal radius and 
tibia.  
 
2.6.2 Secondary thesis objective 
My secondary objective focused on cortical bone and whether any skeletal adaptions occur during 
pregnancy at cortical-rich sites of the proximal radius and tibia using pQCT (in the Gambian and 
Cambridge cohorts) and at distal radius and tibia with HRpQCT (in the Cambridge cohort) to 
determine if changes in the cortical microarchitecture may occur.  
 
2.6.3 Thesis Aims  
My aims were to determine: 
1. Bone mobilisation from the trabecular compartment at the distal radius and tibia between 
early- to late-gestation in: 
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a. A sub-Saharan African population taking part in a 4-way supplementation trial 
using pQCT at the distal radius and tibia (total and trabecular vBMD) 
b. A Cambridge based cohort using pQCT at the 4% distal radius and tibia (total & 
trabecular vBMD) and HRpQCT (trabecular vBMD, trabecular microarchitecture: 
number, thickness, and separation).  
2. Whether changes occur in the cortical compartment from early- to late-gestation in: 
a. Both cohorts using pQCT at the proximal radius and tibia with a focus on cortical 
vBMD and other parameters of bone geometry, mass and distribution (total and 
cortical cross-sectional area, cortical content (BMC), cortical thickness). 
b. Cambridge using HRpQCT to determine cortical vBMD & cortical 
microarchitecture (thickness & porosity). 
3. To determine any predictors of change in 1. and 2. with a specific focus on: 
a. Supplement, parity, and age effects in the ENID cohort 
b. Maternal age in the PABS cohort  
4. To examine the correlation between pQCT and HRpQCT in-vivo measurements in the 




3 ENID Bone Study pQCT Subjects and Methods 
 Introduction  
As outlined in Chapter 2 there are few data from which to quantify a maternal skeletal response to 
pregnancy. However, there are indications of change in maternal bone turnover from bone 
turnover markers. The current evidence base is highly skewed towards high-income countries 
(HIC) with predominantly Caucasian cohorts. No densitometry data have been collected from 
pregnant Sub-Saharan populations living in low and middle income countries (LMIC). The data 
presented here were collected as part of a bone-focused add-on study (PI Prof Ann Prentice) to 
The Early Nutrition and Immune Development (ENID) Trial (PI Dr Sophie Moore, 
ISRCTN49285450). ENID was a longitudinal randomised controlled trial of nutritional 
supplementation which ran from April 2010 in the rural West Kiang region of The Gambia to 
investigate the effects of ante-natal and infant nutritional supplementation on infant immune 
development. The ENID-Bone add on study was to investigate the effects of nutritional 
supplementation on the maternal skeleton and on infant bone development The ENID Trial was 
approved by the joint Gambian Government/MRC The Gambia Ethics Committee (Project 
number SCC1126v2); ENID Bone Study (L2009.66). Data collection took place in a rural 
subsistence farming community located along the river Gambia and its tributaries. The Gambia lies 
just north of the equator at latitude 13oN (Figure 3.1). The study population included all 36 villages 
currently registered within the West Kiang Demographic Surveillance System (DSS; total resident 
population approximately 15,000). 
Following ethical approval local communities were approached and with permission, all women of 
reproductive age (18-45 years) were invited to participate in the study; eligible pregnant women 
received one of 4 antenatal nutritional supplements from <20 weeks of pregnancy until delivery 
(Table  3.1 & 3.2, Figure 3.2) (Moore et al., 2012). The ENID Trial aimed to recruit up to 1000 
pregnant women, to allow for a maximum attrition rate of 20% from withdrawals, out-migrations, 
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pregnancy losses, and infant deaths. Eight hundred and seventy five women were randomised into 
the main trial, and there were 799 live births. It was anticipated that not all participants would 
consent to additional measures and participation in the ENID Bone add-on study, however, the 
majority did and subsequently entered the ENID Bone study. 
The ENID Bone add-on study was powered to detect postpartum changes in maternal DXA bone 
and body composition outcomes. To calculate the minimum differences between pairs of 
supplement group that would be detectable, population variance data were used from a previous 
study of mothers and infants in the same region of The Gambia (Calcium Supplementation in 
Pregnancy, SCC585; ISCRTN96502494). To detect significant changes at the lumbar spine with 
p=0.05 and 80% power a sample size of 800 (200 per group) and 400 (100 per group) were required. 
pQCT was used to collect densitometry data from the radius (3 sites) and tibia (4 sites) at 3 
pregnancy time points: Booking (at approximately 14 weeks of pregnancy; 20 weeks of pregnancy 
(P20) and 30 weeks of pregnancy (P30). This was both the first application of pQCT in a cohort 
of Sub-Saharan pregnant women, and one of few studies to investigate the maternal skeletal 
response to pregnancy in a non-Caucasian population. The collection of pQCT data in the ENID 
Bone study provided a unique dataset to investigate the potential maternal skeletal response to 
pregnancy in a Sub-Saharan African population with a habitually low Ca intake. My role in the 
ENID Bone Study was to a) design specific pQCT pregnancy-related questions, b) analyse and QC 
all of the 9,159 pQCT scans and c) produce and analyse the subsequent pQCT dataset. The pQCT 
scans and other data required for my research were provided to me courtesy of Prof Ann Prentice.  
3.1.1 Primary hypothesis  
My primary hypothesis was that bone mineral mobilisation would occur between mid- to late-
pregnancy from trabecular-rich skeletal sites in the maternal appendicular skeleton. This 
mobilisation would be observable through a decrease in both total and trabecular vBMD at the 
distal radius and tibia. I also hypothesised a potential supplement modulation of pregnancy-induced 
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vBMD change in which groups receiving the food supplement that provided additional protein 
and energy, but contained no Ca (see section 3.2.1.4), would have a greater decrease in vBMD due 
to the displacement of Ca from the maternal diet. 
 
3.1.2 ENID Bone Study pQCT aims  
My aims were to determine in the ENID Bone Study population whether: 
1. Maternal bone mineral is mobilised from trabecular-rich appendicular sites (4% distal 
radius and tibia) between mid- to late-pregnancy (i.e. a decrease in trabecular vBMD)  
2. Pregnancy-induced changes occur in other parameters of bone strength between mid- and 
late-pregnancy, at: 
a. The trabecular-rich distal radius and tibia (total CSA and total vBMD) 
b. The cortical-rich proximal radius and tibia (total CSA, cortical CSA, cortical vBMD, 
cortical BMC, cortical thickness) 
3. Maternal antenatal supplementation or other environmental factors modulate the maternal 
skeletal response to pregnancy.  
3.1.3 ENID Bone Study pQCT primary objective 
My primary objective was to analyse the pQCT data from trabecular-rich distal sites at the radius 
and tibia to determine if a statistically significant decrease in trabecular vBMD could be observed 
between mid- and late- pregnancy, with any potential supplement modulation of a maternal skeletal 
response to pregnancy would be explored  
 
3.1.4 ENID Bone Study pQCT secondary objectives 
Secondary objectives were to explore: 
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1. Whether changes occur in the cortical compartment of the maternal skeleton as measured 
by pQCT at the proximal 33% radius and tibia through decreases in cortical vBMD, total 
CSA, cortical CSA, cortical BMC, and cortical thickness between Booking and P30. 
2. If changes in trabecular and cortical parameters are consistent at;  
a. The distal radius (non-loadbearing) and distal tibia (loadbearing) 
b. The proximal radius (non-loadbearing) and proximal tibia (loadbearing) 
3. Whether the  following are determinants of the above pQCT bone outcomes:  
a. Age 
b. Parity 
c. Change in maternal weight 
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 Study design and data collections 
The following sections provide an account of the design of the ENID Trial and the ENID-bone 
add-on study plus the methods used to collect the data provided to me for my research. 
 
3.2.1 Selection of subjects 
3.2.1.1 Recruitment  
The main ENID Trial aimed to have complete data for 800 mother-infant pairs, 875 rural Gambian 
women were randomised into the main trial, and there were 799 live births. Eligibility criteria are 
outlined in Table 3.1. All women in the main trial were invited before the start of supplementation 
to participate in the ENID Bone add-on; 811 were recruited to the ENID Bone study.  
Table 3.1 Inclusion and exclusion criteria for enrolment into the ENID Trial 
Inclusion Criteria Exclusion Criteria 
Aged 18-45 years Currently pregnant beyond 20 weeks on ultrasound assessment 
Living in the West Kiang DSS area Currently enrolled in another MRC study 
 Severe anaemia at booking (haemoglobin (Hb) less than 7 g/dL) 
 Onset of menopause 
 
3.2.1.2 Consent  
Informed consent was obtained by trained field workers who explained the study to potential 
participants in their native language, covering all aspects detailed in the participant information 
sheet (PIS). Questions that arose during the process were answered by the field worker or if 
necessary referred to the PI for clarification. Participants had the opportunity to speak to a study 
investigator (PI, study midwife or study clinician) if they wished. Written consent was obtained, 
through either a signature or a thumb print (illiterate participants).   
3.2.1.3 Randomisation  
Following enrolment participants were visited monthly by a member of the study team with a short 




a urine sample was collected for pregnancy testing using hCG tests (QuickVue™ One-Step hCG 
Urine Test, bioMérieux, UK). Women who tested positively were invited to MRC Keneba for an 
ultrasound examination, if confirmed as being between 10-20 weeks pregnant, the participant was 
randomised into the trial, and arrangements made for the Booking measurements to be conducted. 
Supplementation commenced the following week. Randomisation into the trial took place in blocks 
of 8 with the use of an automated system, with the eight groups reflecting the 8 possible 
combinations of prenatal and infancy supplements, a simplified version of this is shown in Figure 
3.2 where only the antenatal groups are shown. The 4 maternal supplements were lipid-based 
protein-rich energy and protein supplement (PE), a multi-micronutrient supplement (MMN), these 
two supplements combined (PEMMN), and iron-folic acid (FeFol). More details are given in the 
next section. 
3.2.1.4 Supplement Groups in the ENID Trial    
Supplementation began at <20 weeks pregnancy, the week after the Booking measurements were 
completed. Current national policy in The Gambia recommends a daily supplement of 60 mg iron 
and 400 μg folate (FeFol) to all pregnant women, with the primary aim of reducing iron deficiency 
anaemia. At booking eligible women were randomised to one of 4 intervention arms (Table 3.2, 
Figure 3.2): Iron and Folate (FeFol) as per Gambian Government guidelines; Multiple 
micronutrients (MMN) a combination of 15 micronutrients specifically designed for use in 
pregnancy, as formulated by UNICEF/WHO/UNU. MMN were supplemented at twice the 
recommended daily allowance (RDA) and equal iron and folate to the FeFol arm (Moore et al., 
2012); Protein-energy and iron-folate (PE+FeFol) a lipid based nutritional supplement (LNS) 
providing equal iron and folate to the FeFol arm, with additional energy (746 kcal), protein (20.8 
g), and lipids (52.6 g); Protein-energy and multiple micronutrients (PE+MMN) a micronutrient 
fortified LNS supplement providing the same level of micronutrients as the MMN arm in addition 




The antenatal arm of the trial was partly open, it was not possible to blind the field assistants or 
the women to the supplement type (Tablet vs. LNS, Figure 3.3). All other investigators were 
blinded to which supplement group the women belonged. The supplements were administered to 
participants on a weekly basis by field assistants posted to the community. Supplement compliance 
was assessed by the collection of all unused supplements at the end of each week. Random spot 
checks to assess used and unused supplements were performed on 10% of participants each week 




Figure 3.2 Flow diagram of the ENID Trial detailing the antenatal supplement arms. 
LNS = lipid nutritional supplement, FeFol = iron folate, MMN = multiple micronutrients, PE = protein energy, PEMMN 





Table 3.2 Nutritional composition of daily intake of pregnancy supplements (Moore et al., 2012).  
 
 
Figure 3.3  Field workers assessing compliance and examples of the tablet and LNS supplements. 
Supplement compliance being assessed by the collection of all unused supplements at the end of each week (above), 
tablet supplements (FeFol and MMN, below left), lipid nutritional supplement (LNS, below right). FeFol = iron folate, 
MMN = multiple micronutrients, PE = protein energy, PEMMN = protein energy multiple micronutrients
Nutrients FeFol MMN PE PEMMN 
Iron (mg) 60 60 60 60 
Folate (μg) 400 400 400 400 
Vitamin A (RE μg)  0 1600 2.85 1600 
Vitamin D (IU)  0 400 0 400 
Vitamin E (mg)  0 20 4.2 20 
Vitamin C (mg)  0 140 2.25 140 
Vitamin B1 (mg)  0 2.8 0.3 2.8 
Vitamin B2 (mg)  0 2.8 0.45 2.8 
Niacin (mg)  0 36 1.35 36 
Vitamin B6 (mg)  0 2.8 0.15 2.8 
Vitamin B12 (μg)  0 5.2 0.1 5.2 
Zinc (mg)  0 30 3.3 30 
Copper (mg)  0 4 1.05 4 
Selenium (μg)  0 130 6.15 130 
Iodine (μg)  0 300 2.6 300 
Energy (kcal) 0 0 746 746 
Protein (g) 0 0 20.8 20.8 
Lipids (g) 0 0 52.6 52.6 
All women received 60 mg Iron and 400 μg Folate. All women were randomised to supplementation from booking for antenatal care 
(<20 weeks gestation) until delivery. Nutrient levels across supplement groups are highlighted by colour (e.g.. all women receive equal 
iron and folate,  highlighted in yellow). FeFol = iron folate, MMN = multiple micronutrients, PE = protein energy, PEMMN = protein 




3.2.2 Research teams and sites 
The collection of all anthropometry and bone densitometry data took place at the MRC Unit The 
Gambia, Keneba. MRC Keneba is a rural field station situated in the Kiang West region, located in 
the village of Keneba, the largest village in the DSS. The Bakary Dibba Research Centre hosts the 
work of the Calcium, Vitamin D and Bone Health (CDBH) group, who conduct all the Gambian 
projects for Prof Ann Prentice (Figure 3.4).  The facility contains pQCT and DXA for assessing 
bone density, geometry and distribution, infant and adult body composition and there are fully 
trained, experienced Gambian staff who perform the scanning, under the guidance of Dr Kate 
Ward and Prof Ann Prentice.  
 
Figure 3.4 Women attending MRC Keneba for procedures during the ENID Bone Study. All densitometry data were 









Table 3.3 Members of the research team involved in ENID Bone Study pQCT component  
 
 Post Duties  
Mícheál Ó Breasail  PhD student  MRC EWL  ENID Bone pQCT Study design  
Research question design 
Data auditing ENID Bone pQCT 
Scan grading ENID Bone pQCT 
Scan analysis ENID Bone pQCT 
Post analysis processing pQCT 
Statistical analysis ENID Bone pQCT 
Prof Ann Prentice  Director and NBH CDBH Programme Head EWL/MRC Keneba ENID Bone study design and conduct  
Dr Landing Jarjou  Senior scientist, CDBH lead MRC Keneba ENID Bone study design and conduct  
Dr Kate Ward  Associate Professor: bone physiology MRC EWL  ENID Bone study design and conduct  
Dr Gail Goldberg  Senior scientist: population aspects EWL/MRC Keneba ENID Bone study design and conduct  
Dr Sophie Moore Senior Scientist, MRC Keneba, ENID Trial PI  ENID Trial  study design and conduct  
Yankuba Sawo  Bone Scanning Manager MRC Keneba Study conduct and scan acquisition 
Michael Mendy Senior imaging and records coordinator MRC Keneba  Scan acquisition 
Mustapha Ceesay Senior  imaging and sample coordinator MRC Keneba Scan acquisition 
Mariama Jammeh Field assistant/imaging team 
Fatou Manneh Field assistant/imaging team 
Isatou Camara Field assistant 
Darren Cole  Data Operations Manager  MRC EWL  Development of Microsoft Access 
tool for post analysis scan 
processing 
Aron Sherry  Research assistant  EWL Scan grading ENID Bone pQCT 
Lauren Oliver  Research assistant  EWL Scan grading ENID Bone pQCT 




 Outcome Measurements relevant to the pQCT study  
Anthropometric measurements including height, weight, forearm (ulna) length, lower leg (tibia) 
length, waist and hip circumference, mid-upper-arm circumference (MUAC), and body mass index 
(BMI) were obtained at Booking, P20, and P30 during pregnancy. pQCT was used to measure total 
area, total and trabecular volumetric bone mineral density (vBMD) at the distal radius and tibia, in 
addition to cortical vBMD and related parameters of cortical BMC, cortical CSA, and cortical 
thickness,  at the proximal radius and tibia. These outcome measures are summarised in Table 3.4 
and described in detail in Chapter 1. 
Table 3.4 Summary of study outcome measures recorded in the ENID Bone Study and respective units presented in 
Chapters 3 and 4 
Anthropometry Peripheral QCT  
Height (cm) Distal radius and tibia 
Weight (kg) Total bone density (mg/cm3) 
Radius length (mm) Trabecular density (mg/cm3) 
Tibia Length (mm) Total CSA (mm2) 
 Proximal radius and tibia 
 Cortical BMC (mg/mm) 
 Cortical density (mg/cm3) 
 Cortical CSA (mm2) 
 Cortical thickness* (mm) 
 Total CSA (mm2) 
* calculated using circular ring model (Chapter 1.4) 
 
3.3.1 Collection of anthropometric data  
Standing height was obtained without headwear or shoes under standardized conditions (horizontal 
Frankfort plane) to the nearest 0.1 cm by stadiometer (Magnimetre stadiometer; CMS Weighing 
Equipment Ltd) (Figure 3.5). Participants were instructed to remove footwear and to stand erect 
with feet together and with the posterior aspects of their heels and shoulders against the wall with 
knees and back straight. They were asked to bring their heads forward into the Frankfort plane (i.e. 
the line between the left eye and superior border of the external auditory meatus, was horizontal).  
Weight was measured to the nearest 0.1 kg while the subjects wore light clothing and no shoes 
using a digital scale (Wylux digital scales; CMS Weighing Equipment Ltd), routinely calibrated to 




Index (BMI) was calculated by dividing the participants weight (kg) by their height (m) squared, 
this was expressed in kg/m2.  
 
Figure 3.5 The measurement of standing height and weight during the collection of anthropometric data 
 
3.3.2 Bone Densitometry - pQCT scanning  
Peripheral pQCT data (Table 3.4) were obtained by trained technicians using an XCT 2000TM and 
an XCT 2000LTM bone densitometer (Stratec Medizintechnik, Pforzheim, Germany). All data were 
processed using the manufacturer’s software (Stratec XCT version 6.2.) and standard operating 
procedures (SOP_0373) were followed for all procedures at each time point. The procedure, 
including the initial scout scan and successive measurements were explained clearly to the 
participant prior to scanning. Participants were asked not to talk, and to avoid moving during the 
procedure.         
 
3.3.3 Limb length measurement  
Object length (to the nearest mm) measured using a tape measure between prominent bony 
landmarks. Participants were asked to remove footwear and clothing from the lower non-dominant 
leg unless impracticable (e.g. injury, metal implant) which was measured from the tibial plateau to 




participant seated, feet flat on the floor, and their lower leg at 90˚ to thigh. The length of the tibia 
was measured from the medial malleolus to the tibial plateau using a tape measure to record the 
distance of the straight line between these two points to the nearest 0.5 mm (Figure 3.6). Radial 
object length, at the non-dominant arm unless impracticable (as above),  was obtained with the arm 
on bent at a right angle, and the distance between the olecranon (near elbow) and the distal edge 
of the ulnar styloid process (bony prominence at wrist) measured with a tape measure to the nearest 
0.5 mm (Figure 3.6).  Scan sites were located by the pQCT scout view as a defined percentage of 
object (limb) length measured from a physiologically defined reference line at the distal end of the 
radius or tibia. 
 
Figure 3.6 Schematic diagram highlighting the physiological landmarks used to determine ulna and tibia length 
The correct measurement of ulna and tibia object length is important to ensure reproducible scans are acquired 
within participants and to ensure scan slices are obtained at the same percentage sites for all study participants. 
At the forearm the distance between A: the ulnar styloid process, and B: the olecranon was measured with a tape 
measure to provide the radius object length. At the lower leg the tibia object length was measured by tape measure 
from C: tibial plateau, to D: medial malleolus. Adapted from Madden et al. (2011) 
 
3.3.4 pQCT scan acquisition  
Scan sites and parameters are defined by the pQCT measurement mask, this was selected by the 
operator prior to scanning, entry of the object length in mm allowed the automatic calculation of 
appropriate scan sites. Scanning could begin once the operator ensured the limb was positioned 






process of the tibia or ulna respectively (Figure 3.7). First a scout view (SV) was obtained, this is  a 
3 cm coronal view, at the lower leg the distal joint surface of the tibia, fibula, and talus are visible; 
while at the forearm the distal surfaces of the radius, ulna, and the start of the ossa carpi can be 
seen (Figure 3.7).  An automatically placed reference line was visually assessed by the operator and 
correctly repositioned as appropriate (Figure 3.7). If there was difficulty identifying the correct 
region the participant was repositioned and the scout scan was repeated. 
                     
Figure 3.7 Scanograms or scout views at the forearm and lower leg as obtained with pQCT  
 
Scout views of the tibia (above) and the radius (below), “R” indicates the reference line in both scans. The tibia 
reference line should be placed in the middle of the distal end of the tibia as above. The cortical endplate of the 
radius is used as an anatomical landmark.          
  
Once the reference line was correctly positioned, the scan began (Figure 3.7). Scan sites (i.e. 
preselected percentages of the object length) were determined by the pQCT measurement mask 
selected by the operator prior to scanning. All scans were obtained using a voxel size of 0.5 mm 
and slice thickness of 2 mm. A CT scan speed of 30 mm/s was used for all slices, and a scout view 
speed of 40 mm/s was used for all scout views. Due to the resolution of XCT scanners specific 
sites are selected for the analysis of trabecular either or cortical bone.  In the ENID Bone study 
scans were acquired at 4%, 33%, and 66% radius, and at 4%, 38%, 50%, and 66% tibia (Figure 3.9). 
Scan images were visually inspected, as pQCT is very sensitive to movement resulting in scan 
distortion and movement artefacts (Figure 3.8), if a scan slice was of poor quality the participant 










doses of ionising radiation during scanning, a set of radius/tibia scans had an effective dose 
equivalent of <3.2 μSv per visit, the total exposure of 9.6 μSv from being scanned at all 3 time 
points, is the equivalent of a day and half of background radiation in Cambridge and considered 
very low. pQCT scanners have negligible scatter however, the fetus will be exposed to a very small 
amount of radiation because X-rays pass through the mother’s body – the calculation of fetal dose 
is discussed in detail in Chapter 6.   
 
Figure 3.8 Sites at which pQCT scans were obtained – with relevant cross-section:  
Above, Participant being scanned at the forearm with pQCT, in ENID Bone the RADIUS~1 mask was used and 
examples of scan images from the 4%, 33%, and 66% radius are displayed (right). Below, the same participant is 
being positioned for a lower leg scan, data from the lower leg were acquired using the TIBIAMRC mask: example 




3.3.5 pQCT Quality Assurance (QA)  
Daily QA scans were performed with a specifically designed phantom throughout the study period 
to test scanner performance. Weekly cone phantom scans were also performed on both scanners 
to ensure the linearity of the results and to confirm the precision of the repositioning of the scanner.  
During this procedure three different density ranges are measured (Figure 3.9).  Inter-operator 
coefficients of variation are tabulated below (Table 3.5). 
Table 3.5 Coefficients of variation for pQCT bone outcome measures  
Radius Tibia 
Bone outcome CV Bone outcome CV 
Total vBMD  2.1% Total vBMD  0.9% 
Trabecular vBMD  2.6% Trabecular vBMD  1.2% 
Total CSA 3.4% Total CSA  1.3% 
Cortical BMC 3.4% Cortical BMC 0.4% 
Cortical vBMD  1.1% Cortical vBMD 0.3% 
Cortical CSA  3.0% Cortical CSA  0.6% 
Cortical thickness  5.6% Cortical thickness  1.8% 
Total CSA  6.4% Total CSA  1.5% 
These were measured by performing repeated measures on 31 adult Gambian subjects, vBMD = volumetric bone mineral density, BMC = 
bone mineral content, CSA = cross-sectional area 
               
 
Figure 3.9 Standard QA scan (left), cone QA scan (right).  
QA scans were performed daily during the study period, while QC scans were acquired weekly. Any inconsistencies 




3.3.6 Post-hoc powering for ENID Bone pQCT data analysis  
The ENID Bone Study design was constrained by that of the main trial and was powered to detect 
changes in DXA-measured aBMD and body composition during lactation (see above). At that time, 
there were no suitable published pQCT data from pregnancy to base a formal sample size 
calculation on. Therefore, to establish whether meaningful changes in maternal bone during 
pregnancy would be detectable from the pQCT data, I calculated a post-hoc sample size using 
previous DXA data from our group. Those data showed significant changes in maternal BMC, 
measured by DXA, from a pre-pregnancy baseline measurement to shortly postpartum (Olausson 
et al., 2008). I used PS: Power and Sample Size Calculation version 3.1.2 (Dupont and Plummer, 
1998) to calculate the numbers required to reproduce the effect sizes seen by Olausson et al. (2008), 
a change in DXA lumbar spine size adjusted-(SA)BMC from pre-pregnancy to 2 weeks postpartum 
of -2.6% (±4.2). 188 per group would be needed to detect between-group differences with a power 
of 0.9, and alpha of 0.05, while for within-group differences with a power of 0.9, and alpha of 0.5, 
35 participants per group were required. This was a pragmatic approach in the absence of suitable 
pQCT data on which to calculate the sample-size for my analysis to detect meaningful change 
within-groups. 
 
3.3.7 Scan grading and processing of pQCT scans  
3.3.7.1 Post-processing - MRC Elsie Widdowson Laboratory (EWL) 
Cleaning and processing of the pQCT data was conducted at the MRC Elsie Widdowson 
Laboratory (EWL), Cambridge. This formed a central aspect of my training and involved the 
auditing and inspection of all collected ENID Bone Study pQCT data to ensure it was suitable for 
longitudinal analysis. This is a time intensive process where each scan is individually scrutinised but 
ensures that only data of the highest quality are included in the final dataset for analyses and 
involved: 1) auditing the scan record book against the scans on the pQCT software to identify 




longitudinally (Table 3.7); 3) Grading of each pQCT scan at each site of interest (Figure 3.11); 4) 
queries, i.e. following up missing scans, flagging errors in data entry, cross checking against data on 
MRC Keneba computers. 
This was performed for all pQCT scans collected in the ENID Bone study (n=9,159) and their 
scout views to assess their suitability for inclusion in the subsequent data analysis using an SOP 
(SOP_0373, SOP_0499) designed in-house by imaging experts at MRC EWL. Qualitative analysis 
of the scans through visual inspection defined whether a scan was suitable for inclusion or not 
(Table 3.6, Figure 3.12). Scans were examined for movement or other artefacts, scout views were 
scrutinised to ensure scans were obtained from the correct sites at each time point. Scout views 
were compared longitudinally to ensure scans could be used for analysis of change. Attention was 
also paid to each participant’s recorded object length as such errors may have led to the incorrect 
scan sites being scanned (Figure 3.11), in which case the bone outcome data were unusable and 







Figure 3.10 Flow diagram explaining the pregnancy pQCT data within the context of the ENID Trial and the ENID Bone add-on study  
Number of women who were recruited into the ENID Trial, who were subsequently entered the ENID Bone Study, and who had data collected during pregnancy are highlighted above. 
Loss to follow-up was generally due to self-withdrawal, out-migration, sickness, miscarriage.  A breakdown of pQCT data suitable for longitudinal analysis at each time point at each 




From the spreadsheet I maintained during the audit of participant CT (and scout views) numbers 
and scan grades I was able to write pQCT jobfiles to extract all useable scan data. This requires the 
definition of the appropriate macros and loops required to extract the data. All scans were 
processed using the manufacturer’s software (Stratec XCT version 6.2) which determines the 
standard analysis parameters, and is capable of segregating cortical and trabecular bone by using a 
number of predefined modes (Ferretti, 1999), Stratec XCT 2000L manual, Table 3.6).   
Table 3.6 pQCT analysis modes for standard analysis parameters using Stratec XCT software  
Mode Function  
ContMode Separates the surrounding soft tissue from the outer bone edge by applying a predefined 
threshold to eliminate voxels with an attenuation value below the threshold. 
PeelMode Separates the trabecular region from the cortical shell by stripping a selected proportion of the 
bone from the outer bone edge inwards assigning this as cortical-subcortical while the remaining 
inner portion is classed as trabecular bone. 
CortMode Separates the cortical bone from the subcortical bone by applying a threshold to peel away 
voxels with an attenuation value below the defined threshold, this obtains a cortical bone value. 
 
These modes are used to define the trabecular and cortical regions of interest (ROI) and to separate 
bone from soft tissue. The functions CALCD and CORTBD are applied to these regions to 
estimate total, trabecular, cortical-subcortical, and cortical vBMD, and the bone’s CSA (Ferretti, 
1999).  The thresholds (Section 1.5.3), analysis modes (above) were defined, and ROIs required for 
running the loop analysis to extract the pQCT bone parameters. At the distal sites CALCBD 
analysis using contour mode 1, peel mode 1 at a threshold of 180 mg/cm3 was used, trabecular 
bone was defined as the inner area of 45% of the total CSA. At cortical sites a threshold of 710 
mg/cm3 was selected in conjunction with CORTBD separation mode 1. Total CSA was defined at 
proximal sites at a threshold of 280 mg/cm3. To streamline the process of selecting and filtering 
the appropriate data from the raw pQCT output I assisted the MRC EWL Data Manager in the 
development of an in-house tool (Mr Darren Cole, MRC-EWL 2016) Microsoft Access (Microsoft 





Table 3.7 Grading of pQCT scout views and scan slice quality to determine if suitable for analysis. 
Grading of pQCT scout view examples in Figure 3.11 
0 Perfect: The reference line for the radius goes along the flattest part of the bone, the reference line for 
the tibia goes through the middle of the bone. 
1 Too distal/proximal: The reference is slightly higher/lower than it should be. 
2 Out of range: The reference line is not in the correct position at all.  
Grading of pQCT slices examples in Figure 3.11 
0 Perfect: No red streaks on the scan and the bone is in perfect shape (not distorted) 
1 Slight movement: Small amounts of red patches/steaks  
2* Medium “streaky” movement: Large “streaky” red movement patches, the shape of the bone is 
distorted due to movement and there may be small “breaks” in the scan image. 
3 Unusable: Red streaky patches covering most of the scan picture, the bone doesn’t look circular in 
shape- pulled by the movement, with large “breaks” in the scan image.   




Figure 3.11 Scan grading explained with examples from the forearm. 
Above: examples of graded scans at the 4% radius based on the criteria cited in Table 3.7. Middle and bottom left: 
scout views of the distal radius, “R” indicates the reference line and “M1” where the first measurement slice would 
be taken based on the reference line. Middle and bottom right scan slices from the distal radius that correspond to 
the scout views on the left. In (a) the reference line has been positioned too distally, grade “2”, with the 
corresponding slice being unusable. In scout view (b) the reference line is correctly positioned - grade “0”. 


















3.3.7.2 Differences between XCT pQCT scanners  
During the initial exploratory analysis of the pQCT data I observed a noticeable difference in bone 
outcome measures obtained from the XCT 2000 and XCT 2000L, with a tendency for data from 
the XCT 2000 to be higher regardless of time point or supplement group. Baseline scans were 
acquired at Booking prior to supplementation, and no between-group differences in any population 
baseline characteristics were found. The raw between-scanner percentage differences at Booking 
are summarised in Table 3.8, consistent differences were seen at all time points. While the study 
protocol had stipulated participants should be scanned consistently at each visit on the same 
scanner that was used for their scan at Booking. 158 participants were scanned on both scanners 
during the study partially due to downtime on the XCT 2000L. The proportions of participants 
with scans on both machines versus those with all their scans on either the XCT 2000 or XCT 
2000L were similarly distributed within the supplement groups at each visit (Table 3.9). To adjust 
for potential confounding due to scanner differences and to ensure that these between- scanner 
differences did not attenuate any potential pregnancy-induced effects a number of options were 
available. These options fell into two categories: 
1. Cross-calibrating the two scanners by collecting new data : 
a. Using an appropriate phantom such as the European Forearm Phantom (EFP) 
b. Performing in-vivo measures on a cohort of healthy adults on both scanners 
2. Adopting a statistical approach to adjust for the between-machine difference without the 
need to collect new scan data: 
a. Pooling historical data from previous studies using these two devices to determine 
an appropriate adjustment by which to calibrate the data.  
b. A study-specific approach by which data from one scanner would be calibrated to 
the other by calculating an appropriate conversion factor.  
c. Adjusting within the modelling of the ENID Bone pQCT data for the effects of 




The option of collecting further data (EFP or in-vivo) would be time consuming, requiring the 
acquisition of an appropriate phantom or in the case of scanning new participants for cross- 
calibration obtaining ethical approval to collect the data. This was beyond the timeframe of this 
study. The benefits of adopting a statistical approach included already having access to the 
necessary data, but also the flexibility in choosing how to approach the problem. Initially, it was 
decided to perform a study-specific adjustment using the ENID Bone data rather than pooling 
these data with those from previous studies. While in other studies participants had been scanned 
on different scanners cross-sectionally, the ENID participants had been scanned longitudinally. 
Initially I treated the XCT 2000L scanner as the reference machine and used this for the purposes 
of plotting the data. However, for the final analysis of the dataset I adopted a more flexible 
approach by treating switching from one machine to the other as I would any other categorical 
variable. This approach appeared to be satisfactory in making allowance for potential confounding 
caused by the use of different scanners, however, as a precaution models were also fitted for the 
subset who did not change scanner (Appendix C). 
Table 3.8 Mean differences (%) at Booking between pQCT parameters obtained on XCT 2000 vs XCT 2000L at the 
forearm and lower leg.  
Bone outcomes Radius Tibia 
Total vBMD 4.9% 5.0% 
Trabecular vBMD 4.8% 5.0% 
Total CSA -1.1% -1.1% 
Total CSA proximal -0.6% 1.1% 
Cortical vBMD 3.8% 4.2% 
Cortical BMC 4.6% 5.6% 
Cortical CSA 0.8% 1.4% 
Cortical thickness 1.5% 1.1% 
vBMD = volumetric bone mineral density, CSA = cross sectional area 
 
Table 3.9 Participants scanned in each supplement group at each visit scanned on the XCT2000 and XCT2000L    
 FeFol MMN PE PEMMN 
Visit 2000 2000L 2000 2000L 2000 2000L 2000 2000L 
Booking 75 101 77 98 78 96 78 96 
P20 68 91 72 92 64 91 59 92 
P30 63 96 73 97 69 90 63 93 





 Data cleaning and initial data exploration  
All data exploration, cleaning and manipulation to create a final dataset containing anthropometry 
and scans of suitable quality for longitudinal analysis were conducted in R version 3.3.1 primarily 
with the use of the following packages: dplyr version 0.5.0 (Wickham and Francois, 2016) and 
tidyverse version 1.1.1 (Wickham, 2017) for general data manipulation, and ggplot2 version 2.2.1 
for plotting (Wickham 2009).  
 
3.4.1 Data consolidation 
Of the total data recorded in the initial check sheet a total of 2,232 and 2,131 radius and tibia scans 
were respectively available for this study. Of these, 1,933 radius and 1,994 tibia scans could be 
accounted on the scanners and were of a suitable grade for analysis. These were extracted using 
the manufacturer’s software (Stratec XCT version 6.2) following the relevant SOP (SOP_0499). 
These longitudinal pQCT data were combined with subject level data including supplement arm, 
parity, and anthropometry to create a master dataset for analysis. During data consolidation I found 
some inconsistencies between measurement dates for the anthropometry data and those for pQCT. 
The anthropometry dates were more accurate because they are entered manually into the pQCT 
from the anthropometry forms and treated as reference dates for all participants in the dataset. 
However, care was taken when combining the datasets to ensure that the dates of scanning were 
closely matched to their corresponding pQCT data. The approach applied allowed the dates of 
pQCT scans to vary by a defined margin either side of the reference anthropometry date. 
Observations for 20 participant time points were not satisfactorily matched to the reference dates 
and were excluded from analysis.  
Further to the grading process above the data were also scrutinised through the use of box and 
whisker plots to identify implausible extreme outliers (defined as 1.5 times the interquartile range 




calculated within-subject change in all pQCT bone outcomes between visits. These were 
investigated further by visual inspection of the scans and scout views, of which those of clearly 
poor scan quality, inaccurate positioning, or ill-defined ROI were removed (Table  3.10) from the 
dataset. At this stage I identified several participants where object length differed between time 
points, these individuals were systemically identified (Table 3.11), and if object length differed by 
≥5 mm from that individuals other scans the data were excluded, anthropometric and subject level 
data were retained in the dataset and can be found in the full population baseline descriptive 
statistics in Appendix C.   
 
Table 3.10 Number of pQCT scans excluded from the dataset after being identified as extreme outliers at the distal 
and proximal radius and tibia at Booking, P20, and P30 from box and whisker plots. 
 Radius 4% Radius 33% Tibia 4% Tibia 38% 
Booking 7 9 3 2 
P20 8 10 3 1 
P30 10 10 3 0 
Total 25 29 9 3 
 
Table 3.11 Number of pQCT scans excluded from the dataset due to object length differences >5 mm at the radius 
and tibia at Booking, P20, and P30. 
 Radius Tibia 
Booking 1 4 
P20 0 1 
P30 2 1 
Total 3 6 
 
Table 3.12 Number of scan slices analysed at the distal and proximal radius and tibia in the master dataset at 
Booking, P20, and P30.  
 Radius 4% Radius 33% Tibia 4% Tibia 38% 
Booking 683 685 621 622 
P20 614 618 570 572 
P30 613 625 569 572 
Total  1910 1928 1760 1766 
% of collected  85% 86% 83% 83% 
Note that although both distal and proximal slices are obtained during the same scan if movement artefacts were present at one slice 
but not the other only the affected slice would be excluded, this explains the inconsonant number of data points form distal and 





Object length discrepancies can be attributed to data collection on two scanners as object was re-
measured each time a new participant was enter on a scanner, where the same scanner is used 
throughout object length remains linked to the participant ID on that scanner. A 5 mm difference 
is small and within the bounds of inter-operator error even when optimal positioning is used and 
as such the data useable. The number of data at the distal and proximal sites of interest are 
summarised in Table 3.12.  
 
3.4.2 Absolute within-group changes between baseline and follow up 
For all pQCT data absolute between-visit change was calculated by subtracting the baseline bone 
outcome measure values from their respective follow-up values. Subsequently I used single-sided 
t-tests to determine if the absolute within-group change in all variables differed significantly from 
zero. 
 
3.4.3 Modelling of longitudinal pQCT data 
Model and covariate selection was determined by my primary and secondary objectives of exploring 
potential pregnancy-induced changes in the trabecular and cortical compartments of the maternal 
skeleton and any potential supplement modulation. However, as between-scanner effects emerged 
during my initial exploratory analysis, a categorical variable indicating scanner model was also 
included (Section 3.3.5). Although there were several approaches that could be applied to meet 
these requirements, I initially planned to use multilevel models (MLM), which were conducted 
using the LME4 package (Bates et al., 2015). However, as I will discuss in detail below, following 
my initial use of MLM, I eventually decided to use multiple regression analysis in base R, which 
allowed me to control for scanner differences while investigating whether any pregnancy-induced 




3.4.4 Model selection  
3.4.4.1 Multilevel models (MLM) 
MLM are statistical models of parameters that vary at more than one level (i.e. nested). These 
models allow for variation in the outcome measures from two sources, between individuals (fixed) 
and within individuals (random), to be considered separately. The within-individual variation 
represents changes in the outcome over time. Random effects allow for the variation in unobserved 
measures in the individual to be considered. For example, an individual whose measures show a 
smaller change than an individual whose covariates are otherwise identical. Fixed effects in general 
can be thought of as measures that are fixed or unlikely to vary widely over the course of the study, 
such as the number of children or age. Random effects are allowed to vary between individuals 
while fixed effects apply to all individuals. The benefits of using MLM over a repeated-measures 
ANOVA include: the flexibility of not being limited to considering time as a categorical variable; 
the ability to deal with unequal time intervals between observations; the ability to handle 
unbalanced data (i.e. missing data for subjects across time points).  
Table 3.13 Overview of multilevel models tested on the ENID Bone pQCT data 
Model  Random intercept Time effect (weeks from P20) Random Slope Additional Random Slope 
1 Yes No No  No 
2 Yes Linear No  No 
3 Yes Quadratic  No No 
4 Yes No Non correlated slope No 
5 Yes Linear Non correlated slope No 
6 Yes Quadratic  Non correlated slope No 
7 Yes No Yes Yes 
8 Yes Linear Yes Yes 
9 Yes Quadratic  Yes Yes 
 
My initial MLM (Table 3.13) centred time (i.e. gestation stage) on P20 due to the wider variation in 
time at Booking, time was expressed in week from P20, and explored as linear and quadratic terms. 
However, when these models were built up to explore variation in the ENID Bone pQCT bone 
outcomes the baseline results were not plausible, making it increasingly complex to model 
pregnancy-related change with this statistical method. From this point forward I decided to model 




1) more data points were available at Booking vs P20; 2) this ensured the maximum period over 
which to explore changes in maternal bone; 3) no significant between-group differences at 
Booking, as would be expected from the randomisation process prior to supplementation.  
3.4.4.2 Multiple regression analysis 
Multivariate linear regression models allowed me to explore differences between Booking and P30 
while adjusting for machine bias and my a priori covariates. This allowed me the flexibility to 
determine any supplement effects, which were coded as a binary dummy variable on the basis of 
whether they contained PE or MMN (Table 3.14). A similar approach was applied to the scanner 
differences. Finally, for ease of interpretation, I centred maternal age (subtracting the mean age of 
women in the ENID-bone cohort from each participant’s baseline age). Since the intercept 
represents an estimate of the mean when all predictors are at their reference level (i.e. 0 for 
continuous variables), the intercept (or reference group) in these models can be interpreted as 
representing women: 1) in the FeFol supplement arm (i.e. control); 2) that were scanned on the 
same scanner at Booking and P30; 3) not change scanner during the study; 3) of mean age (29.6 
years). The intercept is expressed in the original units of each respective variable.  
The β coefficients of the other independent variables indicate the difference in change over time 
from the reference/intercept. By adding (or subtracting) these to the reference we can determine 
the change in the different supplement groups (i.e. the mean differences between Booking and 
P30). For example to determine the effect size of supplementation in the MMN group for a given 
pQCT outcome measure the β coefficient for MMN is added to that of the intercept as all women 
in the MMN group also received FeFol. 
 
3.4.5 Covariate selection  
The selection of co-variates in the modelling of change in pQCT bone outcomes between visits 




whether a statistically significant decrease in trabecular vBMD occurs between early- and late- 
pregnancy at the distal radius and tibia. The selection of confounders for the base models was 
partly due to participants being scanned across the two pQCT machines (see Section 3.3.5). 
Participants fell into four different scenarios, i.e. being scanned on XCT 2000 (Scanner 1)/XCT 
2000L (Scanner 2) twice, or starting on the XCT 2000/XCT 2000L and being scanned at P30 on 
the other machine (Chapter 4 Tables 4.10 & 4.11). A categorical variable “machine_cat” was used 
to control for participants who switched from the XCT2000L to the XCT2000, or from the 
XCT2000 to XCT2000L between Booking and P30. No major differences were found when 
models were run with this categorical machine variable compared to models performed on the 
subset of women who did not change scanner (Appendix C). As the ENID Bone Study had 
recruited women across a large age range (18-45 years) I also adjusted all models by maternal age. 
Following on from my base models I subsequently added supplement group to enable me to detect 
within-group changes between Booking and P30. 
3.4.5.1 Maternal age and parity  
As outlined previously as women age, natural age-related changes occur and the study population’s 
age range was wide. Women in rural Gambia often have many children and the mean parity tends 
to be high and strongly correlated with maternal age. This was also the case for women in this study 
(R2 = 0.73, Figure 3.12). While in the literature associations have reported between parity and 
maternal bone outcomes independent of age (Specker and Binkley, 2005), in previous studies at 
MRC Keneba it has been shown repeatedly that while age and parity may each be predictive of a 
particular measure, this is often lost for both of them when included together in regression models. 
It was not, therefore, possible to include both age and parity in the same model so I took the 
decision to include only maternal age (years) as it had less clustering around discrete values. Thus, 






Figure 3.12 Correlation of parity and age in the ENID Bone study (adjusted R2 = 0.73), regression line in red.  
 
3.4.5.2 Maternal antenatal supplementation  
Additionally I built up the initial models outlined below in Tables 5.4 and 5.5 to include supplement 
group, this was necessary due to the ENID Trial design, supplementation was coded into four 
categories based on whether participants received MMN or PE as part of their intervention 
(TRUE) or whether they did not (FALSE).  This allowed for intercept to represent the FEFOL 
group (i.e. FALSE, FALSE). 
Table 3.14 Coding of supplement in ENID Bone pQCT models  
 Supplement contains MMN Supplement  contains PE 
FEFOL FALSE FALSE 
MMN TRUE FALSE 
PE FALSE TRUE 
PEMMN TRUE TRUE 
FeFol = iron folate, MMN = multiple micronutrients, PE = protein energy, PEMMN = protein energy multiple micronutrients 
 
3.4.5.3 Weight change  
It was hypothesised that the effects of supplementation could modulate maternal weight gain and 
body composition. At baseline, there were no significant differences in weight between the 4 
supplement groups. When the weight change between Booking and P30 is visualised (Figure 3.13) 




analysis and found no significant supplement modulation of maternal weight gain between Booking 
and P30. Weight gain did not appear to differ between the groups nor was it predicated by 
supplement arm. In consequence, weight change was not included in the final models.  
                   
Figure 3.13 Distribution of weight change between Booking to P30 weight in the supplement groups   
No baseline weight differences between supplement groups were reported. Linear regression to explore the 
relationship between supplement groups and maternal weight gain found no significant supplement effects on 
maternal weight gain between visits. FEFOL = iron folate, MMN = multiple micronutrients, PE = protein Energy, 
PEMNN = protein energy + multiple micronutrients. 
 
3.4.6 Final model selection  
Ultimately two models were applied to all pQCT data Model 1 (Figure 3.14) adjusted for the 
machine bias in addition to maternal age (see section 3.4.5): 
𝑀𝑜𝑑𝑒𝑙 1: 𝑌𝑖 = 𝛽𝑜 + 𝛽1𝑚𝑎𝑐ℎ𝑖𝑛𝑒 + 𝛽2𝑎𝑔𝑒 + 𝜖 
Model 2 added supplement effects (as binary dummy variables, Figure 3.15) to Model 1 to allow 
the effect of MMN, PE, and a PE x MMN interaction term to be explored.  
𝑀𝑜𝑑𝑒𝑙 2: 𝑌𝑖 = 𝛽𝑜 + 𝛽1𝑚𝑎𝑐ℎ𝑖𝑛𝑒 + 𝛽2𝑎𝑔𝑒 + 𝛽3𝑃𝐸 ∗ 𝑀𝑀𝑁 + 𝜖 












Figure 3.14 Example of Model 1 applied to trabecular vBMD the 4% distal tibia.  
In the above, taking trabecular vBMD as an example the intercept represents the absolute change between visits 
in mg/cm3 for a participant of mean age who was scanned on the same scanner at Booking and P30. This example 
highlights the need to control for changing scanner showing as evidenced by the opposite direction and similar 
magnitude of the beta-coefficients for changing scanner in either way.  
 
 
Figure 3.15 Example of Model 2 applied to the cortical vBMD at the 33% proximal radius  
In the above, taking cortical vBMD as an example the intercept represents the absolute change between visits in 
mg/cm3 for a participant receiving FEFOL, of mean age who was scanned on the same scanner at Booking and P30. 
Supplement effects can be interpreted as highlighted in the text boxes above. FEFOL is highlighted in green where 
the intercept can be taken as is, however, to interpret the change in a woman who received MMN the effect of 
MMN must be added to that of the intercept (as all women will have received FEFOL, yellow). This also holds true 
for those who received the PE supplement (blue, intercept + PE). For women who received PEMNN it is necessary 






4 ENID Bone Study Results 
 
 Introduction  
My analysis explored whether there was change in the entire cohort but also whether ante-natal 
supplementation modulated any pregnancy-induced changes in the trabecular compartment. In the 
same manner I explored my secondary objective which focused on the cortical-rich proximal sites 
of the radius and tibia to determine if any pregnancy-induced adaptations occurred in cortical bone 
density, mass, distribution, or strength. As at trabecular-rich sites I needed to consider whether 
supplementation modulated change in cortical bone outcomes during gestation. Finally my models 
explored the influence of potential determinants of change such as maternal age.  
 
 Baseline descriptive characteristics  
Complete case analysis for participants at Booking and P30 (i.e. included in my final models) was 
carried out and showed no difference to the entire ENID bone pQCT cohort (Appendix C), these 
data are presented in Table 4.1. No statistically significant between-group differences were found 
between supplement arms as examined by ANOVA with a post-hoc Tukey test (Table 4.1) this 
was expected because of randomisation. The distribution of age, height, weight, and weight change 




               
Figure 4.1 Distribution of maternal age (years), height (cm), weight (kg), and parity by supplement group at Booking. 
No statistically significant between-group differences were observed at Booking. Parity was calculated as the sum of living children, children who died, and stillbirths, minus the number 




Table 4.1 Baseline descriptive statistics for participants with complete data at Booking and P30 for the 4 supplement groups in the ENID Bone Study, mean (SD) 
  
 FeFol MMN PE PEMMN 
 n=143 n=151 n=141 n=129 
Age (years) 29.73 (6.52) 29.33 (6.60) 29.19 (6.57) 30.05 (7.19) 
Weight (kg) 55.18 (8.76) 55.19 (10.06) 55.95 (9.39) 56.23 (10.88) 
Height (cm) 161.86 (6.25) 161.89 (5.68) 161.94 (5.69) 161.65 (5.90) 
Sitting height (cm) 80.24 (3.04) 80.31 (2.99) 80.08 (3.12) 80.02 (4.09) 
Parity, median [IQR]              5 [2, 6] 4 [2, 6] 4 [2, 6] 4 [2, 6] 
4% Radius n=136 n=136 n=135 n=123 
Total vBMD (mg/cm3) 318.53 (42.05) 321.12 (46.86) 321.58 (42.95) 320.46 (44.96) 
Trabecular vBMD (mg/cm3) 159.49 (34.30) 162.79 (36.02) 163.51 (35.03) 158.85 (37.04) 
Total CSA (mm2) 337.06 (41.67) 334.06 (38.45) 339.95 (42.17) 333.41 (46.68) 
33% Radius n=137 n=145 n=136 n=122 
Total CSA (mm2) 119.70 (16.51) 119.32 (15.76) 122.41 (17.66) 119.54 (16.93) 
Cortical vBMD (mg/cm3)    1239.93 (39.05) 1245.71 (37.98) 1243.53 (38.47) 1241.60 (35.76) 
Cortical BMC (mg/mm)    93.50 (11.76) 94.46 (10.60) 95.72 (11.32) 93.52 (10.41) 
Cortical CSA (mm2)        75.38 (8.84) 75.80 (7.99) 76.93 (8.45) 75.34 (8.22) 
Cortical Thickness (mm) 2.43 (0.24) 2.45 (0.21) 2.46 (0.25) 2.44 (0.23) 
4% Tibia n=120 n=125 n=114 n=118 
Total vBMD   (mg/cm3)        282.82 (39.21) 285.26 (37.10) 288.09 (35.29) 280.52 (35.45) 
Trabecular vBMD (mg/cm3)     191.02 (34.92) 192.69 (30.00) 194.14 (30.73) 189.27 (29.98) 
Total CSA (mm2)    949.27 (112.26) 935.17 (108.58) 941.56 (110.92) 945.26 (116.34) 
38% Tibia n=119 n=129 n=114 n=119 
Total CSA (mm2)        382.03 (54.33) 377.37 (52.24) 379.55 (42.04) 375.50 (46.12) 
Cortical vBMD (mg/cm3)       1232.43 (36.32) 1233.61 (39.40) 1232.32 (40.06) 1233.11 (36.53) 
Cortical BMC (mg/mm)    280.75 (37.92) 280.74 (38.81) 285.15 (33.20) 277.32 (31.84) 
Cortical CSA (mm2)       227.76 (29.71) 227.44 (29.46) 231.18 (23.91) 224.75 (23.47) 
Cortical Thickness (mm) 4.04 (0.43) 4.07 (0.46) 4.14 (0.44) 4.03 (0.39) 
Between-group baseline differences were tested by ANOVA with posthoc Tukey Test. FeFol = iron folate, MMN = multiple micronutrients, PE = protein energy, PEMMN = protein energy multiple micronutrients, vBMD = 




 Unadjusted analyses of change between Booking and P30  
Change in all bone outcomes between Booking and P30 was computed, and independent t-tests 
were used to determine if the change was significantly different to zero (i.e. p<0.05). No significant 
differences were found in trabecular vBMD or in total vBMD at either the distal radius or tibia. 
Small but statistically significant differences were found at the cortical-rich proximal radius and 
tibia for several changes in bone outcomes between visits these data are tabulated in Table 4.2 (all 
p<0.05). Data for a reduced subset who did not change scanner can be found in Appendix C. 
Following stratification by supplement group, I repeated this process and found statistically 
significant within-group differences between Booking and P30 in parameters of bone geometry 
cortical CSA (proximal radius and tibia) in the MMN group only (Table 4.4, all p<0.05).  
Table 4.2 ENID Bone Study pQCT bone parameters of interest at Booking and absolute change by P30, mean (SD) 
for participants who had data at both time points. 
 
                    Booking Change by P30  
4% Radius  n=530 
Total vBMD (mg/cm3) 320.42 (44.12) 0.35 (18.65) 
Trabecular vBMD (mg/cm3) 161.21 (35.53) 0.83 (11.00) 
Total CSA (mm) 336.18 (42.19) 1.32 (22.18) 
33% Radius  n=540 
Total CSA (mm2) 120.24 (16.71) -0.25 (11.14) 
Cortical vBMD (mg/cm3)    1242.77 (37.85) 2.86 (36.12) 
Cortical BMC (mg/mm)    94.32 (11.05) 0.34 (3.49)* 
Cortical CSA (mm2)        75.87 (8.38) 0.09 (1.72) 
Cortical Thickness (mm) 2.45 (0.23) 0.01 (0.17) 
4% Tibia   n=477 
Total vBMD   (mg/cm3)        284.15 (36.81) 0.27 (10.61) 
Trabecular vBMD (mg/cm3)     191.77 (31.43) 0.19 (7.39) 
Total CSA (mm2)    942.74 (111.79) -1.41 (27.22) 
38% Tibia   n=481 
Total CSA (mm2)        378.57 (48.97) 0.59 (14.82) 
Cortical vBMD (mg/cm3)       1232.89 (38.00) 2.26 (29.34) 
Cortical BMC (mg/mm)    280.94 (35.66) 0.85 (9.41)* 
Cortical CSA (mm2)       227.74 (26.90) 0.31 (3.12)* 
Cortical Thickness (mm) 4.07 (0.43) 0.00 (0.12) 






Table 4.3 ENID Bone Study pQCT bone parameters of interest in their respective units of measurement at Booking with the absolute change by P30 mean (SD) for participants  
who had data at both time points following stratification by supplement group 
 
 FeFol MMN PE PEMMN 
 Booking Change by P30 Booking Change by P30 Booking Change by P30 Booking Change by P30 
4% Radius n   =  136 n   =  136 n   =  135 n   =  123 
Total vBMD (mg/cm3) 318.53 (42.05) -0.43 (19.07) 321.12 (46.86) 2.29 (21.07) 321.58 (42.95) -0.71 (18.90) 320.46 (44.96) 0.22 (14.72) 
Trabecular vBMD (mg/cm3) 159.49 (34.30) 0.53 (11.02) 162.79 (36.02) 1.21 (12.05) 163.51 (35.03) 0.42 (11.24) 158.85 (37.04) 1.20 (9.51) 
Total CSA (mm2) 337.06 (41.67) 1.45 (23.02) 334.06 (38.45) -0.80 (22.71) 339.95 (42.17) 3.25 (23.19) 333.41 (46.68) 1.42 (19.41) 
33% Radius n   =  137 n   =  145 n   =  136 n   =  122 
Total CSA (mm2) 119.70 (16.51) -1.52 (11.26) 119.32 (15.76) 0.19 (9.72) 122.41 (17.66) 0.54 (12.46) 119.54 (16.93) -0.20 (11.03) 
Cortical vBMD (mg/cm3)    1239.93 (39.05) 5.25 (34.80) 1245.71 (37.98) 1.59 (36.96) 1243.53 (38.47) -0.23 (39.36) 1241.60 (35.76) 5.11 (32.73) 
Cortical BMC (mg/mm)    93.50 (11.76) 0.34 (3.47) 94.46 (10.60) 0.64 (3.92) 95.72 (11.32) -0.02 (3.45) 93.52 (10.41) 0.38 (3.01) 
Cortical CSA (mm2)        75.38 (8.84) -0.05 (1.67) 75.80 (7.99) 0.42 (1.90)* 76.93 (8.45) 0.00 (1.60) 75.34 (8.22) -0.04 (1.63) 
Cortical Thickness (mm) 2.43 (0.24) 0.02 (0.18) 2.45 (0.21) 0.02 (0.16) 2.46 (0.25) -0.01 (0.19) 2.44 (0.23) 0.00 (0.17) 
4% Tibia n=120 n=125 n=114 n=118 
Total vBMD   (mg/cm3)        282.82 (39.21) -0.64 (8.73) 285.26 (37.10) 0.39 (11.52) 288.09 (35.29) -0.08 (12.31) 280.52 (35.45) 1.42 (9.54) 
Trabecular vBMD (mg/cm3)     191.02 (34.92) -0.07 (7.17) 192.69 (30.00) -0.01 (7.66) 194.14 (30.73) 0.36 (7.87) 189.27 (29.98) 0.50 (6.89) 
Total CSA (mm2)    949.27 (112.26) 0.04 (21.98) 935.17 (108.58) -3.15 (26.09) 941.56 (110.92) 1.95 (26.85) 945.26 (116.34) -4.29 (32.85) 
38% Tibia n   =  119 n   =  129 n   =  114 n   =  119 
Total CSA (mm2)        382.03 (54.33) -1.63 (15.01) 377.37 (52.24) 1.79 (17.09) 379.55 (42.04) 1.08 (10.91) 375.50 (46.12) 1.03 (15.19) 
Cortical vBMD (mg/cm3)       1232.43 (36.32) 0.82 (25.67) 1233.61 (39.40) 3.69 (32.20) 1232.32 (40.06) 0.63 (32.21) 1233.11 (36.53) 3.69 (26.77) 
Cortical BMC (mg/mm)    280.75 (37.92) 0.46 (7.76) 280.74 (38.81) 1.50 (11.02) 285.15 (33.20) 0.26 (10.36) 277.32 (31.84) 1.09 (8.03) 
Cortical CSA (mm2)       227.76 (29.71) 0.20 (2.64) 227.44 (29.46) 0.63 (3.96)* 231.18 (23.91) 0.13 (3.00) 224.75 (23.47) 0.22 (2.61) 
Cortical Thickness (mm) 4.04 (0.43) 0.02 (0.13) 4.07 (0.46) 0.00 (0.14) 4.14 (0.44) 0.00 (0.09) 4.03 (0.39) 0.00 (0.11) 
*p<0.05 Independent T-test change vs zero, FeFol = iron folate, MMN = multiple micronutrients, PE = protein energy, PEMMN = protein energy multiple micronutrients,  vBMD = volumetric bone mineral density, 
CSA = cross sectional area 
 
Model 1 reference group: women of mean age at Booking, who were scanned on the same pQCT scanner at Booking and P30 
Model 2 reference group: women of mean age at Booking, who were scanned on the same pQCT scanner at Booking and P30, and were in the 
FeFol arm (i.e. control group) 
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 Adjusted analyses of change between Booking and P30 
 
4.4.1 Distal 4% radius 
The results of the 1Model 1 at the distal tibia are presented in Table 4.4. In women of an age at the 
mean age of the cohort who did not change scanner, a small but statistically significant increase in 
trabecular vBMD (<1%) was found (p<0.001). With the addition of supplement group in 2Model 
2 the increase in trabecular vBMD at the distal radius was no longer statistically significant (Table 
4.5). No effect was observed for maternal age (also a proxy for parity) at the 4% distal radius in 
either model. 
 
4.4.2 Proximal 33% radius 
Small (<1%) but statistically significant increases were found in the reference group for both 
cortical vBMD and cortical BMC (Table 4.4, both p<0.05). Maternal age had a small but statistically 
significant age effect on cortical vBMD and cortical BMC, indicating that the increases in these 
parameters were lower the older the participants were (Table 4.4, both p<0.05).  
Controlling for supplement group increased the effect-size of the increase in cortical vBMD 
(p<0.001) and cortical BMC (p<0.01) in the reference group. However, the increase remained small 
in magnitude representing <1% of a change (Table 4.5). The modest age effect remained significant 
for cortical vBMD and cortical BMC (both p<0.05).  In Model 2, small but statistically significant 
supplement effects on the change in cortical vBMD and BMC were detected between Booking and 
P30 (all p<0.05). PE was found to be a significant negative predictor of cortical vBMD (p<0.01) 
i.e. there was less of an increase, almost attenuating the effects of FeFol.   
 
 
Model 1 reference group: women of mean age at Booking, who were scanned on the same pQCT scanner at Booking and P30 
Model 2 reference group: women of mean age at Booking, who were scanned on the same pQCT scanner at Booking and P30, and were in the 
FeFol arm (i.e. control group) 
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Cortical BMC also decreased in the PE arm compared to the reference group, however although 
statistically significant, the effect size was negligible (p<0.05). 
The MMN only supplement, was also found to attenuate the significant increase in cortical vBMD, 
which increased to a lesser extent in women in this arm than the reference. In the MMN arm a 
small significant increase in cortical CSA was found compared to the reference group (p<0.05). 
The combined PE and MMN supplement behaved differently to PE and MMN alone: where alone 
the increases in cortical vBMD were below that of the reference group; combined in the PEMMN 
arm there was an increase in cortical vBMD that exceeded that of the reference group (8.90 mg/cm3 
compared to 8.40 mg/cm3) (Table 4.5).                
     
4.4.3 Distal 4% tibia  
At the distal tibia there were small but statistically significant increases in the reference group for 
both total and trabecular vBMD using 1Model 1 (both p<0.01). As seen at the distal radius these 
small increases in total and trabecular vBMD were attenuated in 2Model 2, and no supplement 
effects were found at the 4% distal tibia (Table 4.7). Maternal age was not a significant predictor 
of any parameter at the distal tibia in either model. 
 
4.4.4 Proximal 38% tibia 
There were small but statistically significant increases in several parameters at the cortical-rich 
proximal tibia from Model 1: cortical vBMD (p<0.001), BMC (p<0.001), and cortical CSA 
(p<0.01) increased between Booking and P30. Maternal age did not significantly influence these 
increases. Model 2 attenuated the significant increase in cortical CSA.  
 
Model 1 reference group: women of mean age at Booking, who were scanned on the same pQCT scanner at Booking and P30 
Model 2 reference group: women of mean age at Booking, who were scanned on the same pQCT scanner at Booking and P30, and were in the 
FeFol arm (i.e. control group) 
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However, significant increases in cortical vBMD (p<0.001) and BMC (p<0.01) remained at the 
38% proximal tibia in the reference group. No additional supplementation effect was found for 
MMN, PE, or PEMMN (Table 4.7), nor was maternal age a significant predictor. 
 
Model 1 reference group: women of mean age at Booking, who were scanned on the same pQCT scanner at Booking and P30 





Table 4.4 Summary of Model 1 for change in bone outcome measures at the 4% distal and 33% proximal radius between Booking and P30.  
 




Total CSA 4% 
(mm2) 










XCT2000L to XCT2000 17.31 (3.08)c 13.70 (1.62)c 7.35 (3.89) 1.70 (1.86) 62.82 (3.76)c 6.77 (0.36)c 1.50 (0.28)c 0.03 (0.03) 
         
XCT2000 to XCT2000L -17.95 (2.53)c -16.41 (1.33)c -10.35 (3.20)b -0.88 (1.64) -71.40 (3.30)c -6.53 (0.32)c -0.92 (0.24)c -0.03 (0.03) 
         
Age -0.08 (0.11) 0.02 (0.06) 0.05 (0.15) 0.10 (0.07) -0.38 (0.15)a -0.03 (0.01)a -0.005 (0.01) -0.002 (0.001) 
         
Constant 0.91 (0.83) 1.52 (0.44)c 1.90 (1.05) -0.34 (0.53) 5.14 (1.07)c 0.47 (0.10)c 0.07 (0.08) 0.01 (0.01) 
Observations 521 521 521 531 531 531 531 531 
R2 0.15 0.32 0.03 0.01 0.61 0.62 0.08 0.01 





Model 1 reference group: women of mean age at Booking, who were scanned on the same pQCT scanner at Booking and P30 
Model 2 reference group: women of mean age at Booking, who were scanned on the same pQCT scanner at Booking and P30, and were in the FeFol arm (i.e. control group) 
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Total CSA 4% 
(mm2) 










PE -0.58 (2.12) -0.28 (1.11) 1.75 (2.67) 2.00 (1.36) -8.01 (2.71)b -0.60 (0.26)a 0.01(0.20) -0.03 (0.02) 
         
MMN 2.19 (2.12) 0.70 (1.12) -1.82 (2.68) 1.70 (1.34) -5.39 (2.67)a 0.10 (0.26) 0.42 (0.20)a -0.01 (0.02) 
         
XCT2000L to XCT2000 17.20 (3.09)c 13.70 (1.63)c 7.41 (3.91) 1.56 (1.87) 63.56 (3.73)c 6.79 (0.36)c 1.47 (0.28)c 0.03 (0.03) 
         
XCT2000 to XCT2000L -17.98 (2.54)c -16.39 (1.34)c -10.35 (3.21)b -0.91 (1.64) -71.18 (3.27)c -6.53 (0.31)c -0.93 (0.24)c -0.03 (0.03) 
         
Age -0.07 (0.12) 0.02 (0.06) 0.05 (0.15) 0.10 (0.07) -0.40 (0.15)b -0.04 (0.01)a -0.004 (0.01) -0.002 (0.001) 
         
PExMMN -0.79 (3.05) 0.26 (1.61) -0.10 (3.85) -2.50 (1.94) 13.89 (3.88)c 0.60(0.37) -0.40 (0.29) 0.02 (0.03) 
         
Constant 0.31 (1.51) 1.25 (0.80) 1.95 (1.91) -1.55 (0.97) 8.40 (1.94)c 0.57 (0.19)b -0.05 (0.14) 0.02 (0.02) 
Observations 521 521 521 531 531 531 531 531 
R2 0.15 0.32 0.03 0.01 0.62 0.63 0.09 0.02 
vBMD = volumetric bone mineral density, CSA = cross sectional area, BMC = bone mineral content, a= p<0.05, b= p<0.01, c=p<0.001 
 
 
Model 1 reference group: women of mean age at Booking, who were scanned on the same pQCT scanner at Booking and P30 
Model 2 reference group: women of mean age at Booking, who were scanned on the same pQCT scanner at Booking and P30, and were in the FeFol arm (i.e. control group) 
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Table 4.6 Summary of Model 1 for change in bone outcome measures at the 4% distal and 38% proximal tibia between Booking and P30.  
 




Total CSA 4% 
(mm2) 










XCT2000L to XCT2000 21.21 (1.27)c 10.51 (1.11)c -13.90 (5.37)b 19.81 (2.55)c 64.42 (2.31)c 19.65 (0.88)c 4.07 (0.51)c -0.06 (0.02)b 
         
XCT2000 to XCT2000L -22.83 (1.06)c -14.47 (0.92)c 7.00 (4.48) -15.97 (2.20)c -74.32 (1.99)c -22.97 (0.76)c -4.54 (0.44)c 0.03 (0.02) 
         
Age 0.03 (0.04) 0.02 (0.04) 0.07 (0.19) 0.05 (0.09) -0.10 (0.08) -0.02 (0.03) -0.004 (0.02) -0.0004 (0.001) 
         
Constant 0.91 (0.32)b 0.77 (0.28)b -1.20 (1.34) 0.68 (0.66) 4.39 (0.59)c 1.52 (0.23)c 0.42 (0.13)b 0.005 (0.01) 
Observations 474 474 474 478 478 478 478 478 
R2 0.63 0.44 0.02 0.21 0.83 0.76 0.28 0.02 
vBMD = volumetric bone mineral density, CSA = cross sectional area, BMC = bone mineral content, a= p<0.05, b= p<0.01, c=p<0.001 
 
Model 1 reference group: women of mean age at Booking, who were scanned on the same pQCT scanner at Booking and P30 
Model 2 reference group: women of mean age at Booking, who were scanned on the same pQCT scanner at Booking and P30, and were in the FeFol arm (i.e. control group) 
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Table 4.7 Summary of Model 2 for change in bone outcome measures at the 4% distal and 38% proximal tibia between Booking and P30. 




Total CSA 4% 
(mm2) 










PE 0.34 (0.84) 0.52 (0.73) 2.62 (3.54) 2.55 (1.75) -0.60 (1.58) -0.31 (0.60) -0.09 (0.35) -0.02 (0.02) 
         
MMN 0.51 (0.82) -0.24 (0.72) -3.04 (3.46) 2.76 (1.70) 0.65 (1.54) 0.36 (0.58) 0.28 (0.34) -0.02 (0.02) 
         
XCT2000L to XCT2000 21.30 (1.27)c 10.53 (1.11)c -14.17 (5.38) b 19.57 (2.56)c 64.52 (2.31)c 19.65 (0.88)c 4.05 (0.51)c -0.06 (0.02)a 
         
XCT2000 to XCT2000L -22.79 (1.06)c -14.49 (0.93)c 6.69 (4.48) -16.05 (2.20)c -74.21 (1.99)c -22.93 (0.76)c -4.53 (0.44)c 0.03 (0.02) 
         
Age 0.03 (0.04) 0.02 (0.04) 0.09 (0.19) 0.06 (0.09) -0.11 (0.08) -0.03 (0.03) -0.004 (0.02) -0.0004 (0.001) 
         
PExMMN 1.22 (1.17) 0.30 (1.03) -3.93 (4.98) -2.84 (2.44) 2.30 (2.21) 0.42 (0.84) -0.20 (0.49) 0.02 (0.02) 
         
Constant 0.17 (0.59) 0.57 (0.52) 0.09 (2.50) -1.25 (1.23) 3.76 (1.12)c 1.38 (0.43)b 0.37 (0.25) 0.02 (0.01) 
Observations 474 474 474 478 478 478 478 478 
R2 0.64 0.44 0.03 0.21 0.83 0.76 0.28 0.02 




 Discussion and conclusions from ENID Bone Study  
These pQCT data from the ENID Bone Study indicate that significant mobilisation of bone 
mineral from the maternal skeleton does not occur in rural Gambian women during pregnancy. I 
had hypothesised that a maternal response to pregnancy would be most plausible at trabecular-rich 
sites. However, to the contrary, Model 1 found statistically significant increases in total (tibia) and 
trabecular vBMD (radius and tibia) although these were no longer significant after adjusting for 
supplement group (Model 2). Most interestingly, I found strong evidence of change in the cortical 
compartments of both radius and tibia during pregnancy, with small but statistically significant 
increases in cortical vBMD and BMC at both sites (Model 1). These increases remained following 
adjustments for supplement group, though supplement modulation of these increases was only 
observed at the radius (Model 2). This was the only notable difference between loadbearing and 
non-loadbearing sites. These data suggest statistically significant pregnancy-induced adaptations in 
the cortical compartment of the maternal appendicular skeleton between mid- to late-gestation, 
however, any clinical or physiological significance of these increases would be negligible as all were 
<1%, however, such changes may reflect changes in the Ca homeostasis. 
While the potential for supplement effects was hypothesised at both distal and proximal sites, 
supplement modulation of change was only significant at the proximal radius. Possible mechanisms 
for between-group differences had been theorised as the displacement of dietary Ca from the 
maternal diet in these mothers with a habitually low Ca intake, or a possible effect of 
supplementation on maternal weight gain during gestation. In the case of Ca displacement, I would 
have expected to see greater mobilisation of bone mineral in the PE and PEMMN arms of the 
study, which was not the found. If maternal weight gain had been influenced we could have 
expected increased weight gain in women receiving PE and PEMMN compared to the MMN and 
FeFol arms. However, weight gain did not differ markedly in the supplement groups between 





In the PE only arm the increase in cortical vBMD at the radius was almost fully attenuated, while 
less of a change compared to FeFol (although clinically negligible in magnitude) was found in 
cortical BMC. Similarly supplementation with MMN partially attenuated the increase in cortical 
vBMD compared to FeFol at the radius. In women receiving MMN only a significant increase was 
found in cortical CSA compared to the FeFol women. Most curiously the effect of the PExMMN 
interaction term acted in the opposite direction of PE or MMN alone and women in the PEMMN 
arm had an increase in cortical vBMD greater than the reference group. It is difficult to determine 
through what mechanism these subtle differences may be acting, however, a potential reason for 
these unusual finding may relate to the particularly poor compliance of participants in the LNS 
arms of the ENID Trial (Moore, personal communication 2018). While these supplement-effects 
are statistically significant, they are extremely small in magnitude. The effects of maternal age and 
parity were also explored as determinates of change in bone outcomes during pregnancy, while 
significant age effects were found for cortical vBMD and cortical BMC, older women had a lower 
increase in these parameters vs the reference group, the magnitude of these however was very small 
and unlikely to be of any clinical or physiological significance at this stage of the lifecourse. 
The lack of mineral mobilisation from trabecular-rich distal sites is in keeping with some evidence 
from studies using DXA and SPA during pregnancy where few changes have been reported at the 
distal forearm (Christiansen et al., 1976, Cross et al., 1995, Kolthoff et al., 1998, Black et al., 2000, 
More et al., 2001). Our findings at the distal radius are in contrast to Wisser et al. (2005) where 
decreases in trabecular vBMD were observed in pregnant Swiss women using a different pQCT 
technique. However, the slight increases seen in cortical bone in the Gambian study may be in-
keeping with the conservation of cortical bone reported by Wisser et al. (2005) at the forearm. The 
lack of mineral mobilisation from the cortical compartment of the forearm is also line with DXA 
data during pregnancy (Cross et al., 1995, Kolthoff et al., 1998, Black et al., 2000, More et al., 2001, 




a possible conservation of bone mineral at cortical-rich sites of the appendicular skeleton, which 
could perhaps also be extended to pregnancy (Laskey et al., 1998, Olausson et al., 2008). 
There are several limitations to this work that must be considered. Although, dietary data were 
collected in ENID Bone these were not allocated to me for analysis as part of my PhD. This was 
a pragmatic decision as although diet plays a crucial in maintaining bone health, it would have 
changed the scope of my project and would not have been feasible within the time constraints of 
the project. An important aspect that cannot be accounted for is that mineral mobilisation may 
have occurred prior to Booking. Limited data (Purdie et al., 1988) suggest the potential for 
trabecular mobilisation in early-pregnancy which are reversed near term (Shahtaheri et al., 1999) 
although this seems somewhat unlikely as fetal demand is low in the first trimester and greatest in 
late gestation. Although the BTM evidence mostly supports a resorptive state in late gestation 
through increases in resorption markers rising from the first trimester (Cross et al., 1995, Black et 
al., 2000, Yoon et al., 2000, Moller et al., 2013), some formation markers have been reported to 
increase also: increases in P1NP (Naylor et al., 2000, Kaur et al., 2003a); P1CP (Black et al., 2000, 
Naylor et al., 2000); and BAP (Black et al., 2000, Naylor et al., 2000, Yoneyama and Ikeda, 2010) 
have been found into the third trimester. These bone formation markers must be cautiously 
interpreted due to potential fetal or placental origin. On balance it is unlikely that pregnancy-
induced mobilisation would have been initiated and reversed within the course of several months, 
prior to lactation-induced mobilisation. Given the evidence for late-pregnancy being a resorptive 
state, it may be that to detect potential decreases in the maternal appendicular skeleton with pQCT 
data may need to be collected closer to term. 
It is well documented in the literature that during lactation maternal bone mineral is mobilised 
preferentially from trabecular-rich sites. In contrast I found no evidence of mobilisation until 30 
weeks of pregnancy for either the distal radius or tibia, it is possible that this may represent the 
conservation of maternal trabecular bone during pregnancy. Whether there is mobilisation from 




Despite finding no evidence of bone mineral mobilisation during pregnancy in this study, 
mobilisation may occur in pregnancy through other mechanisms which are not detectable with 
pQCT, such as changes in maternal trabecular (i.e. trabecular thickness, trabecular number, 
trabecular separation) or cortical (thickness and porosity) microarchitecture. These would require 
a higher resolution technique to be used. To further describe changes in the trabecular 
compartment of the maternal appendicular skeleton beyond trabecular vBMD as measured with 
our pQCT XCT 2000/2000L, more advanced modalities such as high- resolution pQCT, which 
have a much greater resolution (i.e. voxel size of 82 μm vs 0.5 mm of the XCT2000/2000L) may 
be required. 
In summary these data provide a unique insight into maternal bone mineral homeostasis during 
pregnancy in rural Gambian women. As these are the first such densitometry data collected during 
gestation in either a Sub-Saharan African population or a population with a habitually low Ca intake 
during pregnancy, it is difficult to compare these findings to the literature which has mostly 
accumulated from white women in HIC. In contrast to my hypotheses of bone mineral 
mobilisation between Booking and P30 in this population, it may be that conservation of bone 
mineral is an adaptation to a habitually low Ca intake and is normal in this population. These data 
highlight that although there is some evidence to support bone mineral mobilisation in women 
with high Ca intakes and high quality diets in HIC, such assumptions may not hold true in all 
populations especially where dietary quality is lower and Ca intake habitually low. My findings from 
the ENID bone data may be summarised as a lack of pregnancy-induced bone mineral mobilisation 
between Booking and P30 in the maternal appendicular skeleton with: 
1. Conservation or small increases of bone mineral in the trabecular compartment (radius and 
tibia) 
2. Small but significant increases cortical compartment in vBMD and BMC at: 
a. The loadbearing  38% proximal tibia 




3. Significant supplement effects of negligible magnitude found at the proximal radius  
4. Significant but extremely small maternal age effects confined to the proximal radius, 
increases lower in older mothers.  
In conclusion although the magnitude of change seen in the ENID Bone Study pQCT analysis was 
small and increases were observed in cortical vBMD and BMC contrary to my initial hypothesis of 
bone mineral mobilisation, there may lasting consequences of these small changes if they prove to 
be cumulative across multiple pregnancies. Previous research has shown that repletion of lactation-
induced mineral mobilisation occurs post-lactation in this population. It is possible that the 
physiological response to pregnancy in women with habitually low Ca intakes is such that bone 




5 Pregnancy and Bone Study Subjects and Methods 
 
  Introduction   
The Pregnancy and Bone Study (PABS) was a longitudinal observational study designed to 
investigate whether bone mineral changes occur in the maternal appendicular skeleton during 
pregnancy. I was responsible for the design, ethical approval and management of the study together 
with all data analysis and interpretation. Ethical approval was obtained from the East of England 
– Essex Research Ethics Committee (REC) (Project ID 199857) to recruit up to 100 women aged 
30 to 45 years from the Cambridge area to participate in the study. Pregnant women (n=53) were 
recruited from within the catchment area of the Rosie Cambridge University Hospital Trust (CUH), 
and healthy non-pregnant non-lactating (NPNL, n=37) women were recruited from the 
community. Data collection occurred between March 2017 and April 2018, bone densitometry data 
from participants at two time points in mid- and late-pregnancy using peripheral pQCT and 
HRpQCT. NPNL participants were scanned contemporaneously to account for age-associated 
changes (Uusi-Rasi et al., 2007, Burt et al., 2017).  
 
5.1.1 PABS hypothesis 
My primary hypothesis was that maternal trabecular volumetric BMD (pQCT and HRpQCT) in 
the appendicular skeleton would decrease from mid- to late-pregnancy due to maternal bone 
mineral mobilisation from trabecular-rich skeletal sites, and that changes in trabecular 
microarchitecture would also be observed (HRpQCT). 
 
5.1.2 PABS Aims  




1. Maternal bone mineral is mobilised between mid- to late-pregnancy from trabecular-rich 
sites in the maternal appendicular skeleton measured as decreases in trabecular vBMD 
(pQCT and HRpQCT) and changes in trabecular microarchitecture compared to NPNL 
controls. 
2. Adaptations occur in the cortical compartment between mid- and late-pregnancy: 
a. Distal sites: cortical vBMD and microarchitecture (HRpQCT). 
b. Diaphyseal sites: cortical vBMD, BMC, CSA, and thickness (pQCT) 
 
5.1.3 PABS objectives  
The primary objective of this study was to determine whether pregnancy-induced bone mineral 
mobilisation occurs between 14-16 weeks and 34-36 weeks of pregnancy in my primary outcome 
measures of trabecular vBMD (pQCT and HRpQCT) and trabecular microarchitecture (HRpQCT: 
trabecular number, separation, and thickness).   
Secondary objectives were to explore: 
1. Whether changes occur in the cortical compartment between early- to late-gestation: 
a. At proximal radius and tibia with a focus on cortical vBMD, cortical BMC, cortical 
CSA, cortical thickness, and total CSA (pQCT) 
b. At the distal radius and tibia to determine cortical vBMD, cortical thickness, and 
cortical porosity (HRpQCT) 
2. To determine any predictors of change in 1. and 2. with a specific focus on: 
a. Maternal age  
b. Weight change 
c. Parity  
3. Correlation between pQCT and HRpQCT in-vivo measurements for trabecular vBMD, 





Figure 5.1 Catchment area of Cambridge University Hospitals Trust of which the Rosie Hospital is a member shown 
in context of the East of England Nomenclature of Territorial Units for Statistics (NUTS) region. Source 
https://www.cuh.nhs.uk/sites/default/files/misc/Trust-Catchment-Area-Map-A4-NEW.PDF 
 
 Pre-study Work-Up  
Study design was undertaken with the support and supervision of Ass. Prof. Kate Ward and Prof. 
Ann Prentice of the Nutrition and Bone Health group (NBH) at Medical Research Council Elsie 
Widdowson Laboratory (MRC EWL) Practical advice was received from my thesis advisory 
committee, Dr. Sophie Moore (King’s College London) and Dr. Catherine Aiken (University of 
Cambridge).  
Measurement timings: I planned to include at least two pregnancy time points to detect mid- to 
late-pregnancy changes in maternal bone outcomes. For logistical and ethical reasons the first visit 
could not be prior to each participant’s 12 week antenatal ultrasound scan when due date is 
estimated and potential fetal abnormalities may be detected. Recruitment took place at this 
ultrasound scan appointment, as few data support early pregnancy mineral mobilisation, allowing 
visit 1 to be booked between 14-16 weeks gestation. This was as close to the first trimester as 
possible, while allowing for: a) for appropriate screening; b) adequate time to reflect on 
participation; c) flexible scheduling of visits around each participant’s other appointments. When 




changes to be detected in late pregnancy; b) minimising participant burden; c) reducing loss to 
follow up from premature deliveries. Thirty four to 36 weeks gestation met these criteria, and was 
similar to the timing of the late-pregnancy time points in other densitometry studies (Wisser et al., 
2005, Moller et al., 2012) and is 4-6 weeks later in the third trimester than the final ENID Bone 
visit. I considered including an interim visit. However, this would increase participant burden and 
was not central to my primary hypothesis, I therefore did not include this extra visit. I also 
considered including a potential postpartum visit for a DXA scan but because this additional data 
would: a) be confounded by the initiation of lactation; b) significantly increase the timeframe of 
the study; c) DXA data would be cross-sectional only and d) was not central to my research 
question, I decided not to include this measurement. 
Diet: I considered the collection of dietary intake data during pregnancy using either 4 day weighed 
intake diaries or potentially food frequency questionnaires (FFQ). 4 day weighed intake diaries 
would greatly increase participant burden and for this reason were not collected. The use of an 
FFQ was considered further and advice was received from Dr. Gail Goldberg (MRC EWL) and 
Prof. Sian Robinson (MRC LEU) about the practicalities and efficacy of using an FFQ in my study 
population. Using or adapting an FFQ would present several challenges: the use of CALQUEST 
would not be appropriate as it has not validated for use in pregnancy, while the use of an FFQ 
validated in pregnancy such as that used in SWS may not be appropriate given the socio-
demographic differences between Cambridge and Southampton. Also Olausson et al. (2008) found 
no association between maternal Ca intake and the bone outcomes on which PABS was powered. 
Reluctantly, I took the pragmatic decision against collecting dietary data to reduce burden of the 
study interventions.  
Recruitment site: A meeting with Dr. Hanna Missfelder-Lobos (Consultant and Specialty Lead 
in Obstetrics and Fetal Medicine), at the Rosie Maternity Hospital, Cambridge University Hospitals 
Trust (CUH) was convened to discuss the feasibility and logistics organising a study at the Rosie. 




ethical approval. Descriptive statistics from a six-year period (2008-2013) were provided by Dr. 
Catherine Aiken (Consultant in Obstetrics and Fetal Medicine) and helped demonstrate the 
feasibility of recruiting the necessary number of women in the age range of 30-45 years which 
formed my primary inclusion criterion (Tables 5.1 and 5.2, Figure 5.1). Setting a lower age limit at 
30 years would allow the study to have a higher mean age than most studies discussed in Chapter 
2 and above the national mean age of pregnancy in England and Wales (30.5 years, ONS 2017). 
An upper age limit of 45 years was established as very few pregnancies reported across the 6 year 
period to women aged ≥45 years (Figure 5.1, Table 5.2). As discussed in chapter 2 women having 
later pregnancies may be more vulnerable to potential bone mineral mobilisation during pregnancy 
as: a) mobilisation may take place against background of gradual age related mineral loss, b) there 
may be less time to replenish any mobilised mineral before menopause. I considered recruiting only 
primiparous women in this age range to reduce possible confounding from previous pregnancies 
and periods of lactation, though this would have been unfeasible as it would greatly reduce the 
proportion of potential participants from 52% of all pregnancies (aged 30-45 years) to 14% of all 
pregnancies (primiparous & aged 30-45 years) at the Rosie Hospital (Table 5.2). 
 
Table 5.1 Maternal age (years) distribution from Jan 2008-Dec 2013 – 32,079 deliveries at Addenbrooke’s. 
1st Quartile Median Mean 3rd Quartile 






Figure 5.2 Distribution of pregnant women giving birth at the Rosie Hospital CUH (2008 - 2013) in 5 year age bands 



































Table 5.2 Numbers of deliveries by parity and maternal age (total from 6 years) n = 32,079  
 
To reduce potential confounding in the pregnant arm, I screened out potential study volunteers 
who had conceived using IVF or had a twin/multiple pregnancy. The need for IVF may indicate a 
possible underlying medical condition and without a detailed medical history it would not be 
possible to know whether this may have affected their BMD prior to pregnancy. Additionally, if 
bone mineral is mobilised during pregnancy it is plausible that multiple fetuses would require a 
greater mobilisation of maternal bone mineral; biochemistry and bone turnover markers in twin 
pregnancies have been reported to differ to singleton pregnancies (Nakayama et al., 2011, Goswami 
et al., 2016). To reduce this potential confounding, women with twin pregnancies were not 
recruited. Additionally a number of more general exclusion criteria were applied to both groups 
(see Section 5.4.1, Table 5.3). 
 
5.2.1 Sample size calculation  
Prior to the initiation of this study there were no suitable published pQCT data from pregnancy 
on which to base a formal sample size calculation. This study was therefore powered to be able to 
reproduce the effect sizes seen by Olausson et al. (2008) who observed a change between baseline 
and postpartum measurements of 2.6% (±4.2) in DXA-measured size-adjusted BMC at the lumber 
spine. It was calculated to have a power of 0.9, and alpha of 0.05, that a sample size of 35 
participants would be required to detect within group change in BMD from baseline to the 3rd 
trimester of pregnancy similar to Olausson et al. (2008). 
Parity 
Maternal age (years) 0 1 2 3 4 5 6 7 8 9 10 11 
<15 17 3 3 0 0 0 0 0 0 0 0 0 
15-20 701 533 164 22 10 3 0 0 0 0 0 0 
20-25 1604 1868 686 197 51 15 4 0 2 0 0 0 
25-30 2851 3928 1249 359 123 51 16 9 1 0 0 0 
30-35 2910 5183 1722 406 165 63 30 9 4 2 0 0 
35-40 1306 2470 1120 338 155 54 26 6 2 1 1 2 
40-45 250 327 199 82 32 15 8 1 1 1 0 0 




 Final Study Design  
The PABS was designed to detect within group change in pregnant women aged 30-45 years and 
in NPNL women in the same age category. As described above an early pregnancy time point of 
14 – 16 weeks gestation was selected for the baseline visit, with follow-up data collected twenty 
weeks later (34-36 weeks). The NPNL group were scanned with a similar length of time between 
visits. Ethical approval for this study was sought on the 07/07/2016 from the East of England – 
Essex Research Ethics committee and was obtained on the 08/09/2016. The study protocol and 
all supporting documents were submitted and approved by the R&D department at Cambridge 
University Hospitals Trust with Dr Jeremy Brockelsby (Consultant in Obstetrics and Fetal 
Medicine and Clinical Director in Obstetrics and Gynaecology) acting as our local collaborator 
providing clinical oversight at the Rosie Hospital.  
 
Figure 5.3 Schematic overview of the Pregnancy and Bone Study (PABS) 
The above figure highlights recruitment, screening, and procedures performed at each visit. NPNL = non-pregnant 
non-lactating. The two sites involved in the Pregnancy and Bone Study (PABS), above the Elsie Widdowson 
Laboratory (MRC EWL) where all procedures took place. Below, the Rosie hospital which was our recruitment site 





 Selection of subjects  
5.4.1 Eligibility criteria  
Criteria for the inclusion and exclusion of potential participants were selected to ensure that we 
recruited women within our age range of interest, with no previous history of medical conditions 
or significant use of medications affecting bone health as summarised in table 5.3.  
Table 5.3 Eligibility criteria used during recruitment of pregnant and non-pregnant non-lactating (NPNL) 
participants in the pregnancy and bone study (PABS) 
 
5.4.2 Recruitment  
Recruitment of pregnant participants, between late March and October 2017, occurred while 
women attended their 12 week ultrasound scans and was led by research midwives not directly 
involved in the women’s current clinical care. Potential participants were informed about the study, 
and had an opportunity to discuss any concerns. Contact details were obtained if women were 
interested in taking part and, if unsure, they were given a copy of the PIS to take away to consider. 
In addition to the active recruitment of pregnant women from the Rosie, posters and leaflets were 
also placed in the ultrasound department with the contact details of the research team. Posters were 
also distributed locally, in shops, gyms, and educational institutions. Gumtree was used to advertise 
the study in the local Cambridge area.  NPNL from the community were recruited using several 
Pregnant Women Healthy NPNL Women 
Inclusion Criteria 
Aged 30-45 years Aged 30-45 years 
Singleton pregnancy Living within travelling distance of the Rosie 
Natural conception 
>3 months after the cessation of lactation from 
previous child 
Living within travelling distance of the Rosie Ability to give written, informed consent 
>3 months after the cessation of lactation from 
previous child prior to this pregnancy 
 
Ability to give written, informed consent  
Exclusion Criteria 
Known condition affecting bone/calcium metabolism Pregnant at screening/trying to conceive 
Use of medication affecting bone/calcium metabolism Known condition affecting bone/calcium metabolism 
Immobilisation Use of medication affecting bone/calcium metabolism 
Conception by IVF Immobilisation 
Prolonged periods of amenorrhea Prolonged periods of amenorrhea 





methods. An email was circulated to staff within MRC EWL seeking potential recruits. Emails were 
also sent to individuals from the MRC EWL Volunteer database, which contained the details of 
former volunteers who had consented to being contacted for future research, and were in the 
required age range. As above, posters and Gumtree were used to advertise locally so that if 
interested potential participants could contact the research team for further information. 
5.4.2.1 Telephone Screening 
Potential participants were screened with a telephone-based screening questionnaire to assess 
eligibility (Appendix E). Those found eligible received an appointment date and time for their first 
visit. If there was uncertainty whether a potential participant was eligible, Dr. Kate Ward was 
consulted. 
5.4.2.2 Obtaining informed written consent  
All participants were given a minimum of 24 hours to consider participation in the study prior to 
written consent being obtained. During screening, potential participants had an opportunity to ask 
questions relating to the study. All potential participants who had given their contact details to the 
study midwives received a copy of the PIS. Potential pregnant participants who had seen the 
adverts elsewhere were sent a copy of the PIS via email following the screening process, as were 
all NPNL participants. At visit one, informed written consent was obtained from all participants 
in a private room by trained members of the research team, who explained the study in full as 
detailed in the PIS. Questions that arose during the process were answered by the team member 
acquiring consent or if necessary referred to the principal investigator for further clarification. 
Written consent was obtained on two copies of the PIS (signed and dated), and the consent forms 
(signed and initialled). Participants were made aware that they could freely withdraw consent at any 
point during the study. Permission was also obtained to inform their GP of their participation in 





Figure 5.4 Diagram of number of participants screened, and then subsequently scanned at each time point. 
A comprehensive break-down is provided in Tables 6.10 and 6.11 as not all participants have complete data at each 
time point. 
 
5.4.2.3 Screening between study visits  
The eligibility of women in the pregnancy arm of the study was reassessed from their medical notes 
by a research midwife at week 30 of pregnancy (Figure 5.3). This also ensured that participants who 
had unfortunate pregnancy outcomes, would not be contacted directly by the research team to 
avoid causing any additional distress.  Additionally this mid-pregnancy screening would identify 
participants who had moved out of area or lost the ability to give informed consent.   
 
5.4.3 Research Team and Research Sites 
Our primary recruitment site was the Ultrasound Department of the Rosie Hospital, while all 
investigative procedures took place at the MRC Elsie Widdowson Laboratory, Cambridge (Figure 
5.4). The research team and those who supported the study are listed in Table 5.4. Scanning was 
primarily performed by me but support was provided by a number of additional trained 
technologists when required. 
Premature delivery = 1 
Exclusion on midwives advice = 1 





Table 5.4 Members of the research team in the Pregnancy and Bone Study (PABS) 
 
 
 Selection of Outcome Measures 
Anthropometric measures of height (cm), weight (kg), forearm length (mm), and lower leg length 
(mm) were obtained at visit 1 (Table 5.5), at visit 2 only weight was repeated. Bone densitometry 
was conducted at both visits and included scans using a Stratec 2000LTM pQCT (Stratec 
Medizintechnik, Pforzheim, Germany) and HRpQCT (XtremeCT, Scanco Medical AG, 
Brüttisellen, Switzerland) at the forearm and lower leg to measure volumetric bone mineral density 
(vBMD) and related parameters of bone geometry and structure, which effect overall bone 
strength. 
 
Individual  Role  Duties  





Scan grading pQCT/HRpQCT 
Scan analysis HRpQCT 
Data processing  
Data analysis  
Ass. Prof. Kate Ward PhD supervisor Study design 
Oversight 
Prof. Ann Prentice  Group Leader/Director MRC-EWL Study design 




Dr Sophie Moore Thesis Advisory Committee Study design 
Dr Catherine Aiken  Thesis Advisory Committee Study design 
Julie Holgate  
Sue Tiplady 
Research Midwives  Recruitment  
Mid-pregnancy screening 
Rebecca McGrath  Research Assistant Screening 
Data Collection 
Data entry 
Dr Sumantra Ray Study Clinician  Clinical support 
Dr Jeremy Brockelsby  Collaborator/Local  Clinical oversight  
Darren Cole Head of Data Operations at MRC-EWL Database design  
pQCT Access tool design 
Sophie Yelland Placement student  Data entry  












5.5.1 Collection of anthropometric measures 
Height was obtained without footwear using standard operating procedures to the nearest 0.1cm 
using a stadiometer (Seca GmbH, Hamburg, Germany).  Weight was measured to the nearest 0.1 
kg while the subjects wore light clothing without footwear using a digital scale (Seca GmbH, 
Hamburg, Germany), which were routinely calibrated to ensure accuracy. Body Mass Index (BMI) 
was calculated by dividing the participants weight (kg) by their height (m) squared, this was 
expressed in kg/m2.  
5.5.1.1 Musculoskeletal Questionnaire  
A musculoskeletal questionnaire was administered to all participants at each visit to collect relevant 
information relating to the participant’s musculoskeletal health including family history of 
musculoskeletal disease, previous fractures, conditions that may affect bone or Ca homeostasis, use 
of medications that may affect bone or Ca homeostasis, contraceptive use, and the use of vitamin 
and mineral supplements. Lifestyle factors such as smoking, alcohol consumption, and physical 
activity were also assessed. Details of their reproductive history such as gravidity, parity, and 
whether they had previously breastfed were also collected in the questionnaire. These data were 
entered by members of the research team.  
Outcome 14-16 weeks 34-36 weeks 
Anthropometric Measurements 
Height (cm)   
Weight (kg)   
Forearm length (mm)   
Lower leg length (mm)   
Questionnaire Measurements 
Musculoskeletal Questionnaire    
pQCT 
Radius   
Tibia   
HRpQCT 
Radius   




5.5.2 Bone Imaging 
Volumetric BMD and related parameters of bone strength were measured (pQCT and HRpQCT) 
twice during the study period at the forearm and lower leg. All procedures were conducted at MRC 
EWL in a dedicated scanning room located within the purpose built volunteer suite. All scans were 
performed by trained investigators in compliance with local radiation use guidelines (IRMER, IRR 
2017). Due to ethical considerations and to put pregnant participants at ease the option of wearing 
a lead apron as used clinically (Lead equivalence 0.35 mm) was offered to pregnant participants. 
Prior to the submission of the study for ethical review the dose and associated risk of the bone 
imaging procedures were quantified and approved by the East Anglian Regional Radiation 
Protection Service and were considered to be low (Table 5.6). Dosimeters present in the scanning 
rooms monitor the level of X-ray scatter from the devices and the EWL records indicate that no 
scatter is detectable within the scan rooms. The total effective dose to the participant was estimated 
to be <18.4 μSv (Table 5.6). The effective fetal dose was calculated to at <10 μSv. This effective 
dose presents no risk of any deterministic (acute) effects. Any future risk was quantified using the 
Health Protection Agency’s “Protection of Pregnant Patients during Diagnostic Medical Exposures 
to Ionising Radiation” (Health Protection Agency, 2009). The increased risk of cancer occurring in 
the infant up to the age of 15 due to the exposure (10 μSv) will be ~1 in 1,300,000, much lower 
than the natural risk of childhood cancer in the UK (1 in 500). Wearing the lead apron over the 
abdomen reduced the risk by a factor of approximately 10.  
Cambridgeshire is considered to be a low background radiation area in the UK (~7 μSv/day) 
meaning that the exposure to a woman in this study was equivalent of less than three days of 
background radiation in Cambridgeshire, or less than a quarter of the exposure from a return 
transatlantic flight (~80 μSv). MRC EWL has strict policies for the use of ionising radiation and 






Table 5.6 Maternal effective dose in microSieverts (µSv) per scan, estimates provided by the East Anglian Regional 
Radiation Protection Service (EARRPS) 
 
 
All acquired scans were reviewed by me, any unusual or abnormal scans were brought to the 
attention of Dr Kate Ward and the study clinician, Dr Sumantra Ray. If required, scans could be 
sent for review by musculoskeletal health experts at Cambridge University Hospitals who would 
decide if clinical follow up was required via the participant’s GP.  
 
Figure 5.5  Location of pQCT regions of interest (ROI) and HRpQCT volume of interest (VOI) at the radius and tibia 
Location of pQCT and  HRpQCT scan sites at the radius (top) and tibia (bottom), shown with corresponding pQCT 
scan images (centre left) An example of HRpQCT 3D reconstruction of the distal tibia is displayed centre right. For 
contrast radius scan slices(top right) from pQCT (voxel size 0.5 mm) and HRpQCT (voxel size 82 μm) are shown from 
almost equivalent sites note the difference in scan detail as a result of the discrepancy in resolution
Procedure Estimated visit dose Total Estimated study dose 
pQCT scan of the tibia <1.6 μSv <3.2 μSv 
pQCT scan of the radius <1.6 μSv <3.2 μSv 
HRpQCT scan of the tibia <3 µSv <6 µSv 
HRpQCT scan of the radius <3 µSv <6 µSv 




5.5.3 High Resolution peripheral-QCT  
HRpQCT scanning was performed using a first generation XtremeCT (Scanco Medical AG, 
Brüttisellen, Switzerland) and all scans were assessed using the manufacturer’s image processing 
language software (μCT Evaluation Program v6.0; Scanco Medical AG, Brüttisellen, Switzerland). 
The following scan settings were used for all scans: an X-ray potential of 60 kVp, X-ray tube current 
of 900 μA, integration time of 100 mins, matrix size of 1536 x 1536 and voxel size of 82 μm. This 
system enables the simultaneous acquisition of a stack of 110 CT slices, which correspond to a 9 
mm section along the axial direction; the result is a volume of interest of the scanned distal radius 
and tibia. Prior to scanning, the procedure, including the initial scout scan and measurements, was 
explained clearly to the participant. The participant was seated in an adjustable chair and the same 
arm/leg scanned as with pQCT. The limb was immobilised in a carbon fibre cast (Figure 5.7). 
 
Figure 5.6 Carbon fibre casts allow for the limb to be immobilised during scanning.  
Left, tibia cast with adjustable insoles and calf pads. Right, radius cast with pads of different sizes. 
 
At baseline if the participant’s non-dominant limb had previously been fractured the 
manufacturer’s instructions to select the dominant side were followed. At follow-up if an injury 
had occurred to the previously scanned radius or tibia, the unaffected limb on the opposite side 
was scanned. The cast maintained the position of the participant’s forearm or lower leg in the 




necessary to select the proper rubber foot-well fittings (Figure 5.7). For the radius it was necessary 
to rotate the joint so that the dorsal side of the limb touched the cast; foam was then used on the 
other side and the straps were attached. The height of the chair was adjusted as required, particularly 
during the leg measurement, to ensure that the participant’s leg was in a horizontal position within 
the gantry.  
5.5.3.1 HRpQCT Scan Acquisition 
Prior to scanning pre-calibration was required, it was necessary to first specify which mask to apply 
(i.e. left/right and radius/tibia). An incorrect mask will scan the wrong region (incorrect limb) 
and/or at the wrong angle (incorrect side). Pre-calibration was performed without the participant 
in the scanner so as not to expose them to unnecessary ionising radiation. In-keeping with the 
manufacturer’s guidelines and as described in detail by Boutroy et al. (2005) antero-posterior 2D 
scout views were performed to determine the region to be scanned (Figure 5.8). 
 
Figure 5.7 Examples of the correct positioning of reference line at the distal radius and tibia 
 
A reference line was manually placed at the endplate of the radius and tibia (Figure 5.6), with the 
first CT slice 9.5 mm and 22.5 mm proximal to the reference line for the distal radius and distal 
tibia, respectively. Following this, a stack of parallel CT slices were acquired using a 2D detector 
array. The entire volume of interest was automatically separated into a cortical and a trabecular 
region. All scans were acquired by trained technicians using the standard positioning techniques as 




(see below), if present the participant was asked if they would consent to a second scan being 
performed. 
5.5.3.2 HRpQCT Image Grading  
The quality of the HRpQCT measurements of the distal radius and tibia was assessed using a five- 
grade scale as outlined Pauchard et al. (2012) and recommended by the manufacturer (1, excellent; 
2, good; 3, acceptable; 4, poor; 5, unacceptable) (Pauchard et al., 2012). Scans graded 1 to 4 were 
included in the analysis, grade 5 images with significant motion artefacts causing inblurring and 
discontinuities in the cortical shell were excluded (Figure 5.9). 
 
Figure 5.8 HRpQCT scan grading for inclusion in data analysis.  
Grade 5 scans are excluded from the final dataset (red box). Scans of grade 4 (green solid box) and below are 
acceptable for inclusion in analysis. I tested grade 4 against grade 3 (dashed green box) scans and found little 




5.5.3.3 HRpQCT Scan Analysis 
All analyses were performed using the manufacturer’s software installed on a HP AlphaStation 
DS25 operating in a VMS environment (Hewlett-Packard, Palo Alto, CA, USA). The first stage of 
the standard analysis began using a semi-automated, hand-drawn contouring system to delineate 
the periosteal surface. This contour line was applied around the periosteal boundary of the cortex 
in the first (most distal) CT slice to separate the bone from the surrounding soft tissue. The semi- 
automatic contour script applied a contour line to all CT slices within the stack. Manual checking 
of all slices allowed for the amendment of the contour line if required (Figure 5.10). Following this 
a threshold-based algorithm was used to separate cortical from trabecular compartments (Laib et 
al., 1998). This threshold was based on the assumption that trabecular bone is one-third of the 
apparent cortical vBMD (Burrows et al., 2010). The CT slices were binarised (i.e. converted into 
grey scale images) and subsequently the cortex was segmented from the trabecular compartment 
using a Gaussian filter and threshold which removed thin trabeculae and noise from the images, 
allowing for the separate analysis of the cortical and trabecular compartments (Laib and 
Ruegsegger, 1999). Following this, the linear (X-ray coefficient) attenuation values of the CT slices 
were converted into hydroxyapatite (HA) mineral densities using a calibration phantom and a 
beam-hardening correction (see below). 
This process allowed for the direct estimation of whole, cortical, and trabecular vBMD. Total bone 
area was calculated by averaging the total area of each CT slice. In the standard analysis cortical 
thickness was calculated as mean cortical volume divided by the periosteal surface. On average the 
thickness of the trabecular rod and plate structures fall between 100 to 150 μm which is the 
equivalent of 1-2 voxels.  As a result of this several XtremeCT trabecular structural parameters (i.e. 






Figure 5.9  Contouring the periosteal perimeter examples of appropriate, adequate, inadequate contouring at the 
distal radius 
The above examples show the difference between appropriate, adequate, inadequate contouring of the periosteal 
perimeter at the distal radius. Correct region of interest select involves the use of an automated contouring 
algorithm but requires the subjective assessment of each slice by the operator to correct any errors or suboptimal 
contouring:  A (above left) shows correct contouring no action necessary; B above centre is adequate but would 
benefit from adjustment; C (above right) highlights incorrect and unusable contouring. Of the 3 examples C would 
require correction prior to the evaluation of the scan as a section of bone tissue is not included in the volume of 
interest (VOI) and thus the outcome measures will be affected if not manually corrected by the operator.  
 
As outlined in Chapter 1 PVEs can occur which reduces precision (Laib et al., 1998, Laib and 
Ruegsegger, 1999, Cheung et al., 2013). With the exception of Tb.N all trabecular parameters are 
derived. Tb.N is calculated by using a 3D ridge extraction algorithm, which measures inter- 
trabecular distances between the “centre points of the trabeculae” (i.e. ridges), by placing a sphere 
between the ridges (Figure 5.11) (Laib et al., 1997, Laib et al., 1998, Laib and Ruegsegger, 1999). 
Tb.N is defined as the inverse of the mean spacing of the mid-axes and does not depend on the 
assumptions of the plate-and-rod model (Boutroy et al., 2005). Longitudinal HRpQCT data were 
selected for analysis if a suitable common region was present in baseline and follow-up scans; only 
scans with ≥80% matched region were included. This was to ensure that the mean values obtained 
from the VOI were not disproportionately affected by scanning physiologically dissimilar regions 
at the two visits. This approach is in-keeping with published longitudinal data (Burt et al., 2017).  






Figure 5.10 Schematic diagram of HR-pQCT trabecular microarchitectural parameters.  
Trabecular number (Tb.N) is calculated by placing a sphere between two trabecular ridges and measures the inter-
trabecular distance. Right: trabecular compartment as measured with HRpQCT with an integration time of 100 ms 
(the same as used in PABS). Adapted from Laib and Ruegsegger (1999). 
 
5.5.3.4 HRpQCT Quality Assurance (QA) 
Quality Quality control testing was performed on a weekly basis and quality assurance on a daily 
basis using a calibration phantom (Scanco Medical AG, Bruttisellen, Switzerland) to monitor the 
performance of the scanner and to ensure there was no drift in the measurements. In addition to 
the standard phantom, the scanner was pre-calibrated before every subject was scanned. The 
manufacturer’s phantom is composed of 5 cylinders containing a mixture of hydroxyapatite and 
resin (Figure 5.12). The mineral concentrations of these cylinders were 0, 100, 200, 400 and 800 
mgHA/cm3. The value of 0 mgHA/cm3 equates to that of a soft tissue background devoid of 
mineral. Short term precision values for cortical and trabecular BMD have been shown to range 





Figure 5.11 HR-pQCT calibration phantom scanned daily during the study period.  
The mineral concentrations of these cylinders were 0, 100, 200, 400 and 800 mgHA/cm3. QC1 (daily) and QC2 
(weekly) shown far left and far right. Images obtained from Scanco Medical 
 
 
Table 5.7 Coefficients of variation for HRpQCT parameters from the standard analysis Pagiossi et al (2014). 
Parameter  Radius (%) Tibia (%) 
Total vBMD  1.1 0.2 
Trabecular vBMD  1.1 0.3 
Cortical vBMD  4.8 0.1 
Trabecular number 4.3 3.0 
Trabecular  thickness  3.8 2.9 
Trabecular separation  4.4 3.0 
BV/TV 1.2 0.3 
Cortical thickness  2.7 0.4 
Cortical porosity  12.7 5.2 
vBMD = volumetric bone mineral density, BV/TV = Trabecular bone volume/bone volume 
 
 
5.5.4 Peripheral QCT Scanning  
Standard operating procedures (SOP_0373, SOP_0499) were followed for all procedures to obtain 
the outcome measures listed in Table 5.6 at each time point. These are consistent with those used 
in the ENID Bone Study (Section 3.3.2). The scanning procedure including the initial scout scan 
and successive measurements were explained to participants prior to scanning. The participants 
were made comfortable, asked not to talk, and instructed to keep perfectly still during the procedure 




5.5.4.1 Limb length measurement  
Scan sites were located by the pQCT scout view as a set percentage of object (limb) length 
measured from a physiologically defined reference line at the distal end of the long bone. Object 
length was measured using a metal ruler between prominent bony landmarks. Participants were 
asked to remove footwear and clothing from the lower non-dominant leg (unless impracticable) 
which was measured from the tibial plateau to the medial malleolus (ankle) with a metal ruler to 
record the distance, in a straight line, between these two points to the nearest 0.5 mm. For radius 
length, as above the non-dominant side was always used. Radial object length was obtained with 
the arm on the non-dominant side bent at a right angle, and the distance between the olecranon 
(near elbow) and the distal edge of the ulnar styloid process (bony prominence at wrist) measured 
with a metal ruler to the nearest 0.5 mm. 
5.5.4.2 pQCT Scan Acquisition  
Scan parameters were specified in the measurement mask (Figure 5.6), the object length is entered 
to automatically calculate the scan site. The operator ensured that the limb was centrally positioned 
before scanning, with the limb positioned so that the laser light was distal to the medial 
malleolus/ulnar styloid process of the tibia or ulna respectively. Next, a scanogram was obtained 
to allow visual assessment in the positioning of the reference line which the software automatically 
places; if incorrect this line was repositioned manually as appropriate. The scout scan was repeated 
if the operator failed to identify the correct region due to poor positioning or participant 
movement. Once the reference line was in the correct region, the acquisition of scan images began. 
The scan sites were determined by the mask selected by the operator prior to scanning. All pQCT 
scans were obtained using a voxel size of 0.5 mm and slice thickness of 2 mm. A CT scan speed of 





Figure 5.12  Masks used in PABS and sites selected by the mask  
Scan slices at the distal and proximal radius were obtained using the RADIUS~1 mask in all participants, scans at 
4%,33%, and 66% of the radius length are shown above. At the distal and proximal tibia the TIBIA4S mark (below) 
was used to obtain scan data at 4%, 14%, 38%, and 66% of the tibia length. Note that when a subject’s leg was too 
wide to obtain data comfortably at the 66% tibia an alternative mask, called TIBIA was used to obtain data at the 
3 other tibial sites. 
 
Scans were acquired at 4%, 33%, and 66% radius sites (Radius~1 mask), and at 4%, 14%, 38%, 
and 66% tibia sites (Tibia4S mask). The only deviation from this protocol was the use of the TIBIA 
mask of 4%, 14%, and 38% for participants whose lower leg was too wide to fit through the gantry 
at 66% of the tibia. All scan images were visually inspected by me directly following scan 
completion. The pQCT scanner is very sensitive to movement which can result in scan distortion. 
If a scan slice was particularly poor the participant was asked if they would consent to a rescan. 
Scan grading and data processing are consistent with the methods outlined for the ENID Bone 
pQCT data in Chapter 3 but briefly, at distal sites CALCBD analysis using contour mode 1, peel 
mode 1 at a threshold of 180 mg/cm3 was used with trabecular bone defined as the inner area of 
45% of the total CSA. At cortical sites the threshold of 710 mg/cm3 was selected for cortical bone 
parameters and analysed using CORTBD separation mode 1.  Total CSA at proximal sites was 





by Darren Cole (Manager of Data Operations at MRC EWL) with my technical input and testing, 
to select and filter the appropriate data for our outcome measures of interest prior to statistical 
analysis and data modelling in R.  
5.5.4.3 pQCT Quality Assurance (QA)  
Calibration of the XCT 2000LTM system was performed on a routine basis with a specifically 
designed phantom. Daily QA scans were performed throughout the study period to test scanner 
performance. Weekly QC scans were also performed by the research team as required. The inter-
operator precision for each scan site is summarised in Table 5.8. These were measured by 
performing two repeat scans on 30 participants at MRC EWL, Cambridge. 
Table 5.8 Coefficients of variation (CVs) for pQCT parameters as measured by Stratec XCT 2000L 
Parameter Radius Tibia 
Total vBMD  4.28% 1.10% 
Trabecular vBMD  2.27% 0.94% 
Total CSA (distal) 4.03% 1.61% 
Total CSA (proximal) 3.71% 1.01% 
Cortical CSA  1.97% 0.89% 
Cortical vBMD  0.89% 0.41% 
Cortical BMC  1.78% 0.59% 
Cortical thickness  4.25% 1.49% 
 vBMD = volumetric bone mineral density, CSA = cross sectional area, BMC = bone mineral content  
 
 PABS data management  
All data from screening questionnaires, measurement visits and the midwife screening was entered 
into the study database by the research team. The PABS database was developed on Microsoft 
Access by Darren Cole (MRC EWL Head of Data Management). Researchers were able to read, 
create and edit data generated and the database was backed up on a daily basis. Participant ID 
numbers were assigned in the database at the point of telephone screening. These were 
automatically generated when a new record was created. Once an ID number was assigned, it 





Table 5.9 Documentation entered into the database from each of the study time points 
Study form Visit 1 Visit 2 
Telephone screening  Ahead of visit 1 X 
Consent   X 
CRF visit 1  X 
Musculoskeletal questionnaire visit 1  X 
CRF visit 2 X  
Musculoskeletal questionnaire visit 2 X  
Mid-pregnancy midwife screening form X  Ahead of visit 2 
CRF= case report form 
 
All data collected at the visits e.g. CRF and musculoskeletal questionnaire, were subsequently 
entered into this database by members of the research team (Table 5.9). Following 10% checks of 
the entered data, the relevant data were selected and extracted to create a database containing all 
subject level anonymised data. As described above bone densitometry data were extracted from 
both the pQCT and HRpQCT following the auditing and grading of all scans. pQCT, 
anthropometry and questionnaire data were combined in preparation for analysis.   
 
5.6.1 Data cleaning and preparation for analysis  
Further to the grading processes outlined in detail in Chapter 4 for pQCT data and above for 
HRpQCT, the extracted data were also scrutinised in R through the use of box and whisker plots 
to identify extreme outliers (>1.5 times the IQR), the relevant scans and scout views were visually 
inspected and scans of poor quality or inaccurate positioning were subsequently removed from the 
analysis dataset. Incorrect ROIs were amended and then the data were re-extracted. In addition to 
examining outliers in the absolute values from both scanners, I also explored the change in the 
outcome measures of interest to detect any change that may have been the result of poor/incorrect 
positioning (i.e. seem exceedingly large). Again these data were plotted with box and whisker plots 






Table 5.10 HRpQCT scans at the distal tibia, number acquired and number subsequently used in longitudinal 
analyses of scan grade ≤4 and with ≥80% common region. 
 Pregnant (n = 53) NPNL (n = 37) 
 Tibia Radius Tibia Radius 
Acquired visit 1  50*# 49*# 37 36 
Acquired visit 2 40# 37# 34 31 
Longitudinal analysis  35 33 33 27 
*machine down time resulted in 3 participants not having baseline scans  
 
Table 5.11 Number of pQCT scans excluded from the dataset after being identified as extreme outliers at the distal 
and proximal tibia at visit 1, visit 2, or the between visit change using box and whisker plots*. 
 Tibia Radius 
 4% 14% 38% 4% 33% 
 P N P N P N P N P N 
Acquired visit 1  53 37 53 37 53 37 53 37 53 37 
Acquired visit 2 46 37 46 37 46 37 46 37 46 37 
Longitudinal analysis* 46 34 46 35 46 35 42 35 45 37 
*scan images were visually inspected before any data were omitted from subsequent analyses 
 
 
 Statistical methods  
All statistical analyses presented below were conducted in R version 3.3.1 primarily using dplyr 
(version 0.5.0, Wickham and Francois, 2016) and tidyverse (version 1.1.1, Wickham, 2017) for 
general data manipulation, and ggplot2 (version 2.2.1, Wickham 2009) for graphics in addition to 
ggfortify (version 0.4.5, Horikoshi and Tang, 2016). MASS (version 7.3-51, Ripley et al, 2018) was 
used to assist the generation of linear regression models. Data presented from regression models 
were tabulated using stargazer (Hlavac, 2018). 
 
5.7.1 Initial analysis and testing for normalcy after initial cleaning of the data 
Histograms were used to explore whether the data were normally distributed. Between-group 
differences at baseline were explored by independent t-tests where the data were normally 
distributed; an appropriate non-parametric test (Mann-Whitney U test) was used where the data 




5.7.1.1 Absolute within-group changes between baseline and follow up 
For all HRpQCT and pQCT data absolute between-visit change was calculated by subtracting the 
baseline bone outcome measure values from their respective follow-up values. Subsequently I used 
single-sided t-tests to determine if the absolute change variables in the Pregnant and NPNL groups 
differed significantly from zero.  
 
5.7.2 Modelling of the longitudinal HRpQCT and pQCT data 
5.7.2.1 Computation of standardised residuals   
Baseline and follow up measures were very tightly correlated so I chose to use a measure of 
conditional change i.e. standardised residuals. Standardised residuals were calculated for all pQCT 
and HRpQCT bone outcome measures using simple linear regression. Follow up outcome 
measures were regressed by their respective baseline values with standardised residuals extracted 
from the models. The use of standardised residuals would allow for the simple comparison of 
change across scanners and the various units and scales of my outcome measures. The use of SD 
scores (Z scores) is routinely used in clinical practice and is a convenient means of visualising 
change e.g. from aging studies it is known that a decrease of 1SD in aBMD at the femoral neck 
doubles the risk of fracture (Marshall et al., 1996). The examination of the standardised residuals 
for all outcome measures of interest through the use of diagnostic plots also allowed for the 
identification of scans that needed further scrutiny with all data and the original scans visually 
inspected (Figure 5.13). If a participant was identified as an outlier on these plots I selected all of 
their scan data for inspection, however, the decision to remove data from analysis was taken 
carefully as several “fast losers” of bone mineral were identified where a) the positioning of the 
scans were almost identical, b) with no change in bone CSA, c) high quality of scan grade/matched 
scan region. Any scans with all of a-c mean that the large between-visit changes would be unlikely 





For pQCT I used diagnostic plots for all parameters to identify scans that required further scrutiny. 
I tabulated the residuals for all parameters for these individuals and to avoid over-cleaning the data 
I based my inclusion criterion on total CSA. The rationale for this was simple, in adults a small to 
moderate change in total CSA over the study time frame would be physiologically unlikely. This 
also avoided the risk of excluding true physiological outliers as seen in Figure 5.13 of total vBMD. 
The criterion I applied was if the standardised residual for total CSA exceeded 1SD for a participant 
then their data would be excluded. Following this approach I had usable longitudinal pQCT data: 
at the 4% distal tibia for 77 subjects; at the 14% tibia for 75 subjects; at the 38% tibia for 77; at the 
4% distal radius for 71 subjects; at the 33% radius for 76. 
For HRpQCT the same approach was applied to identify participants whose scans required 
further scrutiny. These data were then examined with a focus on a) the percentage common region 
between the scans, b) the scan grade at each visit, and c) any implausible changes in parameters of 
bone microarchitecture. At the tibia all scans identified for scrutiny had a very high common region 
and the grade quality of the scans were also good, for this reason no data points were excluded. At 
the radius while the matched common region of scans requiring scrutiny were high, several grade 
4 scans were present at one time point or other. I pragmatically decided not to exclude any of the 
data points from my final models as running the models with these data included/excluded had 





Figure 5.13 Diagnostic plots of the linear regression of pQCT total vBMD at follow up by baseline total vBMD. NPNL 
= non-pregnant non-lactating controls, P = Pregnant.  
 
5.7.3 Model and covariate selection 
Following these steps I performed linear regression adjusting my models as follows to explore 
between-group differences:  
5.7.3.1 Model 1: unadjusted between-group differences  
Model 1 simply explores the between-group difference in the standardised residuals generated 
above where Yi is the standardised residual bone outcome as measured for participant I.  
𝑀𝑜𝑑𝑒𝑙 1: 𝑌𝑖 = 𝛽𝑜 + 𝛽1𝐺𝑟𝑜𝑢𝑝 + 𝜖 
5.7.3.2 Model 2: between-group differences adjusted for height and weight, and age  
If between-group differences emerged in Model 1 it would be important to determine if adjusting 
for height and weight parameters attenuated any findings. Both height and weight are known to be 
associated with inter-individual differences in bone outcome measures particularly in the axial and 




perceptive the relationship between bone and weight is an important one. Greater weight can be 
associated with higher BMD, while gaining weight can potentially increase strain leading to 
increased turnover and increases in BMD and BMC. My decision to use baseline weight only in 
these analyses followed the exploration of weight change as a possible covariate, the use of weight 
change was rejected as it over fitted the models effectively controlling for group twice. The within 
group weight changes are shown below (Figure 5.14). 
 
Figure 5.14 Boxplots of baseline weight, BMI, and weight change stratified by group. 
At baseline NPNL were heavier and had a higher mean BMI than pregnant women, however, neither of these were 
statistically significant. Pregnant women gained significantly more weight than NPNL (p<0.05).  
 
Age was also adjusted for as bone changes naturally occur from mid-life onwards and my target 
population range encompassed women aged 30-45 years (Uusi-Rasi et al., 2007). The models were 
constructed as follows where Yi is the standardised residual bone outcome as measured by pQCT 
for participant I:  




5.7.3.3 Model 3: between-group differences from parsimonious models of best fit  
Covariate selection was defined by several a priori considerations. In addition to baseline weight, 
height and age (Model 2) a number of additional factors were considered. In some populations 
such as The Gambia (see section 3.4.5) parity is highly correlated with maternal age however in 
PABS there was poor correlation (adj R2 = -0.01) and I chose to include both variables. Parity was 
recoded into a binary variable for analysis 0 for nulliparous women or 1 for where parity was ≥1 
(Olausson et al., 2008). Potential environmental confounders were also included: historical or 
current use of hormonal contraceptives which may influence bone; history of smoking (i.e. ever 
smoked) as smoking has been associated with lower BMD and related bone parameters 
(Eleftheriou et al., 2013, Oyen et al., 2014). 
When this initial model was run, with all independent variables included simultaneously, all 
between-group differences detected in Model 1 and 2 were attenuated due to multicollinearity. 
Therefore I used the MASS package to perform backwards elimination of non-significant factors, 
the least significant being removed first, to generate models which could be compared to select a 
model of best fit for each bone outcome. These were compared by ANOVA and the model of best 
fit selected as the model with the lowest AIC value. AIC did not appear to favour the selection of 
an excessive number of covariates as in most models only a handful of covariates were selected in 
the model of best fit. I included group in all models even if group was not selected in the final 
model of best fit to allow for the interpretation of any group differences. 
For all outcome measures of interest the initial model was as follows where Yi is the standardised 
residual for bone outcome as measured by pQCT for participant I:  
𝑀𝑜𝑑𝑒𝑙 3: 𝑌𝑖 = 𝛽𝑜 + 𝛽1𝐺𝑟𝑜𝑢𝑝 +  𝛽2𝑤𝑒𝑖𝑔ℎ𝑡 + 𝛽3ℎ𝑒𝑖𝑔ℎ𝑡 + 𝛽4𝑎𝑔𝑒 + 𝛽5𝑝𝑎𝑟𝑖𝑡𝑦





6 Results from PABS  
In total 53 pregnant women (recruited at the Rosie Hospital (CUH) n=50, recruited from the 
community n=3) met our eligibility criteria and were scanned between 14 – 16 weeks of pregnancy 
(mean 15.5 (SD 0.9) weeks).  A control group of 37 NPNL women was recruited from the 
community through internal MRC unit emails, the MRC EWL VSCS volunteer database, posters, 
and local advertisements.   
 
Figure 6.1 Proportion of participants in each group who completed the study or were lost to follow up. 
Ninety women, 53 pregnant and 37 non-pregnant non-lactating controls (NPNL) were recruited into the Pregnancy 
and Bone Study (PABS). All NPNL completed the study, while 86% of the pregnant group (P, n = 46) completed the 
study. In the pregnant group 5 women were lost to follow up, 1 participant delivered prior to visit 2, and 1 
participant was not contacted following mid-pregnancy screening. 
 
 Baseline descriptive statistics   
Pregnant women had on average a 19.6 (SD 1.6) week difference between baseline and follow-up. 
While this was found to be statistically significantly different compared to that of the control arm, 
21.6 (SD 1.7) weeks (p<0.05), from an aging perceptive 2 weeks can be considered negligible and 




6.1.1 Group differences in age, anthropometry, and parity 
Group characteristics are summarised in Table 6.1 with the baseline mean (SD) for all continuous 
parameters of interest with the exception of parity expressed as median (IQR).  The only significant 
between-group difference at baseline was that the control group had a higher parity.  
Table 6.1 Baseline mean (SD) for anthropometry measures at baseline in non-pregnant non-lactating (NPNL) and 
pregnant groups. Parity is expressed as the median [IQR].  
                              NPNL (n = 37) Pregnant (n = 53) 
Age (years) 36.04 (3.99) 34.90 (3.58) 
Weight (kg) 70.41 (13.70) 68.34 (13.58) 
Height (cm) 164.16 (7.19) 165.13 (5.70) 
BMI 26.19 (5.22) 25.00 (4.51) 
Parity  2 [0, 4] 1 [0, 2]* 
Contraceptives (1 = ever , 2 = never) 1.14 (0.35) 1.06 (0.23) 
Weeks between visits  21.7 (1.7) 19.8 (1.6)* 
*p<0.05, **p<0.01, ***p<0.001 independent t-test between groups at baseline.   
 
6.1.2 Differences at baseline in bone outcomes  
Tables 6.2 and 6.3 contain baseline data from participants with complete data at baseline and follow 
up. Reasons for incomplete data were a) there was a 13% attrition rate (n=7) in the pregnant arm, 
b) HRpQCT down time resulted in 3 participants not having baseline scans, c) unusable scans were 
excluded leading to missing data at either time point. The data presented (Tables 6.2 & 6.3) did not 
differ from that when all baseline data were included nor did the pattern of between-group 
differences differ (Appendix F). Statistically significant between-group baseline differences were 
found for a number of HRpQCT bone outcome measures at the distal tibia. In pregnant women 
at 14-16 weeks gestation, trabecular number (1.98 (0.27) mm-1) was lower compared to NPNL 
controls (2.13 (0.27) mm-1) (p<0.05, Table 6.2). While the mean trabecular thickness of pregnant 
women (0.073 (0.013) mm) was found to be significantly greater than NPNL controls (0.065 (0.014) 
mm) (p<0.05, Table 6.2). At the distal radius no significant between-group baseline differences in 
any HRpQCT bone outcome measures were found. Nor were any significant pQCT between-




                                  
Figure 6.2 Distribution of age (years), height (cm), weight (kg), and parity at visit 1.  
Non-pregnant non-lactating (NPNL) women are in pink, pregnant women (P) are represented in blue. When tested, with t-tests for normally distributed data and Mann-Whitney U tests 




 Single-sided t-test to assess within-group change  
6.2.1 Absolute change within-group change  
6.2.1.1 Tibia: Absolute within-group changes between baseline and follow up 
In pregnant women all HRpQCT bone outcome variables decreased with the exception of 
trabecular number and cortical porosity which increased, all changes were statistically significantly 
different to zero (Table 6.2). While in the control group total vBMD, trabecular vBMD, and 
BV/TV decreased between visits (all p<0.05) cortical thickness increased (p<0.05) (Table 6.2). In 
pregnant women there were significant between visit decreases in all pQCT parameters of total 
vBMD, trabecular vBMD (both p<0.001), total CSA (p<0.05) and cortical subcortical vBMD 
(p<0.01) at the 4% distal tibia, whereas in the control group a drop in trabecular vBMD (p<0.05) 
was the only significant change. At the 14% proximal tibia within-group changes were not found 
in either group. In the pregnant group significant increases in periosteal (p<0.05) and endosteal 
circumferences (p<0.01) were found at the 38% tibia. In NPNL a significant increase was found 
in periosteal and endosteal circumferences (p<0.05), with a decrease in cortical thickness (p<0.05). 
6.2.1.2 Radius: Absolute within-group changes between baseline and follow up 
In the pregnant women significant decreases in total vBMD (p<0.05), trabecular vBMD (p<0.001), 
BV/TV (p<0.001), and cortical vBMD (p<0.01) were found (Table 6.3). While in the NPNL group 
decreases in total vBMD (p<0.05), trabecular vBMD (p<0.001) and BV/TV (p<0.05) were 
statistically significantly different to 0 (Table 6.3). No statistically significant within-group changes 
were found in either group with pQCT at the 4% distal radius, however, within-group differences 
were found at the 33% proximal radius (Table 6.3). In pregnant women the only significant change 
was an increase in cortical BMC (p<0.05), while in the NPNL group significant within-group 
change was found for cortical thickness which increased (p<0.01) and periosteal (p<0.05) and 




Table 6.2 Baseline characteristics (mean (SD)) and within-group absolute change between visits (mean (SD)) for pQCT and HRpQCT bone outcome measures of interest at the tibia in 
non-pregnant non-lactating (NPNL) and pregnant groups in PABS Cambridge.  
 NPNL Pregnant 
 Visit 1 Between-visit change Visit 1 Between-visit change 
HRpQCT distal Tibia n=32 n=33 
Total vBMD (mg/cm3) 315.26 (53.64) -1.50 (3.02)  ‡‡ 317.43 (68.09) -4.69 (6.32) ‡‡‡ 
Trabecular vBMD (mg/cm3) 165.53 (38.02) -2.55 (2.36)   ‡‡‡ 174.68 (41.33) -2.79 (3.59) ‡‡‡ 
Cortical vBMD   (mg/cm3) 921.45 (33.66) -0.85 (6.47) 916.26 (38.81) -7.40 (12.91)‡‡ 
BV/TV 0.14 (0.03) -0.002 (0.002)‡‡‡ 0.15 (0.03) -0.002 (0.003) ‡‡‡ 
Trabecular number (mm-1) 2.13 (0.27) -0.01 (0.15) 1.98 (0.27)* 0.09 (0.15)  ‡‡ 
Trabecular thickness (mm) 0.065 (0.014) -0.0007 (0.0043) 0.073 (0.013) * -0.004 (0.005) ‡‡‡ 
Trabecular separation  (mm) 0.41 (0.06) 0.00 (0.03) 0.44 (0.08) -0.02 (0.03) ‡‡‡ 
Cortical thickness (mm) 1.25 (0.22) 0.01 (0.01) ‡‡‡ 1.21 (0.29) -0.01 (0.02)‡‡ 
Cortical porosity   (%) 99.91 (7.16) 0.03 (0.23) 99.6 (8.3) 0.25 (0.25) ‡‡‡ 
pQCT 4% tibia n=34 n=43 
Total vBMD (mg/cm3) 301.57 (40.36) -0.18 (3.12) 306.25 (47.42) -3.07 (4.89) ‡‡‡ 
Trabecular vBMD (mg/cm3) 219.59 (39.15) -0.89 (2.25) ‡ 227.91 (44.01) -2.16 (3.63) ‡‡‡ 
Total CSA (mm2) 989.76 (111.06) -0.68 (10.75) 980.36 (115.47) -4.73 (13.89) ‡ 
Cortical subcortical vBMD (mg/cm3) 368.61 (44.90) 0.39 (5.54) 370.31 (54.56) -3.81 (7.74) ‡‡ 
pQCT 14% tibia n=32 n=43 
Total CSA (mm2) 416.34 (57.20) -0.46 (3.15) 409.23 (62.70) -0.80 (2.84) 
Cortical vBMD (mg/cm3) 1138.03 (18.84) -0.01 (5.62) 1141.29 (18.33 -2.15 (8.26) 
Cortical BMC (mg/mm) 189.70 (23.34) 0.45 (2.34) 187.06 (25.16) 0.27 (2.56) 
Cortical CSA  (mm2) 166.61 (19.83) 0.38 (2.42) 163.83 (21.38) 0.59 (2.04) 
Cortical thickness  (mm) 2.57 (0.33) 0.01 (0.04) 2.57 (0.41) 0.01 (0.04) 
Periosteal circumference (mm) 73.12 (4.90) -0.01 (0.33) 72.37 (5.51) -0.02 (0.25) 
Endosteal circumference (mm) 56.96 (5.74) -0.04 (0.45) 56.21 (7.03) -0.10 (0.41) 
pQCT 38% tibia n=35 n=42 
Total CSA (mm2) 392.90 (45.52) 1.26 (4.26) 378.45 (43.34) 0.92 (3.94) 
Cortical vBMD (mg/cm3) 1169.09 (24.25) 0.15 (4.63) 1172.08 (19.34) -1.53 (6.05) 
Cortical BMC (mg/mm) 324.76 (40.87) -0.17 (3.47) 315.44 (38.98) -0.26 (4.21) 
Cortical CSA  (mm2) 277.81 (34.70) -0.21 (3.71) 269.21 (33.59) 0.15 (3.75) 
Cortical thickness (mm) 4.91 (0.55) -0.03 (0.08) ‡ 4.84 (0.44) -0.02 (0.08) 
Periosteal circumference (mm) 72.09 (4.59) 0.25 (0.52) ‡‡ 70.75 (4.18) 0.23 (0.60) ‡ 
Endosteal circumference (mm) 41.24 (5.20) 0.47 (0.81) ‡‡ 40.34 (3.52) 0.38 (0.87) ‡‡ 
*p<0.05, **p<0.01, ***p<0.001 independent t-test between groups at baseline; ‡p<0.05, ‡‡p<0.01, ‡‡‡p<0.001 single-sided t-test vs 0.  vBMD = volumetric bone mineral density, CSA = cross sectional area, BV/TV = trabecular 





Table 6.3 Baseline characteristics (mean (SD)) and within-group absolute change between visits (mean (SD)) for pQCT and HRpQCT bone outcome measures of interest at the radius in 
non-pregnant non-lactating (NPNL) and pregnant groups in PABS Cambridge.  
 NPNL Pregnant 
 Visit 1 Between-visit change Visit 1 Between-visit change 
HRpQCT distal Radius n=27 n=33 
Total vBMD (mg/cm3) 334.75 (63.13) -3.15 (7.70) ‡ 334.20 (58.74) -2.89 (6.90)   ‡ 
Trabecular vBMD (mg/cm3) 155.10 (32.80) -2.53 (2.23)  ‡‡‡ 153.28 (39.86) -2.18 (3.34) ‡‡‡ 
Cortical vBMD   (mg/cm3) 916.35 (49.22) -3.45 (10.17) 920.46 (42.47) -4.32 (9.42)  ‡ 
BV/TV 0.13 (0.03) -0.002 (0.002) ‡‡‡ 0.13 (0.03) -0.002 (0.003) ‡‡‡ 
Trabecular number (mm-1) 2.02 (0.23) 0.04 (0.20) 1.95 (0.33) 0.01 (0.19) 
Trabecular thickness (mm) 0.06 (0.01) -0.002 (0.005) ‡ 0.07 (0.01) -0.001 (0.007) 
Trabecular separation  (mm) 0.44 (0.06) -0.005 (0.0419) 0.46 (0.10) -0.002 (0.051) 
Cortical thickness (mm) 0.81 (0.16) 0.003 (0.0307) 0.82 (0.14) -0.005 (0.026) 
Cortical porosity   (%) 66.74 (5.35) -0.10 (0.36) 66.68 (5.80) 0.08 (0.35) 
pQCT 4% Radius n=31 n=40 
Total vBMD (mg/cm3) 323.20 (51.77) 2.85 (14.28) 314.64 (48.69) -1.28 (16.21) 
Trabecular vBMD (mg/cm3) 180.41 (38.03) 0.76 (4.05) 176.45 (32.83) 0.06 (4.95) 
Total CSA (mm2) 328.69 (45.69) -0.44 (12.90) 335.80 (45.41) 0.34 (14.53) 
Cortical subcortical vBMD (mg/cm3) 439.83 (75.29) 4.56 (24.45) 427.56 (68.27) -2.39 (27.76) 
pQCT 33% Radius n=35 n=41 
Total CSA (mm2) 99.43 (12.33) -0.51 (1.52) 98.05 (12.56) 0.09 (1.32) 
Cortical vBMD (mg/cm3) 1218.13 (17.45) -1.32 (7.72) 1217.49 (15.81) 2.97 (12.35) 
Cortical BMC (mg/mm) 88.88 (9.37) 0.19 (0.99) 87.66 (10.31) 0.40 (1.05) ‡ 
Cortical CSA  (mm2) 72.96 (7.63) 0.24 (1.05) 72.02 (8.55) 0.15 (1.18) 
Cortical thickness (mm) 2.54 (0.21) 0.04 (0.08) ‡‡ 2.55 (0.22) 0.01 (0.07) 
Periosteal circumference (mm) 36.68 (2.08) -0.23 (0.55) ‡ 36.21 (2.34) -0.02 (0.55) 
Endosteal circumference (mm) 20.71 (2.10) -0.48 (0.96) ‡‡ 20.2 (2.3) -0.08 (0.89) 
*p<0.05, **p<0.01, ***p<0.001 independent t-test between groups at baseline; ‡p<0.05, ‡‡p<0.01, ‡‡‡p<0.001 single-sided t-test vs 0.  vBMD = volumetric bone mineral density, CSA = cross sectional area, BV/TV = 







 Group differences in conditional change  
6.3.1 HRpQCT at the distal tibia  
6.3.1.1 Model 1: Group only adjustment  
At the distal tibia significant between-group differences were found in total vBMD with the 
pregnant group decreasing by 0.64 (0.24) SD (p<0.01) (Table 6.4). While no significant changes 
were found in either trabecular vBMD or BV/TV several significant between-group differences 
were found in parameters of trabecular microarchitecture: number (increase by 0.53 (0.24) SD), 
thickness (-0.51 (0.24) SD), and separation (-0.61 (0.24) SD) (all p<0.05). Cortical vBMD was found 
to decline by -0.64 (0.24) SD between groups in the study period (p<0.01). In addition to changes 
in cortical vBMD, cortical microarchitecture was also significantly different between the groups, 
cortical thickness decreased (-1.6 (0.22) SD) while porosity increased (0.83 (0.23) SD) (both 
p<0.001). 
6.3.1.2 Model 2: Between-group differences adjusted for size and age  
Adjusting for size (baseline height and baseline weight) and age at baseline reduced the magnitude 
of the decrease in total vBMD (-0.56 (0.24) SD), however it remained significant (p<0.05). 
Adjusting for size and age slightly modulated the beta coefficients for parameters of trabecular 
microarchitecture increasing the between-group differences found in model 1: number 0.59 (0.24) 
SD (p<0.05), thickness -0.53 (0.24) SD (p<0.05), and separation -0.66 (0.24) SD (p<0.01). Baseline 
weight significant was a positive predictor of trabecular number (p<0.05), while there was a 
negative trend for both trabecular thickness and number. Model 2 reduced the magnitude of the 
decrease in cortical vBMD -0.62 (0.23) SD slightly in magnitude although this between-group 
difference remained significant (p<0.05). Between-group differences in cortical microarchitecture 
parameters remained highly significant (both p<0.001) though the magnitude of the difference in 




6.3.1.3 Model 3:  models of best fit  
As in models 1 and 2 above, using the parsimonious models outlined in Table 6.4 significant 
between-group differences were found in total and cortical vBMD, in addition to both trabecular 
and cortical micro-architecture. Total vBMD was found to decline by -0.49 (0.24) SD in the 
pregnant group vs NPNL (p<0.05), with no statistically significant predictors. No significant 
differences were found in the parameter of trabecular vBMD or BV/TV. Significant between- 
group differences in trabecular number (0.47 (0.23) SD) and separation (-0.54 (0.24) SD) remained 
(both p<0.05) although the between-group difference in trabecular thickness was attenuated (-0.47 
(0.24) SD, p=0.06). Baseline weight (positive) and parity (negative) were significant predictors of 
trabecular number (both p<0.05). Between-group differences remained in both cortical vBMD and 
cortical micro-architecture, cortical vBMD decreased by 0.67 (0.23) SD vs NPNL (p<0.01), while 
cortical thickness fell by 1.01 (0.21) SD (p<0.001). Cortical porosity increased 0.78 (0.23) SD in 
pregnant vs NPNL (p<0.01). Weight was a significant negative predictor of cortical vBMD 
(p<0.01). 
 
Table 6.4 Summarising results of linear regression models testing for group differences in change over time at distal 
tibia with HRpQCT in PABS Cambridge 
Tibia  HRpQCT (n=65) 
Dependant 
variable 
Group β1 p-value Group β2 p-value Group β3 p-value 
Covariates in 
parsimonious model 
Total vBMD -0.64 (0.24) P=0.01 -0.56 (0.24) P=0.02 -0.49 (0.24) P=0.04 age*, contraceptives 
Trabecular vBMD -0.01 (0.25) P=0.95 0.06 (0.25) P=0.83 0.04 (0.25) P=0.9 age 
BV/TV -0.05 (0.25) P=0.84 0.02 (0.25) P=0.92 0.004 (0.25) p=0.9 age 
Trab. number  0.53 (0.24) P=0.03 0.59 (0.24) P=0.02 0.47 (0.23) P<0.05 weight*, parity* 
Trab. thickness  -0.51 (0.24) P=0.04 -0.53 (0.24) P=0.03 -0.47 (0.24) P=0.06 weight, parity 
Trab. separation -0.61 (0.24) P=0.02 -0.66 (0.24) P<0.01 -0.54 (0.24) P=0.02 weight, parity 
Cortical vBMD -0.64 (0.24) P=0.01 -0.62 (0.23) P=0.01 -0.67 (0.23) P<0.01 weight* 
Cortical thickness -1.06 (0.22) P<0.001 -1.03 (0.22) P<0.001 -1.01 (0.21) P<0.001 age 
Cortical porosity  0.83 (0.23) P<0.001 0.83 (0.24) P<0.001 0.78 (0.23) P<0.001 parity 
Model 1 adjusted for group only; Model 2 adjusted for group, baseline height, weight, and age; Model 3 was ran with group, baseline 
height, weight, age, parity, smoking (ever), and contraceptives (ever) with the model of best fit selected by comparing the model AIC values. 
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Figure 6.3 Beta-coefficients of between-group differences from models applied to HRpQCT bone outcomes at the 
distal tibia.  
Model 1 adjusted for group only; Model 2 adjusted for group, baseline height, weight, and age; Model 3 was ran 
with group, baseline height, weight, age, parity, smoking (ever), and contraceptives (ever) with the model of best 
fit selected by comparing the model AIC values. In these parsimonious models total vBMD was adjusted for age, 
contraceptives (ever); trabecular vBMD and BV/TV were adjusted for age; Trabecular number, thickness and 
separation were adjusted for weight and parity; cortical vBMD was adjusted for baseline weight; cortical thickness 
was adjusted for age; cortical porosity was adjusted for parity. vBMD = volumetric bone mineral density, BV/TV = 





6.3.2 pQCT Tibia 4%  
6.3.2.1 Model 1 
Adjusting for group only I found significant between-group differences in total (-0.65 (0.22) SD) 
and cortical subcortical (-0.60 (0.22) SD) vBMD at the distal 4% tibia (both p<0.01). Trabecular 
vBMD showed a trend towards a decrease -0.40 (0.23) (Table 6.5, p=0.08), while no significant 
changes were found in total CSA.  
6.3.2.2 Model 2  
Adjusting for size and age increased the reductions in total and cortical subcortical vBMD, 
respectively -0.68 (0.23) SD and -0.63 (0.22) SD (both p<0.01). Weight, height, or age did not 
predict any of the change in pQCT outcomes at the distal tibia (Table 6.5).  
6.3.2.3 Model 3  
When selecting a best fit model for total vBMD the group only model (above) was found to have 
the lowest AIC (Table 6.5). A statistically significant between-group difference of -0.5 (0.23) SD in 
trabecular vBMD emerged following adjustments for weight, parity, and having ever smoked 
(p<0.05).  A -0.60 (0.22) SD difference in cortical subcortical vBMD between-groups, when 
adjusting for height and ever smoking (p<0.01, Table 6.5).  
 
6.3.3 pQCT at the 14% proximal tibia 
6.3.3.1 Model 1 
When adjusting for group only, no significant between-group differences were found in the 
between visit change in any pQCT bone outcome measures at the 14% proximal tibia (Table 6.5). 
6.3.3.2 Model 2  
Adjusting for baseline height, weight, and age did not reveal any significant between-group 




Baseline weight was found to be a negative significant predictor of cortical vBMD (p<0.01, Table 
6.5).  
6.3.3.3 Model 3  
As in Model 2 the parsimonious models of best fit found no significant between-group differences 
were found in the between visit change in any pQCT bone outcome measures at the 14% proximal 
tibia. Baseline weight remained a significant negative predictor of cortical vBMD (p<0.01, Table 
6.5). 
 
6.3.4 pQCT at the 38% proximal tibia 
6.3.4.1 Model 1 
No significant between-group differences were found in the between visit change in any pQCT 
bone outcome measures at the 38% proximal tibia when the models were adjusted for group only 
(Table 6.5). 
6.3.4.2 Model 2  
No significant between-group differences were found in the between visit change in any pQCT 
bone outcome measures at the 38% proximal tibia when the models were adjusted for size and age. 
Baseline height was found to be a significant positive predictor of change in cortical BMC, cortical 
CSA, and cortical thickness (all p<0.05, Table 6.5).  
6.3.4.3 Model 3  
As in Model 2 no significant between-group differences were found in the between visit change in 
any pQCT bone outcome measures at the 38% proximal tibia (Table 6.5). Baseline height was 
found to be a significant positive predictor of change in cortical BMC, cortical CSA, and cortical 





Table 6.5 Summarising results of linear regression models testing for group differences in change over time at tibia with pQCT in PABS Cambridge 
 
Tibia 4%   (n=77) 
Dependant variable  Group β1 p-value Group β2 p-value Group β3 p-value Covariates in parsimonious model  
Total vBMD  -0.65 (0.22) p=0.004 -0.68 (0.23) p=0.004 -0.65 (0.22) p=0.004 - 
Trabecular vBMD -0.40. (0.23) p=0.08 -0.40 (0.23) p=0.1 -0.50 (0.23) p=0.03 weight, parity, ever smoked 
Total CSA -0.36 (0.23) p=0.1 -0.33 (0.24) p=0.2 -0.36 (0.23) p=0.1 - 
Cortical subcortical vBMD -0.60 (0.22) p=0.008 -0.63 (0.23) p=0.007 -0.60 (0.22) p=0.007 height, ever smoked* 
Tibia 14% (n=75) 
Dependant variable  Group β1 p-value Group β2 p-value Group β3 p-value Covariates in parsimonious model  
Cortical vBMD -0.26 (0.23) p=0.3 -0.13 (0.25) P=0.2 -0.27 (0.23) p=0.2 weight*, contraceptives (ever) 
Cortical BMC -0.08 (0.24) p=0.7 -0.34 (0.23) P=0.61 -0.09 (0.24) p=0.7 - 
Cortical CSA 0.10 (0.24) p=0.7 -0.13 (0.25) P=0.7 0.08 (0.24) p=0.7 weight, contraceptives (ever) 
Cortical thickness 0.14 (0.24) p=0.6 0.10 (0.24) P=0.5 0.17 (0.24) p=0.5 weight 
Total CSA -0.14 (0.24) p=0.6 0.16 (0.24) P=0.6 -0.24 (0.24) p=0.3 parity, contraceptives (ever) 
Periosteal circumference -0.09 (0.24) p=0.7 -0.19 (0.24) P=0.6 -0.09 (0.24) p=0.7 - 
Endosteal circumference -0.15 (0.24) p=0.5 -0.13 (0.25) P=0.4 -0.15 (0.24) p=0.5 - 
Tibia 38% (n=77) 
Dependant variable  Group β1 p-value Group β2 p-value Group β3 p-value Covariates in parsimonious model  
Cortical vBMD -0.28 (0.23) p=0.2 -0.24 (0.23) p=0.3 -0.14 (0.23) p=0.6 age, height, contraceptives (ever) 
Cortical BMC -0.02 (0.23) p=0.9 -0.13 (0.23) p=0.6 -0.13 (0.23) p=0.6 weight, height* 
Cortical CSA 0.10 (0.23) p=0.7 -0.01 (0.23) p=0.9 -0.01 (0.23) p=0.9 weight, height* 
Cortical thickness 0.13 (0.23) p=0.5 0.05 (0.24) p=0.8 0.003 (0.23) p=0.9 height*, contraceptives (ever) 
Total CSA -0.07 (0.23) p=0.8 -0.11 (0.24) p=0.7 -0.06 (0.23) p=0.8 smoked (ever) 
Periosteal circumference  -0.06 (0.23) p=0.8 -0.12 (0.24) p=0.6 -0.06 (0.23) p=0.8 - 
Endosteal circumference  -0.12 (0.23) p=0.6 -0.11 (0.24) p=0.7 -0.12 (0.23) p=0.6 - 
Model 1 adjusted for group only; Model 2 adjusted for group, baseline height, weight, and age; Model 3 was ran with group, baseline height, weight, age, parity, smoking (ever), and contraceptives (ever) with the model of 
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Figure 6.4 Beta-coefficients of between-group differences from models applied to pQCT bone outcomes at the distal 
tibia.  
Model 1 adjusted for group only; Model 2 adjusted for group, baseline height, weight, and age; Model 3 was ran 
with group, baseline height, weight, age, parity, smoking (ever), and contraceptives (ever) with the model of best 
fit selected by comparing the model AIC values. In these parsimonious models total vBMD was adjusted for group 
only; trabecular vBMD was adjusted for baseline weight, parity and ever smoked; total CSA was adjusted for group 
only; cortical subcortical vBMD was adjusted for baseline height and ever smoked. vBMD = volumetric bone mineral 
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Figure 6.5 Beta-coefficients of between-group differences from models applied to pQCT bone outcomes at the 14% 
proximal tibia.  
Model 1 adjusted for group only; Model 2 adjusted for group, baseline height, weight, and age; Model 3 was ran 
with group, baseline height, weight, age, parity, smoking (ever), and contraceptives (ever) with the model of best 
fit selected by comparing the model AIC values. In these parsimonious models cortical vBMD was adjusted for 
weight and contraceptives (ever); cortical BMC was adjusted for group only; cortical CSA was adjusted for weight 
and contraceptives (ever); cortical thickness was adjusted for weight; total CSA was adjusted for parity and 
contraceptives (ever); both periosteal and endosteal circumferences were adjusted by group only. vBMD = 
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Figure 6.6 Beta-coefficients of between-group differences from models applied to pQCT bone outcomes at the 14% 
proximal tibia.  
Model 1 adjusted for group only; Model 2 adjusted for group, baseline height, weight, and age; Model 3 was ran 
with group, baseline height, weight, age, parity, smoking (ever), and contraceptives (ever) with the model of best 
fit selected by comparing the model AIC values. In these parsimonious models cortical vBMD was adjusted for age, 
height, and contraceptives (ever); cortical BMC was adjusted for weight and height; cortical CSA was adjusted for 
weight and height; cortical thickness was adjusted for height and contraceptives (ever); total CSA was adjusted for 
smoked ever; both periosteal and endosteal circumferences were adjusted by group only. vBMD = volumetric bone 





6.3.5 HRpQCT at the distal radius 
6.3.5.1 Model 1 
No significant between-group differences were found for change in any HRpQCT bone outcome 
measures at the distal radius when the models were adjusted for group only (Table 6.6).  
6.3.5.2 Model 2  
After adjusting for size and age, no significant between-group differences were found at the distal 
radius (Table 6.6). Baseline weight was a positive predictor of trabecular number (p<0.05) but a 
negative predictor of trabecular separation and cortical vBMD (both p<0.05). Age was a positive 
predictor of change in cortical thickness (p<0.05).  
6.3.5.3 Model 3  
The parsimonious models did not significant between-group differences in change at the distal 
radius (Table 6.6). Weight was found to be a positive predictor of trabecular number but a negative 
predictor of both trabecular separation and cortical vBMD at the distal forearm (all p<0.05). 
Maternal age was found to be a positive predictor of total vBMD and cortical thickness (both 
p<0.05). Parity was found to be a negative predictor of trabecular number and a positive predictor 
of trabecular separation (both p<0. 05).  
Table 6.6 Summarising results of linear regression models testing for group differences in change over time at the 
distal radius with HRpQCT in PABS Cambridge  
Distal Radius (n=60) 
Dependant 
variable 
Group β1 p-value Group β2 p-value Group β3 p-value Covariates in 
parsimonious model 
Total vBMD 0.04 (0.26) P=0.9 0.00 (0.26) P=0.9 0.05 (0.26) P=0.9 age* 
Trabecular vBMD 0.13 (0.26) P=0.6 0.17 (0.27) P=0.5 0.13 (0.26) P=0.6 - 
BV/TV 0.11 (0.26) P=0.7 0.17 (0.27) P=0.5 0.11 (0.26) P=0.7 - 
Trab. number  -0.18 (0.26) P=0.5 -0.09 (0.26) P=0.7 -0.10 (0.24) P=0.7 weight*, parity* 
Trab. thickness  0.20 (0.26) P=0.4 0.14 (0.27) P=0.6 0.15 (0.26) P=0.6 weight, parity 
Trab. separation 0.11 (0.27) P=0.7 0.03 (0.26) P=0.9 0.04 (0.25) P=0.9 weight*, parity* 
Cortical vBMD -0.09 (0.26) P=0.7 -0.15 (0.26) P=0.6 -0.16 (0.25) P=0.5 weight*, parity 
Cortical thickness -0.26 (0.26) P=0.3 -0.28 (0.26) P=0.3 -0.24 (0.25) P=0.3 age* 
Cortical porosity  0.49 (0.26) P=0.06 0.48 (0.26) P=0.07 0.48 (0.25) P=0.06 age  
Model 1 adjusted for group only; Model 2 adjusted for group, height, weight, and age; Model 3 was ran with group, baseline height, weight, 
age, parity, smoking (ever), and contraceptives (ever), model of best fit selected by comparing the model AIC values.  β = beta coefficient,  
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Figure 6.7 Beta-coefficients of between-group differences from models applied to HRpQCT bone outcomes at the 
distal radius.  
Model 1 adjusted for group only; Model 2 adjusted for group, baseline height, weight, and age; Model 3 was ran 
with group, baseline height, weight, age, parity, smoking (ever), and contraceptives (ever) with the model of best 
fit selected by comparing the model AIC values. In these parsimonious models total vBMD was adjusted for age; 
trabecular vBMD and BV/TV were adjusted for group only; Trabecular number, thickness and separation were 
adjusted for weight and parity; cortical vBMD was adjusted for weight and parity; cortical thickness and porosity 






6.3.6 pQCT at the 4% distal radius 
6.3.6.1 Model 1 
No significant between-group differences were found in the between visit change in any pQCT 
bone outcome measures at the 4% distal radius when the models were adjusted for group only 
(Table 6.7). 
6.3.6.2 Model 2  
No significant between-group differences were found in the between visit change in any pQCT 
bone outcome measures at the 4% distal radius when the models were adjusted for group, baseline 
height and weight, and age (Table 6.7). The size and age covariates in Model 2 were not predictive 
of changes in pQCT bone outcome measures.  
6.3.6.3 Model 3  
No significant between-group differences were found in the between visit change in any pQCT 
bone outcome measures at the 4% distal radius when the models were adjusted for group, baseline 
height and weight, and age. None of the covariates in the models of best fit were significant 
predictors of change in pQCT bone outcome measures (Table 6.7). 
 
6.3.7 pQCT at the 33% proximal radius 
6.3.7.1 Model 1 
No significant between-group differences were found in the between visit change in any pQCT 
bone outcome measures at the 33% proximal radius when the models were adjusted for group 
only. However a trend towards increase was found in cortical vBMD and total CSA (p=0.06, 




6.3.7.2 Model 2  
No significant between-group differences were found in the between visit change in any pQCT 
bone outcome measures at the 33% proximal radius when the models were adjusted for group 
only. However, when adjusting for baseline height, weight and age a trend towards increase was 
found in cortical vBMD and endosteal circumference (both p=0.08, Table 6.7). A trend towards a 
decrease in cortical thickness was also found (p=0.06). Age was found to be a negative predictor 
of cortical thickness (p<0.05) and a positive predictor of endosteal circumference (p<0.05).  
6.3.7.3 Model 3  
At the 33% proximal radius pregnant woman had thinner cortices -0.5 (0.23) SD and a higher 
endosteal circumference 0.46 (0.23) SD compared to NPNL (both p<0.05, Table 6.7). In addition 
cortical vBMD was found to increase by 0.5 (0.22) SD (p<0.05). Age was a significant predictor 
for both cortical thickness and endosteal circumference (p<0.05). Parity was a significant negative 











Radius  4%   (n=71) 
Dependant variable Group β1 p-value Group β2 p-value Group β3 p-value Covariates in parsimonious model 
Total vBMD  -0.31 (0.24) P=0.2 -0.30 (0.25) P= 0.2 -0.18 (0.24) P=0.5 height, parity, contraceptives (ever) 
Trabecular vBMD -0.18 (0.24) P=0.5 -0.20 (0.25) P=0.4 -0.17 (0.25) P=0.5 weight, parity, smoked (ever) 
Total CSA 0.07 (0.24) P=0.8 0.07 (0.25) P=0.8 0.07 (0.24) P=0.8 - 
Cortical subcortical vBMD -0.30 (0.24) P=0.2 -0.30 (0.25) P=0.2 -0.17 (0.24) P=0.5 height, parity, contraceptives (ever) 
Radius 33% (n=76) 
Dependant variable Group β1 p-value Group β2 p-value Group β3 p-value Covariates in parsimonious model 
Cortical vBMD 0.43 (0.23) P=0.06 0.42 (0.24) P=0.08 0.50 (0.23) P=0.03 parity, smoked (ever) 
Cortical BMC 0.21 (0.23) P=0.4 0.24 (0.24) P=0.3 0.14 (0.23) P=0.6 parity* 
Cortical CSA -0.08 (0.23) P=0.7 -0.05 (0.24) P=0.8 -0.17 (0.23) P=0.5 weight, smoked (ever), parity** 
Cortical thickness -0.41 (0.23) P=0.07 -0.43 (0.22) P=0.06 -0.50 (0.22) P=0.03 age* 
Total CSA 0.40 (0.23) P=0.08 0.39 (0.24) P=0.1 0.34 (0.23) P=0.1 parity* 
Periosteal circumference  0.34 (0.23) P=0.1 0.38 (0.24) P=0.1 0.40 (0.23) P=0.09 age 
Endosteal circumference  0.38 (0.23) P=0.1 0.41 (0.23) P=0.08 0.46 (0.23) P=0.047 age* 
Model 1 adjusted for group only; Model 2 adjusted for group, baseline height, weight, and age; Model 3 was ran with group, baseline height, weight, age, parity, smoking (ever), and contraceptives (ever) with the model of 
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Figure 6.8 Beta-coefficients of between-group differences from models applied to pQCT bone outcomes at the distal 
radius.  
Model 1 adjusted for group only; Model 2 adjusted for group, baseline height, weight, and age; Model 3 was ran 
with group, baseline height, weight, age, parity, smoking (ever), and contraceptives (ever) with the model of best 
fit selected by comparing the model AIC values. In these parsimonious models total vBMD was adjusted for height, 
parity, and contraceptives (ever); trabecular vBMD was adjusted for weight, parity, and smoked (ever); total CSA 
was adjusted for group only; cortical subcortical vBMD was adjusted for height, parity, and contraceptives (ever). 
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Figure 6.9 Beta-coefficients of between-group differences from models applied to pQCT bone outcomes at the 33% 
proximal radius.  
Model 1 adjusted for group only; Model 2 adjusted for group, baseline height, weight, and age; Model 3 was ran 
with group, baseline height, weight, age, parity, smoking (ever), and contraceptives (ever) with the model of best 
fit selected by comparing the model AIC values. In these parsimonious models cortical vBMD was adjusted for parity 
and smoked (ever); cortical BMC was adjusted for parity; cortical CSA was adjusted for weight, smoked (ever), and 
parity; cortical thickness was adjusted for age; total CSA was adjusted for parity; both periosteal and endosteal 





 Discussion of results 
These data provide for the first time compelling evidence of pregnancy-induced alterations in 
maternal bone mineral density and microarchitecture at both the radius and tibia with two novel 
pQCT scanning modalities. My primary objective was to determine whether maternal bone mineral 
was mobilised from trabecular-rich sites, through decreases in trabecular vBMD (HRpQCT and 
pQCT) and the potential reorganisation of trabecular microarchitecture (HRpQCT). Changes in 
trabecular vBMD were found at the distal 4% tibia with pQCT, where a 0.5 SD decrease was found, 
but no significant changes were found in either HRpQCT measured BV/TV or trabecular vBMD. 
As outlined above significant changes in trabecular microarchitecture were found at the distal tibia 
with HRpQCT, however, two interesting findings in relation to trabecular architecture warrant 
discussion. 
Firstly, the significant between-group baseline differences in parameters of trabecular 
microarchitecture may provide indirect evidence of early microarchitectural changes during the first 
trimester of pregnancy: trabecular number was 8% lower in the pregnant group compared to 
NPNL; while trabecular thickness was 12% higher in pregnant women than NPNL. Secondly, 
pregnancy-induced changes in trabecular microarchitecture at the distal tibia may require 
interpretation in the context of cortical compartment alterations, where pregnancy-induced 
reductions in cortical vBMD and cortical thickness alongside an increase in cortical porosity were 
observed. It is possible that the trabecular microarchitectural changes are artefacts of changes in 
the cortical compartment at the trabecular-cortical interface. Endosteal resorption may lead to the 
endocortical surface becoming “trabecularised” with a thinning and increasingly porous shell 
leading to the detection of pores as trabecular struts. Such struts would increase the trabecular 
number, but would also decrease the trabecular thickness and increase porosity. An alternative 
explanation may also relate to the limits of the techniques resolution because at baseline some 
trabeculae may have been too close to one another to be detected as independent branches. As 




detection of an “increase” in trabecular number. These newly detected trabeculae will also be closer 
together which accounts for the declining trabecular separation. In the light of finding changes in 
the trabecular microarchitecture but a lack of change in trabecular vBMD, both Dinn (trabecular 
vBMD of the inner 60% of the trabecular area) and DMeta (the remaining section of the 
compartment) were explored to investigate whether this was due to intra-trabecular compartment 
change rather than cortical changes. No changes were found either in these trabecular parameters 
or in the ratio of Dinn/Dmeta.  
 
Figure 6.10 The endosteal surface can be difficult to define with standard analysis. 
The images above are from the distal tibia of a healthy non-pregnant non-lactating women but highlight the 
difficulties in accurately defining the junction between the trabecular and cortical compartments. An increase in 
porosity in this region could possibly be interpreted as change in trabecular microarchitecture with standard 
analysis.  
As noted, my data suggest marked adaptation within the maternal cortical compartment during 
pregnancy. Pregnancy results in the mobilisation of bone mineral from the cortical compartment 
indicated by decreases in vBMD and adaptations in cortical microarchitecture. This evidence of 
pregnancy-induced cortical adaptation was documented with two distinct imaging techniques, at 
both distal (trabecular-rich) and proximal (cortical-rich) skeletal sites, in both weight bearing and 
non-weight bearing limbs. At the distal tibia HRpQCT revealed a number of significant changes in 
the cortical shell where cortical vBMD and cortical thickness were found to decrease, while the 




No significant between-group differences were found at the distal radius during pregnancy in 
keeping with some of the scientific literature discussed in Chapter 2 (Christiansen et al., 1976, Kent 
et al., 1993, Clark et al., 1995, Kolthoff et al., 1998, Black et al., 2000, More et al., 2001, Moller et 
al., 2012) though the scientific literature is inconclusive as (Wisser et al., 2005) reported wide inter-
individual changes in distal radius trabecular vBMD with pQCT and (Moller et al., 2012) reported 
a significant decrease in distal radius aBMD during pregnancy. Olausson and colleagues did not 
find a difference at the forearm between pre-pregnancy and postpartum scans, which is in keeping 
with several studies suggesting the conservation of bone mineral during lactation at the distal radius 
which in later life is a fracture prone site. However, at the 33% proximal radius a statistically 
significant decrease in cortical thickness alongside a significant increase in endosteal circumference 
suggested the resorption of bone mineral from the endosteal surface. If we consider that the 
changes in trabecular number and thickness at the distal tibia may be artefacts of cortical mineral 
mobilisation it is possible these are evidence of endosteal resorption from endocortical surfaces at 
two peripheral skeletal locations. These data at the forearm would seem to support the hypothesis 
of Garn and others that bone mineral accrued during growth may act as a reservoir for use during 
reproduction. 
In the parsimonious models several of the independent variables were found to be significant 
predictors of change. With HRpQCT at the distal tibia, baseline weight was a positive predictor of 
change in trabecular number (p<0.05) but a negative predictor of cortical vBMD (p<0.05); with 
pQCT at the 3 tibial sites weight was only found to be a significant negative predictor of cortical 
vBMD at the 14% tibia (p<0.05). As at the distal tibia, baseline weight was found to a positive 
predictor of change in trabecular number and a negative predictor of trabecular separation and 
cortical vBMD at the distal radius (all p<0.05). As maternal age was one of the primary recruitment 
criteria of the study and a relatively narrow age band (30- 45 years) was selected, age was still found 
to be a significant predictor of change in several of the models at the distal and proximal radius 




for HRpQCT parameters of total vBMD and cortical thickness at the distal radius (both p<0.05). 
However, in contrast at the proximal radius it was found to be a negative predictor of change in 
cortical thickness but a positive predictor of endosteal circumference (both p<0.05). Interestingly, 
parity emerged as a rather strong predictor of change in several bone outcome measures in both 
limbs. At both the distal tibia and radius parity was a significant negative predictor of trabecular 
number (p<0.05) and at the radius a positive predictor of trabecular separation (p<0.05). At the 
proximal radius it was found to be a strong negative predictor of change in cortical BMC (p<0.05), 
cortical CSA (p<0.01), and total CSA (p<0.05). 
The primary findings of this study suggest that at the distal tibia bone mineral changes are occurring 
in both bone compartments, however, as we begin to move slightly more proximally to the 
HRpQCT scan region cortical changes predominate (decreasing cortical vBMD and thickness with 
increasing porosity) with the possibility of some trabecular microarchitectural reorganisation. No 
changes were found with pQCT at the proximal tibia at either of the 2 cortical-rich proximal sites 
investigated. At the forearm, measurements from both techniques showed the conservation of 
bone mineral at the distal radius, however, in contrast a pattern of change suggesting endosteal 
resorption through a decrease in cortical thickness and endosteal circumference (with an artificial 
increase in cortical vBMD) was found at the proximal radius. 
My findings of a decrease of -0.5 SD in pQCT trabecular vBMD supports my primary hypothesis 
of mineral mobilisation from within the trabecular compartment, in keeping with the findings of 
Olausson et al. (2008) who found significant change in maternal SA-BMC at the lumbar spine of 
2.4% between pre-pregnancy and 2 weeks postpartum. These results are also in line with similar 
studies in the literature (Drinkwater and Chesnut, 1991, More et al., 2001, Pearson et al., 2004, 
Moller et al., 2012). HRpQCT trabecular vBMD did not decrease, however, microarchitectural 
changes were found in several trabecular bone outcome measures at the distal tibia.  Whether this 
reflects trabecular bone mineral mobilisation at the distal tibia or is an artefact of pregnancy-




(-1.01 (0.21) SD), and cortical porosity (0.83 (0.23) SD) is uncertain. Decreases in total vBMD at 
the distal tibia were observed with both HRpQCT and pQCT (-0.49 SD (0.24) and -0.65 (0.22) SD 
respectively). Pregnancy-induced changes at the forearm were all cortical in nature and confined to 
the proximal radius where cortical thickness decreased by -0.50 (0.22) SD and endosteal 
circumference increased by 0.46 (0.23) SD and suggest endosteal resorption at the cortical-rich 
proximal radius. The clinical relevance of these data will depend on the extent to which subsequent 
mobilisation of bone mineral during lactation if these women chose to breastfeed, the length of 




7 In-vivo correlation of pQCT to HRpQCT outcome measures 
 Rationale for analysis  
As discussed in Chapter 1 HRpQCT and pQCT are versatile research tools for bone imaging of 
the appendicular skeleton, providing estimates of vBMD in addition to bone mass, geometry and 
distribution. Few research centres possess or routinely use both modalities and no in-vivo between-
modality correlation or agreement data have been published, however, ex-vivo data have been 
published which show high correlation in vBMD and geometric parameters in cadaveric tibiae at 
the same anatomical location (Lala et al., 2014, Lala et al., 2012). In practical use, however, pQCT 
and HRpQCT scanners do not routinely image the same sites. One of my secondary objectives was 
to explore the in-vivo correlation and agreement of pQCT and HRpQCT techniques; focusing on 
measures of trabecular vBMD, cortical vBMD, and cortical thickness. The major technical 
differences between the techniques are: 
1. Scanner resolution (voxel size) pQCT (0.2-0.5 mm) vs HRpQCT (XtremeCTI, 0.082 mm)   
2. Scan sites for trabecular and cortical outcomes (Figure 7.2): 
a. pQCT and HRpQCT measure trabecular parameters at distinct but physiologically 
similar trabecular-rich distal scan sites. 
b. pQCT cortical measures are obtained at cortical-dominant proximal sites, whereas 
HRpQCT cortical parameters are acquired simultaneously with the trabecular data.  
My aim was to explore correlation and agreement between pQCT and HRpQCT in typical in-vivo 
use. HRpQCT obtains cortical and trabecular parameters at the distal radius and tibia from a 
volume of interest (VOIs, a stack of 104 CT slices), in this analysis all parameters were acquired 
with the manufacturer’s software (Version 6.6). The HRpQCT VOI is determined at a fixed 
distance from the reference line. Cortical parameters represent the mean cortical vBMD and 




mean vBMD of the trabecular region. Sub-regional trabecular Dinn (inner 60%), and Dmeta (outer 
part of the trabecular compartment) are also reported in addition to their ratio. pQCT trabecular 
and cortical compartment data are obtained at physiologically different scan slices (thickness 2 
mm), cortical vBMD is obtained at proximal sites following the removal of non-cortical tissues by 
thresholding (Chapter 1.4), while cortical thickness is derived using a “circular ring model” which 
is discussed in Chapter 1.4. pQCT trabecular vBMD is obtained from the inner 45% of the total 
CSA, a voxel size of 0.5 mm is insufficient to discern cortical from trabecular compartment at their 
ill-defined junction. In PABS many of the observations in the trabecular and cortical compartments 
at both the distal and proximal tibia were similar in direction, and at the distal tibia the magnitude 
of change in pQCT total vBMD and HRpQCT total vBMD were similar. This encouraged me to 
further explore my a priori objective of investigating correlation and agreement between 
techniques.  
 
Figure 7.1 Summary of volumetric BMD parameters obtained from HRpQCT and pQCT.  
HRpQCT (right) schematic illustrates the sub regions measured to provide various vBMD parameters from the distal 
104 slice volume of interest. pQCT scans (centre) following segmentation and thresholding (left) show 
compartment specific vBMD parameters that are site-specific. vBMD = volumetric bone mineral density, D100 = 





 Statistical approach 
The criterion for data inclusion in this analysis was participant baseline data on pQCT and 
HRpQCT of analysis grade (i.e. pQCT scans ≤ grade 2, HRpQCT scan ≤ grade 4). Tibial data were 
selected because more usable pairs (n=85) were available. Between-scanner differences for selected 
outcome measures were tested by paired t-tests; statistically significant differences were present for 
comparisons (all p<0.05). Scatter plots were produced to visualise the relationship between similar 
parameters (Figures 1.1, 1.2 & 1.3) a line of equality was added (i.e. on which all points would lie if 
the two scanner gave exactly the same reading every time) as a visual aid and simple linear regression 
was used to determine the correlation between the pairs (adjusted R2) with the regression line 
plotted. These provided a simple but visually powerful way of interpreting the data to a) explore 
how the real fit differed from the perfect, and b) if systematic differences were present between 
the techniques. Perfect correlation can be present if the points all lie along any straight-line, perfect 
agreement can only be present if the points lie along the line of equality (Bland and Altman, 1986). 
Bland and Altman caution that data which seem to be in poor agreement can produce quite high 
correlations and conceal considerable lack of agreement (Bland and Altman, 1986). I used mean-
difference (Bland Altman) plots to visualise any possible relationship between two measurements. 
The mean of the two measurements is the best estimate of the true value, and the difference should 
be plotted against this rather than either value separately because the difference will be related to 
each (Gill et al., 1985). The bias between techniques can be seen from these plots estimated by the 
mean difference (δ) and the standard deviation of the differences (s) (Bland and Altman, 1986). 
These plots can also be expressed in Z-scores where the data have been standardised, this can be 
useful when dealing with a number of comparisons in different units and on different scales and 
displays the data adjusted from bias, however, although a helpful visualisation particularly when 
the data show high systematic difference (correlation plots) the absolute mean-difference plot 




 Correlation between tibial pQCT and HRpQCT parameters  
7.3.1 Correlation between cortical vBMD and thickness 
Weak to poor correlation found between HRpQCT cortical vBMD and 14% and 38% pQCT 
cortical vBMD (respectively adjusted R2=0.36 and R2=0.15, Figure 7.2) with pQCT showing a 
consistent, but decreasing, bias to higher values within the range or values measured. Good 
correlation (R2=0.68) was found between HRpQCT and 14% pQCT cortical thickness, also with 
a bias to higher values in pQCT. As the regression line initially tracks relatively parallel to identity 
line but diverges slightly at higher values this suggests an increasing systematic difference at very 
high values of cortical thickness (Figure 7.2). In contrast at the 38% pQCT tibia cortical thickness 
was found to show poor correlation to HRpQCT (R2=0.07) (Figure 7.2). 
 
Figure 7.2 Scatter plots of the relationship between pQCT and HRpQCT cortical parameters at the tibia.  
Top: cortical vBMD from 14% pQCT vs HRpQCT (left); 38% pQCT vs HRpQCT (right). Bottom: cortical thickness form 
14% pQCT vs HRpQCT (left); 38% pQCT vs HRpQCT (right). Blue lines represent the regression line and dashed red 
lines the line of equality vBMD = volumetric bone mineral density  
Adjusted R2 = 0.35  Adjusted R2 = 0.15 




7.3.2 Trabecular vBMD parameters at the distal tibia  
Very-strong correlation was found between pQCT and HRpQCT trabecular vBMD (R2=0.87), 
while a lower correlation was found when trabecular inner vBMD (Dinn) replaced trabecular 
vBMD the correlation with pQCT remained strong (R2=0.83). Although there is high correlation 
between the data, in both cases when the plotted the regression line and equality line appear roughly 
parallel suggesting a constant systematic difference between the techniques with pQCT data 
consistently higher than either HRpQCT trabecular vBMD variable, across the range of values 
measured. This systematic difference was slightly greater between pQCT trabecular vBMD and 
Dinn.  
 
Figure 7.3 Scatter plots of the relationship between pQCT and HRpQCT trabecular vBMD parameters at the distal 
tibia. 
Left: pQCT trabecular vBMD and HRpQCT trabecular vBMD; Right: pQCT trabecular vBMD and Dinn (i.e. inner 60% 




 Agreement between pQCT and HRpQCT parameters  
BA plots only define the intervals of agreements, not whether these limits are acceptable or not, 
this must be decided a priori. In all cases below the data were first plotted with the absolute values 




7.4.1 Agreement between cortical vBMD and cortical thickness at the tibia  
Plots for HRpQCT measured and pQCT 14% & 38% cortical vBMD show poor agreement with 
a mean difference of -219 mg/cm3 (95% CI -280;-158) and -251 mg/cm3 (95% CI -320; -181) 
respectively. These large mean-differences are in-line with the very poor correlation found above 
but highlight that between-scanner agreement differs with a bias towards worse agreement at higher 
mean values (x-axis) (Figure 7.4). The standardisation of these Bland-Altman plots show that even 
when these large biases are adjusted for the distribution of data are in both cases roughly fall within 
2SD of the mean differences. 
 
Figure 7.4 Agreement between cortical vBMD from pQCT and HRpQCT. 
Mean-difference and Bland-Altman plots of the pQCT measures of cortical vBMD at 14% (left) and 38% (right) 
compared to HRpQCT measured cortical vBMD. Poor agreement was found between pQCT and HRpQCT cortical 
vBMD at both sites. vBMD = volumetric bone mineral density 
 
Better agreement was found between 14% pQCT and HRpQCT parameters of cortical thickness, 
mean difference -1.31 mm (95% CI -1.72;-0.89), than for 38% pQCT and HRpQCT parameters 




38% tibia vs HRpQCT is understandable given the physiological differences between the scan sites. 
Standardisation reinforced this interpretation as we can see that the differences between means fall 
almost within 1SD of the mean for the 14% site but exceed 2SD at the 38% tibia.   
 
Figure 7.5 Agreement between cortical thickness from pQCT and HRpQCT.  
These plots show better agreement at the 14% than the 38% tibia for cortical thickness compared to HRpQCT 
cortical thickness. The greater agreement seen at the 14% above is due to its greater similarities in location and 
structure to the distal region measured on the HRpQCT 
 
7.4.2 Agreement between trabecular vBMD parameters at the tibia  
As shown form the mean difference plots the HRpQCT trabecular vBMD and Dinn parameters 
were both lower consistently lower than pQCT trabecular vBMD, mean difference of -54.16 
mg/cm3 (95% CI: -24.32;-84.01) and -95.60 mg/cm3 (-61.01;-130.18) respectively. When the data 





Figure 7.6 Agreement between parameters of trabecular vBMD from pQCT and HRpQCT  
Bland-Altman plots show good agreement for pQCT measured trabecular vBMD and HRpQCT parameters of 
trabecular vBMD and Dinn. vBMD = volumetric bone mineral density, Dinn = Density of inner 60%  
 
 
 Discussion and conclusions  
These These analyses formed a secondary objective of this thesis and explored the correlation and 
agreement between the two pQCT modalities in “typical use” due to the paucity of published in- 
vivo data. Both modalities are optimised using different approaches to provide biologically 
meaningful estimates of bone density, mass, shape, strength, geometry, and in the case of HRpQCT 
also microarchitecture. pQCT scanners have a relatively large voxel-size (0.5 mm) but this 
limitation can be, in part, overcome through strategic scan site selection and the application of 
appropriate segmentation and thresholding to produce compartment-specific data. Data are 
typically obtained from sites that are trabecular-rich (4%) or cortical-rich (14%, 38%, 50%, or 66% 
in the case of the tibia), although due to a lack of ISCD guidelines for pQCT many research groups 




cortical and trabecular bone, a trabecular only region is segmented from the total bone volume by 
defining an inner trabecular region (45% of total CSA). Cortical parameters are obtained at sites 
that predominantly contain cortical bone and appropriate thresholds can be applied to exclude 
non-cortical bone. A major advantage of focusing on cortical-rich sites to measure cortical 
parameters is that factors such as bone shape and geometry can be expanded on to provide indices 
of bone strength where the bone is under greatest torsional loading. In contrast HRpQCT 
parameters of cortical and trabecular bone are obtained simultaneously at a VOI containing a 
mixture of trabecular and cortical bone. First generation HRpQCT (XtremeCTI) does not image 
at proximal cortical-rich sites and therefore it is debatable whether this is a true reflection of how 
cortical bone reacts at sites where it is under greatest mechanical strain and loading forces, newer 
generation scanners offer an additional more proximal scan site addressing this limitation. 
HRpQCT scanning protocols had originally been set at a fixed distance from the end plate (unless 
the data were acquired in children), this meant that unlike pQCT there was much greater 
consistency in the region scanned. However, a limitation of this was that people have different 
sized limbs and using a fixed distance from the endplate of the radius and tibia may result in scans 
at sites of rather different composition and which can vary across genders, ages, and ethnicities 
(Ghasem-Zadeh et al., 2017). This has led to the development of protocols that, as with pQCT, a 
scan is performed at a predefined percentage of the length of the radius or tibia. 
Similar between-group differences both in direction and magnitude were found in PABS for several 
bone parameters obtained with pQCT and HRpQCT from Model 2 and Model 3. In this chapter 
the observed high correlation and good agreement at baseline of several outcome measures from 
pQCT and HRpQCT helps contextualise such similarities. Ex-vivo work which has found very 
high correlation when the same site on a bone is scanned (Lala et al., 2012, Lala et al., 2014), in this 
analysis the highest correlation and best agreement between techniques was found at anatomically 
similar sites (similar proportion of cortical-to-trabecular bone). In-vivo interpretation is 




bone’s endplate meaning there is some slight variation in the inter-individual correlation and 
agreement. This variation will be small and likely fall within the coefficient of variation (CV) and 
precision error (PE) of the inter-operator error. Despite these limitations this exploratory analysis 
is useful in illustrating, with the PABS longitudinal findings, the of the ability of pQCT to perform 
well in comparison to the much higher resolution HRpQCT when investigating change in bone 
outcome measures of trabecular vBMD and cortical thickness at physiologically similar sites. pQCT 




8 Summary and discussion of thesis results 
The overarching aim of this thesis was to determine whether maternal bone mineral is mobilised 
from the appendicular skeleton during pregnancy. Prior to beginning ENID Bone data analysis or 
PABS study design I conducted a review (Chapter 2) of the available scientific literature to help 
form my research questions, which suggested that if pregnancy-induced bone mineral changes 
occurred they may not be detectable with bone densitometry techniques until late-gestation when 
Ca transfer to the fetus peaks. Both of my main analyses were constructed on this basis; of 
comparing data obtained from early- or mid- pregnancy when fetal Ca demands are low, to late- 
pregnancy when these demands peak with fetal Ca accrual (Kovacs and Kronenberg, 1997). Much 
of the available scientific literature on pregnancy, in particular the increases in BTMs of resorption, 
tend to align to a considerable extent with the much larger body of lactation data where 
mobilisation of maternal bone mineral has been consistently documented from trabecular-rich sites 
(Sowers et al., 1993, Cross et al., 1995, Laskey and Prentice, 1997, Kolthoff et al., 1998, Laskey et 
al., 1998, Laskey and Prentice, 1999, Akesson et al., 2004, Bjornerem et al., 2017). 
Two major considerations: 1) timing, i.e. when during pregnancy and lactation bone mobilisation 
is occurring; and 2) compartment, i.e. whether from trabecular-rich skeletal sites alone or from 
axial-sites alone; shaped my primary research question and my approach to the analysis of the 
ENID pQCT data and the study design of PABS. Both studies presented in this thesis share a 
common overall aim using similar but distinct methodologies and both addressed my primary 
research question: is bone mineral mobilised from the maternal skeleton between early- and late 
pregnancy? 
My secondary questions were chosen based on the contrasting nature of the discrete populations I 
studied, and would allow me to address what I had identified as major gaps in the available 
literature. The ENID Bone Study pQCT data offered me the opportunity to explore the maternal 




Sub-Saharan subsistence farming community with a habitually low Ca intake (Prentice et al., 1993, 
Prentice, 1994a, Redmond et al., 2014). With few exceptions most studies I encountered during my 
review were conducted in HIC in populations with what could be regarded as mid- to high-Ca 
intakes (Wisser et al., 2005, Olausson et al., 2008, Moller et al., 2012, Olausson et al., 2012, Moller 
et al., 2013). The ENID Bone Study was unparalleled in terms of sample size and although Ca 
intake data were not available for my analysis, all previous work in this population has shown intake 
to be habitually low (Prentice et al., 1993, Prentice, 1994a, Sawo et al., 2013). The inclusion criteria 
for PABS aimed to ensure a higher mean participant age than the majority of previously published 
pregnancy and bone studies in the light of rising maternal age in the UK and possible implications 
for recovery of bone loss. I aimed to explore the extent to which maternal bone mineral 
mobilisation may occur in women aged 30-45 years, this gave my study a much higher mean age 
than many previously published. To my knowledge this was also the first application of HRpQCT 
in pregnancy. This population were likely to be Ca replete, as previous studies have shown pregnant 
and lactating women in Cambridge to have a habitually high intake of Ca (Laskey et al., 1998, 
Olausson et al., 2008) in contrast to the Gambian women in ENIID Bone.   
 
 Primary thesis objective – trabecular bone  
Trabecular bone is more metabolically active than cortical bone in part due to its structure, 
orientation and much greater surface area. During lactation, studies have consistently reported 
significant transient bone mineral mobilisation from trabecular-rich axial sites such as the hip and 
spine, while newer pQCT techniques have found trabecular microarchitectural change in the 
appendicular skeleton also (Kent et al., 1990, Drinkwater and Chesnut, 1991, Sowers et al., 1993, 
Prentice, 1994a, Kalkwarf and Specker, 1995, Kolthoff et al., 1998, Ritchie et al., 1998, Laskey and 
Prentice, 1999, Pearson et al., 2004, Bjornerem et al., 2017). My primary objective was to explore 
whether a similar pregnancy-induced bone mineral mobilisation could be observed in both studies 




hypothesis, pregnancy-induced decreases in trabecular vBMD reflecting the potential mobilisation 
of Ca from the maternal skeleton were not observed in the ENID Bone pQCT analysis. To the 
contrary, small but statistically significant increases were found at both the radius and tibia in 
trabecular vBMD before adjusting for any potential supplement effects. With the addition of 
supplements to the model these small increases were no longer statistically significant. In contrast 
in PABS, significant decreases in trabecular vBMD were with pQCT in the pregnant group 
compared to the background aging of the NPNL group. Although decreases in HRpQCT 
trabecular vBMD and BV/TV were not found, this may be due to fewer data being available or 
more likely the relative anatomical differences between the pQCT and HRpQCT scan sites. 
Interesting trabecular microarchitectural observations emerged in PABS a) cross-sectionally at 
baseline, and b) with data were modelled longitudinally. Statistically significant baseline differences 
were found between groups in trabecular microarchitectural parameters which could not be 
investigated further due to the study design but are somewhat supportive of the only 
histomorphology data published in pregnancy (Purdie et al., 1988, Shahtaheri et al., 1999) which 
suggested early-pregnancy changes in trabecular microarchitecture from iliac crest biopsies. My 
parsimonious models of change in HRpQCT found statistically significant between-group 
differences in trabecular number (increasing during pregnancy), trabecular separation (decreasing 
in pregnancy), and a trend towards decreasing trabecular thickness in pregnant women compared 
to NPNL. Without significant changes in trabecular vBMD, it is possible that microarchitectural 
differences reflect a potential redistribution of mineral within the trabecular compartment. 
However, it is also possible that these between-group differences could be an artefact of cortical 
mineral mobilisation: with the cortex becoming more porous and cortical thickness decreasing, 
enlarged pores close to the endocortical surface may be detected as thin struts of trabecular bone 
(Figure 6.10). This would artificially increase the mean trabecular number, while decreasing the 
mean trabecular thickness, essentially creating a “trabecularised” surface at the endosteal surface 




The findings from both studies present a contrasting picture of the pregnancy-induced changes in 
the trabecular compartment of the appendicular skeleton between mid- to late-pregnancy. In 
ENID no decreases in trabecular vBMD were observed at either the distal tibia or radius with 
pQCT. In PABS, where pregnant and NPNL women aged 30-45 years old were scanned a 
significant decrease of 0.5 SD in trabecular vBMD (pQCT) was found in pregnant women 
exceeding possible age-effects at the distal tibia. HRpQCT microstructural trabecular change at the 
tibia may reflect cortical rather than trabecular adaptation, no decreases in trabecular vBMD or 
BV/TV were observed. At the radius no significant changes in the trabecular compartment were 
found with either technique at the forearm in contrast to Wisser et al. (2005).  
 
 Cortical compartment changes   
The cortical compartment, in particular the endocortical surface, may act as a potential reservoir 
of Ca that can be drawn upon in times when physiological requirements are greatest. This 
hypothesis stems from the work of Stanley Garn and others who observed that during growth 
mineral accrued at the endosteal surface, which would not “strengthen” the bone compared to if 
that mineral was accrued in the periosteum (Frost, 1987, Schiessl et al., 1998, Schoenau et al., 2001, 
Ward et al., 2005b, Ward et al., 2005c, Wojtys et al., 2015), however, evidence of such change 
proved elusive in the metacarpals when assessed using radiographs (Frisancho et al., 1970, 
Frisancho et al., 1971, Greer and Garn, 1982). The seemingly “preferential” loss of bone mineral 
from the endosteal surface has been observed during menopause (Seeman, 2013). In the context 
of female reproduction and bone health, the findings from my research seem to support a 
preferential release of bone mineral from the endocortical surface of metaphyseal and diaphyseal 
sites during pregnancy, minimising the potential reduction in bone strength as bone total CSA does 
not decrease. 
Statistically significant decreases in cortical vBMD and cortical thickness, with an increase in 




the changes observed in trabecular microarchitecture (increasing trabecular number and decreasing 
trabecular thickness) in the absence of a significant decrease in trabecular vBMD or BV/TV may 
indicate that these are an artefact of resorption from the endosteal surface at the tibial scan region 
rather than true trabecular adaptation. pQCT observations in PABS at the 33% proximal radius 
provide further evidence of pregnancy-induced endocortical resorption i.e. decreasing cortical and 
increasing endosteal circumference. The increase in cortical vBMD at the proximal radius can be 
explained by the loss of mineral at the endosteal surface, as voxels containing demineralised bone 
fall below the analysis threshold the remaining voxels contain bone tissue of higher attenuation and 
therefore density. In the absence of a change in either total CSA or periosteal circumference this 
can be viewed as the preferential mobilisation of bone mineral from a site within the cortex that 
would compromise bone strength the least. In contrast in ENID Bone small but statistically 
significant increases in cortical vBMD and BMC were found at both the radius and tibia, with 
minor supplement effects only found at the forearm.  
 
 Predictors of pregnancy-induced skeletal adaptation 
In addition to my primary and secondary aims of determining whether maternal bone mineral was 
mobilised from the trabecular and cortical compartments of the skeleton, I also wanted to 
investigate whether any predictors of any such changes could be identified in both studies.  
 
8.3.1 ENID Bone predictors  
In the ENID Bone Study the analysis of pQCT bone data I had to control for the fact that antenatal 
supplementation was a major aspect of the ENID Trial. Potential mechanisms for maternal 
supplementation modulating any pregnancy-induced skeletal change were considered in the 
context of a) potential dietary Ca displacement in the two arms receiving LNS (i.e. 746 kcal addition 
energy and 20.6 g protein), or b) influencing maternal weight gain and modulating any potential 




maternal weight gain across gestation may translate into differences in maternal body composition 
which may in turn influence several endocrine pathways. While I lack detailed figures of compliance 
in the ENID Trial, there were suggestions of variable compliance particularly in the LNS arms. As 
I did not have dietary intake data available to me for my pQCT analysis I cannot confirm whether 
supplement consumption actually displaced Ca from the maternal diet. However, what my analyses 
show is that no substantial supplement effects on maternal bone mineral were seen between 
Booking and P30. Although miniscule increases, all below 1%, in cortical vBMD and BMC were 
seen in all groups these are likely of negligible clinical importance at this stage of the lifecourse. 
However, if such increases were to occur across multiple pregnancies there could perhaps be some 
cumulative benefit as documented in one retrospective study in a population of American women 
with high parity (Specker and Binkley, 2005). When within-group weight change for the 4 
supplement arms was plotted the distribution of the data were similar in all groups. I performed 
multiple regression also to investigate whether there was a supplement effect on maternal weight 
gain between Booking and P30 and found no supplement effect in this timeframe. In the ENID 
Bone study women aged 18-45 years old were recruited, however, only minor age effects were 
found at the proximal radius for cortical vBMD and cortical BMC when the when the data were 
modelled suggesting that in this population there is little variation in bone change as a result of 
maternal age or parity. In the context of very low dietary intake this may suggest that physiological 
adaptations are present that preserve maternal bone mineral during pregnancy.  
 
8.3.2 PABS determinants of change in HRpQCT and pQCT outcomes  
At the distal tibia where I found evidence of pregnancy-induced change in total vBMD, age was 
found to be a positive predictor of change (p<0.05). Bone mineral mobilisation was also observed 
at the 33% proximal radius through a thinning of the cortical shell. Maternal age was found to be 
a significant predictor of these changes where it was a negative predictor of cortical thickness and 




differences were found at the distal radius with HRpQCT, age was a significant positive predictor 
of total vBMD and cortical thickness (both p<0.05). 
While no significant between-group differences were found at either the 14% or 38% cortical-rich 
tibia, height was a significant positive predictor of several cortical parameters at the 38% distal tibia: 
cortical BMC, cortical CSA, and cortical thickness (all p<0.05). At the load-bearing tibia weight 
emerged as a significant predictor for a number of HRpQCT and pQCT bone outcome measures. 
While decreases in both total vBMD and cortical vBMD were found, baseline weight was found 
to be a positive predictor of total vBMD but a negative predictor of cortical vBMD (both p<0.05). 
As with HRpQCT cortical vBMD, baseline weight was a negative predictor of pQCT cortical 
vBMD at the 14% tibia (p<0.01). As seen at the tibia with HRpQCT baseline weight was found to 
be a significant negative predictor of cortical vBMD at the non- weight bearing radius (p<0.05). 
Baseline weight was also a positive predictor of trabecular number and a negative predictor of 
trabecular separation (both p<0.05). 
At the tibia parity was only found to be a significant predictor of HRpQCT measured trabecular 
number where it was a negative predictor (p<0.05). This was also seen at the distal radius with 
HRpQCT (p<0.05) but parity was a positive predictor of trabecular separation (p<0.05). At the 
cortical rich 33% radius parity was found to be a negative predictor of cortical BMC (p<0.05), 
cortical CSA (p<0.01) and total CSA (p<0.05) suggesting that small cumulative loss may occur 
across multiple pregnancies. 
The current or historical use of hormonal contraceptives was not found to be a significant predictor 
at any skeletal site although there were very few women who had never used any form of hormonal 
contraceptive in either of the groups (Pregnant n= 6, NPNL n= 3). I did not stratify by variety of 
contraceptive in the analysis in part due to the overlap of methods used. Smoking was a negative 





 Correlation of pQCT and HRpQCT parameters at the tibia  
My comparison of the scanning techniques in the baseline PABS data showed trabecular vBMD 
variables were highly correlated at the tibia, with good agreement found between the variables 
however they diverged at very high values. In contrast cortical vBMD showed poor to weak 
correlations between modalities, and poor agreement at all sites. Cortical thickness, however, had 
good correlation and better agreement between the HRpQCT VOI and the 14% pQCT site. The 
opposite was the case between the 38% pQCT site and the HRpQCT VOI. In the longitudinal 
PABS analysis conventional pQCT detected significant changes in total and cortical vBMD as did 
HRpQCT. These observations on both scanners also gives us greater confidence that if pregnancy- 
induced bone mineral mobilisation had occurred in the ENID Bone Study via decreases in 
volumetric BMD or cortical thickness they would have been detectable with pQCT which provides 
an effective method of acquiring 3D size-independent bone measures at physiologically optimal 
sites to measure both cortical and trabecular compartments. 
 
 Limitations  
There are several limitations that should be addressed in the presentation of these data, I’ll begin 
with limitations common to both projects. Both studies were constrained by practical 
considerations which dictated the stage of pregnancy when scan data were acquired. An ideal study 
design would include pre-pregnancy data collection where data would be obtained from a large 
number of women planning to become pregnant. Women who became pregnant, would have 
baseline pre-pregnancy data from which pregnancy-induced change could be calculated. This 
would make the investigation of first trimester changes in the maternal skeleton possible, of which 
there are some indications of in the literature. Those who did not conceive would be scanned 
longitudinally to account for any natural age-related bone changes. The greatest requirement for 
Ca by the fetus is in the second half of pregnancy, when skeletal growth and developments are at 




requirements are low and when they peak there would be the greatest chance of detecting maternal 
bone mineral mobilisation. Both of the studies presented here scanned into the third trimester of 
pregnancy. The ENID Bone Study was constrained by the time points of the ENID Trial, this tied 
the final pQCT time point during gestation to the P30 or 30 weeks pregnancy visit of the main 
trial. In the context of the lack of significant decreases in the maternal skeleton found in ENID 
Bone, it may be that by 30 weeks any changes in the maternal skeleton are not detectable with 
pQCT, conceivably in the absence of changes in vBMD and BMC microarchitectural redistribution 
could occur as seen in PABS. In PABS where the follow up visit occurred approximately 4-6 weeks 
later, at 34-36 weeks gestation, significant pregnancy-induced changes were observed with both 
pQCT and HRpQCT. 
As discussed at length in Chapter 2, BTM do not present a consistent pattern of bone mineral 
homeorhesis during pregnancy but can with densitometry data provide further context. Both of 
my main analyses solely focus on densitometry outcomes without any complementary bone 
biochemistry or bone turnover markers, this was a pragmatic decision particularly in PABS where 
no bloods were obtained. In my ENID Bone analysis I did not have biochemistry and BTM data. 
In PABS BTM may have proved helpful at baseline where significant between-group differences 
in trabecular microarchitecture were detected but could not be explored further.  
 
 Conclusions  
This thesis has presented novel pQCT data from two separate studies in contrasting populations 
of pregnant women, which suggest that there does not appear to be a uniform maternal skeletal 
response to pregnancy in the appendicular skeleton. These studies showed pregnancy-induced 
bone loss in women accustomed to high Ca intake, and in contrast a lack of bone mineral 
mobilisation in women with habitually low Ca intakes. Although I have not set out to compare 
these two very different groups of pregnant women, the contrast between the pregnancy-induced 




ENID is intriguing. Although we observed some negligible supplement-modulated increases in 
cortical bone parameters in ENID Bone, the most striking finding in these rural Gambian women 
was the complete lack of bone mineral mobilisation between mid- to late- pregnancy. These data 
suggest that fetal Ca demand is satisfied through physiological adaptations other than maternal 
bone mineral mobilisation from the appendicular skeleton. 
In PABS, the release of bone mineral from well-nourished women aged 30-45 years was found at 
both the tibia and radius, however, this varied by site. At the distal tibia, decreases in total and 
trabecular vBMD were found with pQCT, however HRpQCT found no evidence of trabecular 
vBMD falling at the slightly more proximal scan VOI. Despite this, significant changes in trabecular 
microarchitecture were found which support mobilisation but may likely be artefacts of the changes 
in taking place within the cortex as evidenced by decreasing total vBMD, cortical vBMD, and 
cortical thickness and the increase in cortical porosity at the tibia. Similar cortical changes were not 
found in cortical vBMD or thickness with pQCT at the proximal tibia. In contrast to the changes 
found at the distal tibia, no changes were found at the distal forearm which may suggest some 
potential conservation of bone mineral at a more fracture prone site. Evidence of bone mineral 
mobilisation from the proximal radius took the form of decreasing cortical thickness coupled with 
an increasing endosteal circumference, which explains the increase in cortical vBMD. 
The clinical significance of these findings is as of yet unclear but will largely depend on the reversal 
of any mineral losses post-lactation (if they breastfeed) and prior to the beginning of menopause. 
The extent to which cumulative cycles of pregnancy and lactation may interact with the maternal 
skeleton remain unclear, however, a failure to replenish mobilised mineral may be detrimental to 
future bone health. While my research has focused on bone mineral changes across a single 
pregnancy many women will go through more than one cycle of pregnancy and lactation. Further 
research is required to determine potential pregnancy-induced skeletal adaptation in women at 





 Thesis outputs 
 
8.7.1 Awards 
Bone Research Society Conference Winchester 2018: Best Oral Presentation 
“Pregnancy induced changes in bone microarchitecture and density at the tibia as determined 
by single-slice and high-resolution peripheral Quantitative Computed Tomography.” 
 
8.7.2 Peer-reviewed abstracts 
Bone Research Society Conference Winchester 2018: Oral presentation 
“Pregnancy induced changes in bone microarchitecture and density at the tibia as determined 
by single-slice and high-resolution peripheral Quantitative Computed Tomography.” 
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“In-vivo correlation of single-slice peripheral Quantitative Computed Tomography (pQCT) and 
high resolution pQCT for volumetric bone mineral density and geometry at the tibia.” 
Nutrition Society Summer Conference Leeds 2018: Poster presentation 
“Changes in maternal volumetric bone mineral density in the peripheral skeleton during 
pregnancy as determined by single-slice peripheral Quantitative Computed Tomography.” 
Nutrition Society Summer Conference London 2017: Poster presentation 
“Maternal bone mineral changes during pregnancy as measured by peripheral QCT in rural 





Pregnancy induced changes in bone microarchitecture and density at the tibia as 
determined by single-slice and high-resolution peripheral Quantitative Computed 
Tomography. Mícheál Ó Breasail1, Ann Prentice1, Kate Ward1,2 
1MRC Elsie Widdowson Laboratory, 2MRC Lifecourse Epidemiology Unit 
Objectives 
The newborn skeleton contains 25-30g of calcium, although the source of this has not been fully 
qualified. Evidence from DXA studies before and shortly after pregnancy suggests that some of 
this calcium may originate from the maternal skeleton. The aim of this study was to use single- slice 
and high-resolution peripheral quantitative computer tomography (pQCT, HRpQCT) to 
characterise whether pregnancy-induced changes occur in the appendicular skeleton. 
Methods 
Pregnant women were scanned twice, at 14-16 and 34–36 weeks gestation. Premenopausal controls 
were also scanned approximately 20 weeks apart. pQCT scans (XCT 2000L) were obtained at the 
distal (4%) and proximal (14,38%) sites of the non-dominant tibia. HRpQCT (XtremeCTI) scans 
of the distal tibia were also obtained. Outcomes were: distal total and trabecular vBMD, total cross- 
sectional area (CSA), plus for HRpQCT distal cortical vBMD and thickness, trabecular number 
and thickness; pQCT proximal outcomes were cortical vBMD, cortical CSA, cortical thickness, 
and total CSA. Linear regression models were fitted, and the model of best fit selected; covariates 
were group, height, change in weight, baseline age, time between visits, parity, smoking history, 
oral contraceptive use, group*time difference. Groups differences are presented as mean (SE). 
Results 
Ninety (53 pregnant) women, mean(SD) age 35.4(3.8)years, were recruited. No significant 
differences were found between groups at baseline except trabecular thickness which was lower in 
the pregnant group (p<0.05). At follow up pregnant women had significantly lower distal total 
vBMD (-1.9(0.6)%); proximal cortical vBMD (14%-0.9(0.2)%), 38%-0.5(0.2)%). HRpQCT distal 
total (-1.8(0.5)%) and cortical vBMD (-1.8 (0.5)%) were lower in pregnant women, as were distal 
cortical and trabecular thickness (-2.3(0.5)%, -3.9(1.9)% respectively). Trabecular number was 
greater (3.6(1.8)%) in pregnant women. 
Conclusion 
During pregnancy bone mineral is mobilised predominantly from the cortical compartment of the 
distal tibia. These data also suggest there may be early pregnancy changes in trabecular bone which 





In-vivo correlation of single-slice peripheral Quantitative Computed Tomography (pQCT) 
and high resolution pQCT measures at the tibia. Mícheál Ó Breasail1, Ann Prentice1, Kate 
Ward1,2 
1MRC Elsie Widdowson Laboratory, 2MRC Lifecourse Epidemiology Unit 
Objectives 
Single-slice pQCT (pQCT) and high-resolution pQCT (HRpQCT) are available for in-vivo 
measurements of cortical (Ct) and trabecular (Tb) compartments. These techniques measure 
different sites, single slice pQCT at any site along the bone and first generation HRpQCT at distal 
sites. The aim was to explore the agreement between the methods for measures of cortical vBMD, 
cortical thickness, and trabecular vBMD. 
Methods 
The non-dominant tibiae of 76 healthy premenopausal women (mean(SD) age 35.4(3.6) years) were 
measured. Outcomes were: pQCT (XCT 2000L, voxel size 0.5mm) 4% Tb-vBMD, 14% and 38% 
Ct-vBMD and thickness; HRpQCT (XtremeCTI, voxel size 0.82μm) a 9.02mm volume of interest 
(110 contiguous slices) at the distal tibia (Tb-vBMD, Dinner (Dinn), Ct-vBMD and thickness) 
Correlations between comparable parameters were obtained, and Bland-Altman (BA) plots used to 
assess the agreement between the two methods and to detect systematic bias. 
Results 
Ct-vBMD measures on pQCT and HRpQCT were poor-fairly correlated (R2=0.17, 0.37 for 38% 
and 14% tibia respectively). There was good correlation between cortical thickness at 14% pQCT 
site and HRpQCT (R2=0.68) but not at the 38% tibia (R2=0.09). BA plots showed increasing 
systematic difference at both sites with increasing cortical thickness. There were high correlations 
between Tb-vBMD by pQCT and both HRpQCT Tb-vBMD and Dinn (R2 = 0.87, 0.83 
respectively). There was good agreement between the Tb outcomes; pQCT Tb-vBMD was lower 
than both HRpQCT Tb measures mean(95%CI) difference of Tb-vBMD 54 mg/cm3 (-26;-82 
mg/cm3) and Dinn 95 mg/cm3 (-62;-128 mg/cm3). 
Conclusion 
Correlations between cortical vBMD and thickness measured at the proximal (38% pQCT site) 
and distal (HRpQCT) tibia are weak. However cortical measures at the 14% and distal site agreed 
well. Trabecular measures agreed well but cannot be interchanged. To understand cortical bone 





Changes in maternal volumetric bone mineral density in the peripheral skeleton during 
pregnancy as determined by single-slice peripheral Quantitative Computed Tomography. 
By M. Ó Breasail1, A. Prentice1 and K. Ward1,2, 1Medical Research Council Elsie Widdowson 
Laboratory (MRC EWL), CB1 9NL and 2Medical Research Council Lifecourse Epidemiology Unit 
(MRC LEU), University of Southampton, SO16 6YD 
At birth the fetus contains 25-30 g of calcium (Ca), although whether the maternal skeletal stores 
of calcium are a source (in addition to increased intestinal absorption and reduced excretion) is not 
fully known. There is limited evidence from DXA studies before and shortly after pregnancy 
suggesting some mobilisation of maternal Ca stores (1, 2); such mobilisation has been consistently 
observed during lactation (1, 3-5). Peripheral QCT scanners measure volumetric bone mineral 
density (vBMD) and geometry in the appendicular skeleton. To determine if pregnancy induced 
bone mineral changes occur in the appendicular skeleton we scanned pregnant women at the distal 
tibia and radius at two time points during pregnancy (14-16 weeks and 34 – 36 weeks). Healthy 
premenopausal non-pregnant non-lactating controls were also scanned with a similar length 
between visits. 
Data were obtained from 90 (53 pregnant) healthy premenopausal women (mean age 35.4 (SD 3.8) 
years). Scans with pQCT (XCT 2000L, Stratec) were obtained at 4% of the length of the lower leg 
and forearm. Independent t-tests tested for unadjusted differences between change in vBMD. 
Linear regression models were then fitted for total and trabecular vBMD and total cross-sectional 
area (CSA) at the radius and tibia with the terms: (1) height, baseline weight, group and (2) model 
1 plus age, weight change, parity, ever smoked and previous contraception use. In each case the 
model of best fit was selected using backwards stepwise regression for each outcome measure of 
interest. Data are presented from model 2. 
At baseline there were no statistically significant difference between the two groups (p <0.05). 
Between visits the pregnant participants gained 9 (SD 3.4) kg. There were significant decreases in 
the pregnant group compared to non-pregnant controls of: total vBMD 1.8% (SE 0.9) (P< 0.001) 
and in trabecular vBMD 1.4% (SE 0.5) (P< 0.001). These decreases exceed the precision error of 
the scanning technique. No significant changes in tibia total CSA. Testing at the distal radius found 
no statistically significant changes during pregnancy in any of the measured parameters of interest. 
During pregnancy bone mineral is mobilised from the distal tibia, a trabecular rich site. In contrast 
there appeared to be conservation of mineral at the distal radius during pregnancy. The basis for 
the site differences requires further investigation but is consistent with previous DXA studies. 
1. Olausson H, Laskey MA, Goldberg GR et al. (2008) Am J Clin Nutr 88, 1032-1039. 
2. Kaur M, Pearson D, Godber I et al. (2003) Bone 32, 449-454. 
3. Laskey MA &Prentice A (1997) Lancet 349, 1518-1519. 





Maternal bone mineral changes during pregnancy as measured by peripheral QCT in rural 
Gambian women with a habitually low calcium intake. By M. Ó Breasail1, S. Schoenbuchner1, L. 
Jarjou2, S.E. Moore3, A. Prentice1,2, and K.A. Ward1,4, 1MRC EWL, 120 Fulbourn Road, Cambridge, CB1 9NL, UK; 
2MRC Keneba, MRC The Gambia Unit, The Gambia; 3Division of Women’s Health, Kings College London SE1 7EH, 
4MRC Lifecourse Epidemiology, University of Southampton, Tremona Rd, Southampton SO16 6YD 
Evidence from studies of pre- and post-pregnancy bone densitometry or bone turnover markers 
suggest maternal bone mineral is mobilised to satisfy the calcium demands of the fetus(1), which 
at birth contains 25 - 30 g Ca. There are now techniques available that can be used during pregnancy 
to measure changes in the maternal skeleton. We aimed to quantify these changes in a 
supplementation trial (The Early Nutrition and Immune Development (ENID) trial) that 
randomized pregnant women before 20 weeks gestation to receive one of 4 supplements daily until 
term(2). The supplement groups were: control receiving 60 mg iron and 400 μg folate as per 
standard Gambian guidelines, multi-micronutrient (MMN: 15 micronutrients at twice RDA), 
protein energy (PE: 746 kcal and 20.8g protein) or combined PEMMN(2). It was hypothesised that 
there would be a significant decrease in maternal BMD and structure between early and late 
pregnancy. We used peripheral QCT to describe these changes and to explore whether supplement 
type predicted change in bone outcomes. 
814 pregnant rural Gambians aged 18-45 years (mean [SD] 29.6 [6.7] years, median parity 4 (IQR 
2 - 6)) were included in this study. Anthropometric and pQCT data at the distal and proximal radius 
and tibia were obtained at a pre-intervention “booking” visit (mean [SD] 13 [3] wks), week 20, and 
week 30; (only change between booking and P30 will be described). These pQCT measures were 
for distal sites: total and trabecular vBMD, total CSA; for proximal sites: total CSA, cortical vBMD, 
cortical content (BMC), cortical CSA, cortical thickness, and stress-strain index (SSI), an estimate 
of bone torsional strength. A paired samples t-test was used to determine if change between 
booking and P30 was statistically significant. Linear regression models tested whether supplement 
was a significant predictor of change between booking and P30. 
No significant differences were observed between booking and P30 in the whole cohort for total 
vBMD, trabecular vBMD, and total CSA at the either the distal radius or tibia or in total CSA, 
cortical vBMD, cortical thickness, or SSI at the proximal radius. At the proximal radius there was 
a small but significant increase in BMC of 0.4% (SE 0.2%) between baseline and P30 in the whole 
cohort (p<0.05). Cortical vBMD also increased by 0.2% (SE 0.1%) (p=0.07). A similar pattern was 
observed at the proximal tibia where increases occurred in parameters of cortical bone, BMC, 
cortical CSA, and SSI, ranging from 0.1-0.6% (all p<0.05). Cortical vBMD also increased (0.2% SE 
0.1%), but was not statistically significant (p=0.09). Supplement type predicted change at the 
proximal radius where PE supplementation was a significant negative predictor of cortical BMC 
(p<0.05) and of cortical vBMD (p<0.001). In contrast, PEMMN supplementation was a significant 
positive predictor of cortical vBMD (p<0.001) at the proximal radius. Supplement group was not 
a predictor of change in any of the outcomes at the distal tibia. 
These findings suggest that during pregnancy there is no evidence of bone loss from the trabecular-
rich distal radius or tibia and that small increases in cortical bone mineral may occur at the proximal 
radius and tibia that might be modified by supplementation. The lack of substantial change is 
somewhat surprising as in lactation release of bone mineral from trabecular sites has been observed 
consistently and was hypothesised to be the source of bone mineral during pregnancy. Mobilisation 
of bone mineral may occur in pregnancy through other mechanisms such as changes in maternal 
trabecular microarchitecture or cortical porosity, however, these are not detectable with pQCT due 
to limitations of resolution. These may be overcome with the use of more advanced modalities 
such as high resolution-pQCT. 
1. Olausson H, Gail R. Goldberg GR, Laskey MA et al. (2012) Nutr Res Rev, 25, 40–67 
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Appendix A: Training 
Training undertaken during PhD 
Courses and workshops attended  
European Calcified Tissue Society PhD training course 2016 Sienna, Italy 
The Sub-Saharan African MuSculOskeletal Network Training Workshop 2018 Harare, Zimbabwe 
Good Clinical Practice Cambridge, UK 
The Ionising Radiation (Medical Exposure) Regulations (IR(ME)R) 2000 Online 
Human Tissue Act Cambridge, UK 
Good Clinical Practice (GCP) Cambridge, UK 
General Data Protection Regulation (GDPR) training 2018 Online 
An Introduction to R: Software For Statistical Analysis Cambridge, UK 
An Introduction to Solving Biological Problems with R Cambridge, UK 
R: Introduction for Beginners Cambridge, UK 
 
 
Training of staff and students 
During my PhD I was actively involved in supporting several other studies, which 
in addition to performing scans including the training of staff and students at 
MRC EWL, and colleagues in The Gambia and Zimbabwe. I continue to provide 
technical pQCT support to scanning facilities in The Gambia, Zimbabwe, and 
South Africa. 
 
Training of staff and students at MRC EWL, Cambridge, UK 
Carla Greenwood (Placement Student) pQCT scan grading 
Lauren Oliver (Research Assistant)  pQCT scan grading and image analysis 
Dominique Taylor (Placement Student) pQCT scan acquisition, pQCT scan grading, HRpQCT scan 
analysis 
Rebecca McGrath (Research Assistant) pQCT scan acquisition, pQCT scan grading, pQCT scan 
analysis, HRpQCT scan acquisition 
Matthew Harvey (Physician’s Assistant) pQCT scan acquisition, HRpQCT scan acquisition 
Sophie Yelland (Placement Student) HRpQCT scan grading and analysis 
Elise Orford  pQCT scan acquisition, pQCT scan grading, pQCT scan 
analysis, HRpQCT scan acquisition, DXA scan acquisition 
Training of staff at MRC The Gambia, Keneba, The Gambia 
Michael Mendy  Musculoskeletal functional tests training 
Mustapha Ceesay Musculoskeletal functional tests training 
Set up of XCT 2000 system and training of staff at Parirenyatwa Hospital, Harare, Zimbabwe 
Radiographers employed by the University of 
Zimbabwe/Parirenyatwa Hospital 
pQCT scan acquisition, pQCT scan grading, pQCT data 
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Appendix C: ENID Bone pQCT Study supplementary material 
 




Baseline descriptive statistics at Booking for the 4 supplement groups in the ENID Bone 
Study, mean (SD). Between- group baseline differences were tested by ANOVA with 
posthoc Tukey Test 
 
 FeFol MMN PE PEMMN 
4% Distal Radius n = 171 n = 170 n = 171 n = 171 
Season ratio (wet/dry) 89/82 86/85 86/85 86/84 
Total vBMD (mg/cm3) 317.39 (42.44) 322.61 (45.91) 320.71 (44.48) 318.33 (44.08) 
Trabecular vBMD (mg/cm3) 159.30 (33.84) 162.37 (36.46) 160.81 (36.01) 158.60 (36.13) 
Total CSA (mm) 337.88 (40.85) 333.74 (39.91) 340.60 (43.82) 334.36 (44.86) 
33% Proximal Radius n = 171 n = 173 n = 171 n = 170 
Season ratio (wet/dry) 90/81 88/85 87/84 83/87 
Total CSA 120.31 (16.95) 120.12 (16.38) 122.19 (17.14) 118.98 (16.75) 
Cortical vBMD (mg/cm3) 1239.57 (39.15) 1243.61 (39.97) 1241.13 (36.86) 1240.02 (37.08) 
Cortical BMC (mg/mm) 93.51 (11.54) 94.34 (10.61) 95.26 (11.11) 92.75 (10.47) 
Cortical CSA (mm2) 75.42 (8.80) 75.83 (7.91) 76.72 (8.37) 74.80 (8.14) 
Cortical Thickness (mm) 2.42 (0.23) 2.45 (0.22) 2.45 (0.25) 2.42 (0.23) 
SSI (mm3) 228.01 (45.82) 232.80 (44.86) 231.82 (47.51) 225.55 (42.81) 
4% Distal Tibia n = 156 n = 159 n = 147 n = 159 
Season ratio (wet/dry) 83/73 80/79 79/68 81/78 
Total vBMD (mg/cm3) 282.19 (37.62) 283.78 (34.93) 286.50 (35.20) 280.97 (34.76) 
Trabecular vBMD (mg/cm3) 190.55 (33.15) 191.85 (27.89) 193.75 (30.81) 189.97 (29.24) 
Total CSA (mm2) 949.95 (109.66) 941.18 (106.73) 948.02 (110.54) 938.06 (114.70) 
38% Proximal Tibia n = 155 n = 162 n = 147 n = 158 
Season ratio (wet/dry) 83/72 82/80 79/68 81/77 
Total CSA (mm2) 382.98 (52.55) 379.03 (50.45) 380.06 (44.15) 374.85 (48.76) 
Cortical vBMD (mg/cm3) 1233.50 (37.73) 1233.48 (38.54) 1231.07 (38.64) 1231.44 (35.35) 
Cortical BMC (mg/mm) 280.86 (37.63) 281.31 (37.97) 283.43 (35.12) 275.69 (32.72) 
Cortical CSA (mm2) 227.63 (29.17) 227.93 (28.76) 230.04 (26.03) 223.72 (24.28) 
Cortical Thickness (mm) 4.03 (0.44) 4.07 (0.45) 4.12 (0.47) 4.01 (0.39) 
*p<0.05 FeFol = iron folate, MMN = multiple micronutrients, PE = protein energy, PEMMN = protein energy multiple 
micronutrients, vBMD = volumetric bone mineral density, CSA = cross sectional area, SSI = stress strain index. Season coded as 








The following three tables are provided to illustrate the roughly even 
proportion of pregnant Gambians: 
1. At Booking in Wet and Dry season; 
 
2. Supplement by Booking season; 
 





Proportion of scans at each site by season at Booking 
 Distal radius Proximal Radius Distal Tibia Proximal Tibia 
Wet Season 347 348 323 325 
Dry Season 336 337 298 297 





  Proportion of participants in each supplement arm by Booking season.  




















































Wet 86 86 89 86 87 83 90 88 79 81 83 80 79 81 83 82 
Dry 85 84 82 85 84 87 81 85 68 78 73 79 68 77 72 80 





Proportion of participants scanned on the XCT2000/2000L by Booking season. 
 Radius distal scan/proximal scan Tibia distal scan/proximal scan 
 XCT2000 XCT2000L XCT2000 XCT2000L 
Wet 137/143 206/203 127/128 196/197 
Dry 154/158 175/172 128/129 167/165 









Absolute change between Booking and P30 for women who did not change scanner 
 
Baseline pQCT bone outcome measures (Booking) for the all women in the ENID Bone 
Study who did not change scanners between Booking and P30, mean (SD).  
 Booking Change by P30 
4% Radius n=435 
Total vBMD (mg/cm3) 319.23 (44.98) 0.89 (16.81) 
Trabecular vBMD (mg/cm3) 160.51 (35.63) 1.52 (9.03)* 
Total CSA (mm) 335.94 (42.09) 1.91 (21.72) 
33% Radius n=440 
Total CSA (mm2) 119.82 (16.12) -0.33 (11.00) 
Cortical vBMD (mg/cm3) 1239.66 (35.17) 5.09 (22.44)* 
Cortical BMC (mg/mm) 94.05 (10.77) 0.46 (2.13)* 
Cortical CSA (mm2) 75.84 (8.17) 0.06 (1.67) 
Cortical Thickness (mm) 2.45 (0.23) 0.01 (0.17) 
4% Tibia n=407 
Total vBMD (mg/cm3) 281.86 (36.08) 0.91 (5.74) 
Trabecular vBMD (mg/cm3) 190.49 (31.19) 0.77 (5.43) 
Total CSA (mm2) 945.65 (112.59) -1.19 (25.34) 
38% Tibia n=409 
Total CSA (mm2) 377.60 (47.95) 0.69 (11.67) 
Cortical vBMD (mg/cm3) 1230.23 (35.20) 4.38 (11.25) 
Cortical BMC (mg/mm) 280.01 (34.20) 1.52 (4.02)* 
Cortical CSA (mm2) 227.52 (26.26) 0.42 (2.51)* 
Cortical Thickness (mm) 4.07 (0.41) 0.00 (0.11) 











Additional diagnostic plots of ENID pQCT models 
 
Leverage plots that show the main effects for Model 2 i.e. linear regression of between-visit difference in pQCT total 
vBMD (tibia). Model 2: Yi=βo+β1machine +β2age+β3PE*MMN+ϵ. Yi is the absolute change in total vBMD for 
participant I. The error ε represents the difference between what is explained by the systematic part of the model 
and what is observed. Model 2 included supplement effects (as binary dummy variables, Figure 3.15) to allow MMN, 
PE, and a PE x MMN interaction term to be explored. Machine_cat was also included in this model. PE = protein 





Leverage plots that show the main effects for Model 2 i.e. linear regression of between-visit difference in pQCT 
trabecular vBMD (tibia). Model 2: Yi=βo+β1machine +β2age+β3PE*MMN+ϵ. Yi is the absolute change in total vBMD 
for participant I. The error ε represents the difference between what is explained by the systematic part of the 
model and what is observed. Model 2 included supplement effects (as binary dummy variables, Figure 3.15) to 
allow MMN, PE, and a PE x MMN interaction term to be explored. Machine_cat was also included in this model. PE 





Leverage plots that show the main effects for Model 2 i.e. linear regression of between-visit difference in pQCT total 
vBMD (radius). Model 2: Yi=βo+β1machine +β2age+β3PE*MMN+ϵ. Yi is the absolute change in total vBMD for 
participant I. The error ε represents the difference between what is explained by the systematic part of the model 
and what is observed. Model 2 included supplement effects (as binary dummy variables, Figure 3.15) to allow MMN, 
PE, and a PE x MMN interaction term to be explored. Machine_cat was also included in this model. PE = protein 





Leverage plots that show the main effects for Model 2 i.e. linear regression of between-visit difference in pQCT 
trabecular vBMD (radius). Model 2: Yi=βo+β1machine +β2age+β3PE*MMN+ϵ. Yi is the absolute change in total 
vBMD for participant I. The error ε represents the difference between what is explained by the systematic part of 
the model and what is observed. Model 2 included supplement effects (as binary dummy variables, Figure 3.15) to 
allow MMN, PE, and a PE x MMN interaction term to be explored. Machine_cat was also included in this model. 

















Total CSA  
4% (mm2) 
Total CSA  
33% (mm2) 








Age -0.18 0.04 0.14 0.07 -0.30. -0.03a -0.01 -0.002 
 (0.13) (0.07) (0.16) (0.08) (0.17) (0.02) (0.01) (0.001) 
Constant 0.92 1.51c 1.89. -0.34 5.13c 0.47c 0.07 0.01 
 (0.81) (0.43) (1.04) (0.52) (1.07) (0.10) (0.08) (0.01) 
Observations 435 435 435 440 440 440 440 440 
R2 0.004 0.001 0.002 0.002 0.01 0.01 0.001 0.004 
Model 1 reference group: women of mean age at booking. vBMD = volumetric bone mineral density, CSA = cross-sectional area, BMC = bone mineral content, a = p<0.05; b = p<0.01; 




Summary of Model 2 for change in bone outcome measures at the 4% distal and 33% proximal radius between Booking and P30 for women scanned on the same machine at both visits 
 
 
















PE -0.99 -0.02 3.16 2.00 -8.96b -0.48. 0.14 -0.02 
 (2.24) (1.21) (2.90) (1.47) (2.96) (0.28) (0.22) (0.02) 
MMN 3.39 0.36 -2.52 2.43. -6.72a 0.12 0.50a -0.01 
 (2.25) (1.21) (2.91) (1.46) (2.93) (0.28) (0.22) (0.02) 
Age -0.17 0.04 0.13 0.06 -0.29. -0.04a -0.01 -0.002 
 (0.13) (0.07) (0.16) (0.08) (0.17) (0.02) (0.01) (0.001) 
PE*MMN -2.82 0.52 0.90 -2.82 14.50c 0.41 -0.54. 0.02 
 (3.22) (1.74) (4.17) (2.10) (4.23) (0.40) (0.32) (0.03) 
Constant 0.44 1.23 1.35 -1.83. 9.35c 0.54b -0.12 0.02 
 (1.55) (0.84) (2.01) (1.02) (2.06) (0.20) (0.15) (0.02) 
Observations 435 435 435 440 440 440 440 440 
R2 0.01 0.002 0.01 0.01 0.03 0.02 0.01 0.01 
 
Model 2 reference group: women of mean age at booking, who received FeFol. vBMD = volumetric bone mineral density, CSA = cross-sectional area, BMC = bone mineral content, a = 












Total CSA  
4% (mm2) 
Total CSA  
38% (mm2) 








Age 0.02 0.02 0.17 0.07 -0.09 -0.03 -0.01 -0.001 
 (0.04) (0.04) (0.19) (0.09) (0.09) (0.03) (0.02) (0.001) 
         
Constant 0.91b 0.77b -1.21 0.68 4.39c 1.52c 0.43c 0.005 
 (0.28) (0.27) (1.26) (0.58) (0.56) (0.20) (0.12) (0.01) 
 
Observations 407 407 407 409 409 409 409 409 
R2 0.001 0.0004 0.002 0.002 0.003 0.003 0.0005 0.002 






Summary of Model 2 for change in bone outcome measures at the 4% distal and 38% proximal tibia between Booking and P30 for women scanned on the same machine at both visits. 
 
 




Total CSA  
4% (mm2) 
Total CSA  
38% (mm2) 








PE 0.48 0.53 2.20 2.40 -0.84 -0.27 -0.07 -0.02 
 (0.81) (0.77) (3.60) (1.66) (1.60) (0.57) (0.36) (0.02) 
         
MMN 0.49 -0.02 -2.89 2.94. 0.98 0.42 0.19 -0.02 
 (0.79) (0.75) (3.50) (1.60) (1.54) (0.55) (0.35) (0.01) 
Age 0.02 0.02 0.18 0.07 -0.10 -0.03 -0.01 -0.001 
 (0.04) (0.04) (0.19) (0.09) (0.09) (0.03) (0.02) (0.001) 
PE*MMN 1.14 0.22 -3.11 -3.59 2.13 0.12 -0.29 0.02 
 (1.13) (1.08) (5.03) (2.31) (2.22) (0.80) (0.50) (0.02) 
         
Constant 0.14 0.47 -0.01 -1.09 3.74c 1.40c 0.43. 0.02. 
 (0.55) (0.53) (2.46) (1.14) (1.10) (0.39) (0.25) (0.01) 
Observations 407 407 407 409 409 409 409 409 
R2 0.02 0.004 0.01 0.01 0.01 0.01 0.003 0.01 
Model 2 reference group: women of mean age at booking, who received FeFol. vBMD = volumetric bone mineral density, CSA = cross-sectional area, BMC = bone mineral content, a 
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Appendix E: Pregnancy and Bone Study forms 


























































































































Appendix F: Pregnancy and Bone Study 
supplementary material 
Tibia bone outcome measures complete baseline descriptive statistics 
 
 
Baseline mean (SD) for anthropometry and bone outcome measures of interest as measured with pQCT 
and HR-pQCT in non-pregnant non-lactating and pregnant groups. 
 NPNL Pregnant 
HRpQCT Distal Tibia n=37 n=50 
Total vBMD (mg/cm3) 315.18 (50.91) 326.78 (70.65) 
Trabecular vBMD (mg/cm3) 164.31 (37.58) 174.27 (42.84) 
Cortical vBMD (mg/cm3) 918.71 (36.95) 923.69 (39.32) 
BV/TV 0.14 (0.03) 0.15 (0.04) 
Trabecular number (mm-1) 2.17 (0.34) 2.01 (0.33)* 
Trabecular thickness (mm) 0.06 (0.01) 0.07 (0.01)** 
Trabecular separation (mm) 0.41 (0.07) 0.44 (0.10) 
Cortical thickness (mm) 1.25 (0.21) 1.27 (0.30) 
Cortical porosity (%) 99.30 (7.16) 98.90 (8.24) 
pQCT Distal Tibia n = 36 n = 52 
Total vBMD 4% (mg/cm3) 301.95 (40.77) 307.15 (49.01) 
Trabecular vBMD 4% (mg/cm3) 220.18 (39.01) 227.23 (43.83) 
Total CSA 4% (mm2) 980.28 (114.93) 970.97 (114.68) 
Cortical subcortical vBMD (mg/cm3) 368.82 (45.61) 372.49 (57.60) 
pQCT Proximal 14% Tibia n=36 n=53 
Total CSA (mm2) 416.70 (55.03) 411.89 (58.42) 
Cortical vBMD (mg/cm3) 1135.89 (20.06) 1142.47 (17.65) 
Cortical BMC (mg/mm) 188.09 (22.68) 187.55 (23.65) 
Cortical CSA (mm2) 165.52 (19.30) 164.08 (19.97) 
Cortical thickness (mm) 2.55 (0.32) 2.56 (0.40) 
Periosteal circumference (mm) 73.16 (4.72) 72.69 (5.14) 
Endosteal circumference (mm) 57.14 (5.51) 56.60 (6.68) 
pQCT Proximal 38% Tibia n=37 n=53 
Total CSA (mm2) 392.17 (44.35) 377.67 (42.50) 
Cortical vBMD (mg/cm3) 1169.84 (23.78) 1174.16 (18.22) 
Cortical BMC (mg/mm) 324.58 (39.94) 316.50 (40.72) 
Cortical CSA (mm2) 277.48 (33.92) 269.61 (34.86) 
Cortical thickness (mm) 4.90 (0.53) 4.84 (0.46) 
Periosteal circumference (mm) 72.11 (4.47) 70.83 (4.24) 
Endosteal circumference (mm) 41.33 (5.07) 40.43 (3.55) 
vBMD = volumetric bone mineral density, CSA = cross sectional area, BV/TV = trabecular bone 




Radius bone outcome measures complete baseline descriptive statistics 
 
 
Baseline mean (SD) for anthropometry and bone outcome measures of interest as measured with pQCT and HR- 
  pQCT in non-pregnant non-lactating and pregnant groups.  
 NPNL Pregnant 
HRpQCT Radius n=31 n=47 
Total vBMD (mg/cm3) 335.51 (59.82) 324.29 (59.50) 
Trabecular vBMD (mg/cm3) 157.89 (33.28) 150.61 (35.89) 
Cortical vBMD (mg/cm3) 912.43 (49.39) 911.23 (57.87) 
BV/TV 0.13 (0.03) 0.13 (0.03) 
Trabecular number (mm-1) 2.04 (0.25) 1.98 (0.31) 
Trabecular thickness (mm) 0.06 (0.01) 0.06 (0.01) 
Trabecular separation (mm) 0.43 (0.06) 0.45 (0.09) 
Cortical thickness (mm) 0.80 (0.15) 0.79 (0.16) 
Cortical porosity (%) 66.40 (5.15) 67.46 (6.33) 
Radius 4% n=35 n=49 
Total vBMD 4% (mg/cm3) 322.92 (50.68) 315.57 (49.93) 
Trabecular vBMD 4% (mg/cm3) 179.99 (36.84) 176.62 (36.20) 
Total CSA 4% (mm2) 325.51 (44.13) 335.59 (43.25) 
Cortical subcortical vBMD (mg/cm3) 439.66 (73.77) 429.12 (68.86) 
Radius 33% n=36 n=52 
Total CSA (mm2) 100.06 (12.72) 98.59 (11.95) 
Cortical vBMD (mg/cm3) 1217.73 (17.37) 1218.11 (15.23) 
Cortical BMC (mg/mm) 89.40 (9.73) 88.26 (10.20) 
Cortical CSA (mm2) 73.42 (7.99) 72.47 (8.40) 
Cortical thickness (mm) 2.55 (0.20) 2.55 (0.22) 
Periosteal circumference (mm) 36.81 (2.19) 36.47 (2.34) 
Endosteal circumference (mm) 20.81 (2.16) 20.47 (2.39) 
vBMD = volumetric bone mineral density, CSA = cross sectional area, BV/TV = trabecular bone volume/bone volume. *p-value < 0.05, **p- 









Distribution of pQCT and HRpQCT vBMD bone outcome measures at baseline by age 
 









HRpQCT bone outcome measures between-visit change expressed as a percentage in PABS Cambridge 
HRpQCT bone outcomes measures at baseline and change by follow-up expressed in absolute units and percentages at the tibia and radius in PABS, Cambridge 
 
 
 NPNL Pregnant 
 Visit 1 Between-visit change ∆% Visit 1 Between-visit change ∆% 
Tibia n=32 n=33 
Total vBMD (mg/cm3) 315.26 (53.64) -1.50 (3.02)  ‡‡ -0.48 (1.00) 317.43 (68.09) -4.69 (6.32) ‡‡‡ -1.39 (1.73) 
Trabecular vBMD (mg/cm3) 165.53 (38.02) -2.55 (2.36)   ‡‡‡ -1.56 (1.48) 174.68 (41.33) -2.79 (3.59) ‡‡‡ -1.48 (1.97) 
Cortical vBMD   (mg/cm3) 921.45 (33.66) -0.85 (6.47) -0.08 (0.70) 916.26 (38.81) -7.40 (12.91)‡‡ -0.81 (1.37) 
BV/TV 0.14 (0.03) -0.002 (0.002)‡‡‡ -1.56 (1.48) 0.15 (0.03) -0.002 (0.003) ‡‡‡ -1.48 (1.97) 
Trabecular number (mm-1) 2.13 (0.27) -0.01 (0.15) -0.29 (7.18) 1.98 (0.27)* 0.09 (0.15)  ‡‡ 4.58 (7.61) 
Trabecular thickness (mm) 0.065 (0.014) -0.0007 (0.0043) -0.78 (6.92) 0.073 (0.013) * -0.004 (0.005) ‡‡‡ -5.35 (6.68) 
Trabecular separation  (mm) 0.41 (0.06) 0.00 (0.03) 1.10 (7.43)   0.44 (0.08) -0.02 (0.03) ‡‡‡ -3.66 (6.75) 
Cortical thickness (mm) 1.25 (0.22) 0.01 (0.01) ‡‡‡ 0.78 (1.06) 1.21 (0.29) -0.01 (0.02)‡‡ -1.21 (1.75) 
Cortical porosity   (%) 99.91 (7.16) 0.03 (0.23) 0.03 (0.24) 99.6 (8.3) 0.25 (0.25) ‡‡‡ 0.25 (0.25) 
Radius n=27 n=33 
Total vBMD (mg/cm3) 334.75 (63.13) -3.15 (7.70) ‡ -0.90 (2.31) 334.20 (58.74) -2.89 (6.90)   ‡ -0.94 (2.04) 
Trabecular vBMD (mg/cm3) 155.10 (32.80) -2.53 (2.23)  ‡‡‡ -1.74 (1.49) 153.28 (39.86) -2.18 (3.34) ‡‡‡ -1.54 (2.07) 
Cortical vBMD   (mg/cm3) 916.35 (49.22) -3.45 (10.17) -0.37 (1.12) 920.46 (42.47) -4.32 (9.42)  ‡ -0.47 (1.05) 
BV/TV 0.13 (0.03) -0.002 (0.002) ‡‡‡ -1.74 (1.49) 0.13 (0.03) -0.002 (0.003) ‡‡‡ -1.54 (2.07) 
Trabecular number (mm-1) 2.02 (0.23) 0.04 (0.20) 2.06 (10.11) 1.95 (0.33) 0.01 (0.19) 1.27 (10.99) 
Trabecular thickness (mm) 0.06 (0.01) -0.002 (0.005) ‡ -2.93 (8.58) 0.07 (0.01) -0.001 (0.007) -1.79 (9.76) 
Trabecular separation  (mm) 0.44 (0.06) -0.005 (0.0419) -0.86 (9.61) 0.46 (0.10) -0.002 (0.051) -0.01 (9.93) 
Cortical thickness (mm) 0.81 (0.16) 0.003 (0.0307) 0.50 (3.98) 0.82 (0.14) -0.005 (0.026) -0.75 (3.40) 
Cortical porosity   (%) 66.74 (5.35) -0.10 (0.36) -0.16 (0.56) 66.68 (5.80) 0.08 (0.35) 0.07 (0.52) 
Total vBMD (mg/cm3) 334.75 (63.13) -3.15 (7.70) ‡ -0.90 (2.31) 334.20 (58.74) -2.89 (6.90)   ‡ -0.94 (2.04) 
*p<0.05, **p<0.01, ***p<0.001 independent t-test between groups at baseline; ‡p<0.05, ‡‡p<0.01, ‡‡‡p<0.001 single-sided t-test vs 0.  vBMD = volumetric bone mineral density, CSA = cross sectional area, BV/TV = 




Plots of ENID and PABS pQCT total vBMD at baseline and follow visits  
 
Tibia total vBMD (pQCT) at baseline and follow up visits (by week of pregnancy) for ENID (red), PABS pregnant 
(PREG, blue), and PABS (NPNL, green). Dashed lines represent 1SD, 







Radius total vBMD (pQCT) at baseline and follow up visits (by week of pregnancy) for ENID (red), PABS pregnant 
(PREG, blue), and PABS (NPNL, green), Dashed lines represent 1SD, solid lines represent 2SD. 
 
 
 
